#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence
#Text=Evidence suggests that disturbances in neurobiological mechanisms of reward and inhibitory control maintain addiction and provoke relapse during abstinence.
1-1	0-5	Acute	_	
1-2	6-8	D3	_	
1-3	9-19	Antagonist	_	
1-4	20-29	GSK598809	_	
1-5	30-41	Selectively	_	
1-6	42-50	Enhances	_	
1-7	51-57	Neural	_	
1-8	58-66	Response	_	
1-9	67-73	During	_	
1-10	74-82	Monetary	_	
1-11	83-89	Reward	_	
1-12	90-102	Anticipation	_	
1-13	103-105	in	_	
1-14	106-110	Drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-15	111-114	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-16	115-122	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-17	123-133	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-18	134-142	Evidence	_	
1-19	143-151	suggests	_	
1-20	152-156	that	_	
1-21	157-169	disturbances	_	
1-22	170-172	in	_	
1-23	173-188	neurobiological	_	
1-24	189-199	mechanisms	_	
1-25	200-202	of	_	
1-26	203-209	reward	_	
1-27	210-213	and	_	
1-28	214-224	inhibitory	_	
1-29	225-232	control	_	
1-30	233-241	maintain	_	
1-31	242-251	addiction	_	
1-32	252-255	and	_	
1-33	256-263	provoke	_	
1-34	264-271	relapse	_	
1-35	272-278	during	_	
1-36	279-289	abstinence	_	
1-37	289-290	.	_	

#Text=Abnormalities within the dopamine system may contribute to these disturbances and pharmacologically targeting the D3 dopamine receptor (DRD3) is therefore of significant clinical interest.
2-1	291-304	Abnormalities	_	
2-2	305-311	within	_	
2-3	312-315	the	_	
2-4	316-324	dopamine	_	
2-5	325-331	system	_	
2-6	332-335	may	_	
2-7	336-346	contribute	_	
2-8	347-349	to	_	
2-9	350-355	these	_	
2-10	356-368	disturbances	_	
2-11	369-372	and	_	
2-12	373-390	pharmacologically	_	
2-13	391-400	targeting	_	
2-14	401-404	the	_	
2-15	405-407	D3	_	
2-16	408-416	dopamine	_	
2-17	417-425	receptor	_	
2-18	426-427	(	_	
2-19	427-431	DRD3	_	
2-20	431-432	)	_	
2-21	433-435	is	_	
2-22	436-445	therefore	_	
2-23	446-448	of	_	
2-24	449-460	significant	_	
2-25	461-469	clinical	_	
2-26	470-478	interest	_	
2-27	478-479	.	_	

#Text=We used functional magnetic resonance imaging to investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay task (MIDT), and response inhibition using the Go/No-Go task (GNGT).
3-1	480-482	We	_	
3-2	483-487	used	_	
3-3	488-498	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-4	499-507	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-5	508-517	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-6	518-525	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[2]	
3-7	526-528	to	_	
3-8	529-540	investigate	_	
3-9	541-544	the	_	
3-10	545-550	acute	_	
3-11	551-558	effects	_	
3-12	559-561	of	_	
3-13	562-565	the	_	
3-14	566-570	DRD3	_	
3-15	571-581	antagonist	_	
3-16	582-591	GSK598809	_	
3-17	592-594	on	_	
3-18	595-607	anticipatory	_	
3-19	608-614	reward	_	
3-20	615-625	processing	_	
3-21	625-626	,	_	
3-22	627-632	using	_	
3-23	633-636	the	_	
3-24	637-645	monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-25	646-655	incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-26	656-661	delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-27	662-666	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-28	667-668	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-29	668-672	MIDT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-30	672-673	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[3]	
3-31	673-674	,	_	
3-32	675-678	and	_	
3-33	679-687	response	_	
3-34	688-698	inhibition	_	
3-35	699-704	using	_	
3-36	705-708	the	_	
3-37	709-711	Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-38	711-712	/	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-39	712-717	No-Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-40	718-722	task	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-41	723-724	(	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-42	724-728	GNGT	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-43	728-729	)	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[4]	
3-44	729-730	.	_	

#Text=A double-blind, placebo-controlled, crossover design approach was used in abstinent alcohol dependent, abstinent poly-drug dependent and healthy control volunteers.
4-1	731-732	A	_	
4-2	733-745	double-blind	_	
4-3	745-746	,	_	
4-4	747-765	placebo-controlled	_	
4-5	765-766	,	_	
4-6	767-776	crossover	_	
4-7	777-783	design	_	
4-8	784-792	approach	_	
4-9	793-796	was	_	
4-10	797-801	used	_	
4-11	802-804	in	_	
4-12	805-814	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[6]	
4-13	815-822	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[6]	
4-14	823-832	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[6]	
4-15	832-833	,	_	
4-16	834-843	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[7]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[8]	
4-17	844-853	poly-drug	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[7]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[8]	
4-18	854-863	dependent	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[7]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[8]	
4-19	864-867	and	_	
4-20	868-875	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
4-21	876-883	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
4-22	884-894	volunteers	_	
4-23	894-895	.	_	

#Text=For the MIDT, there was evidence of blunted ventral striatal response to reward in the poly-drug-dependent group under placebo.
5-1	896-899	For	_	
5-2	900-903	the	_	
5-3	904-908	MIDT	_	
5-4	908-909	,	_	
5-5	910-915	there	_	
5-6	916-919	was	_	
5-7	920-928	evidence	_	
5-8	929-931	of	_	
5-9	932-939	blunted	_	
5-10	940-947	ventral	_	
5-11	948-956	striatal	_	
5-12	957-965	response	_	
5-13	966-968	to	_	
5-14	969-975	reward	_	
5-15	976-978	in	_	
5-16	979-982	the	_	
5-17	983-1002	poly-drug-dependent	_	
5-18	1003-1008	group	_	
5-19	1009-1014	under	_	
5-20	1015-1022	placebo	_	
5-21	1022-1023	.	_	

#Text=GSK598809 normalized ventral striatal reward response and enhanced response in the DRD3-rich regions of the ventral pallidum and substantia nigra.
6-1	1024-1033	GSK598809	_	
6-2	1034-1044	normalized	_	
6-3	1045-1052	ventral	_	
6-4	1053-1061	striatal	_	
6-5	1062-1068	reward	_	
6-6	1069-1077	response	_	
6-7	1078-1081	and	_	
6-8	1082-1090	enhanced	_	
6-9	1091-1099	response	_	
6-10	1100-1102	in	_	
6-11	1103-1106	the	_	
6-12	1107-1111	DRD3	_	
6-13	1111-1112	-	_	
6-14	1112-1116	rich	_	
6-15	1117-1124	regions	_	
6-16	1125-1127	of	_	
6-17	1128-1131	the	_	
6-18	1132-1139	ventral	_	
6-19	1140-1148	pallidum	_	
6-20	1149-1152	and	_	
6-21	1153-1163	substantia	_	
6-22	1164-1169	nigra	_	
6-23	1169-1170	.	_	

#Text=Exploratory investigations suggested that the effects of GSK598809 were mainly driven by those with primary dependence on alcohol but not on opiates.
7-1	1171-1182	Exploratory	_	
7-2	1183-1197	investigations	_	
7-3	1198-1207	suggested	_	
7-4	1208-1212	that	_	
7-5	1213-1216	the	_	
7-6	1217-1224	effects	_	
7-7	1225-1227	of	_	
7-8	1228-1237	GSK598809	_	
7-9	1238-1242	were	_	
7-10	1243-1249	mainly	_	
7-11	1250-1256	driven	_	
7-12	1257-1259	by	_	
7-13	1260-1265	those	_	
7-14	1266-1270	with	_	
7-15	1271-1278	primary	_	
7-16	1279-1289	dependence	_	
7-17	1290-1292	on	_	
7-18	1293-1300	alcohol	_	
7-19	1301-1304	but	_	
7-20	1305-1308	not	_	
7-21	1309-1311	on	_	
7-22	1312-1319	opiates	_	
7-23	1319-1320	.	_	

#Text=Taken together, these findings suggest that GSK598809 may remediate reward deficits in substance dependence.
8-1	1321-1326	Taken	_	
8-2	1327-1335	together	_	
8-3	1335-1336	,	_	
8-4	1337-1342	these	_	
8-5	1343-1351	findings	_	
8-6	1352-1359	suggest	_	
8-7	1360-1364	that	_	
8-8	1365-1374	GSK598809	_	
8-9	1375-1378	may	_	
8-10	1379-1388	remediate	_	
8-11	1389-1395	reward	_	
8-12	1396-1404	deficits	_	
8-13	1405-1407	in	_	
8-14	1408-1417	substance	_	
8-15	1418-1428	dependence	_	
8-16	1428-1429	.	_	

#Text=For the GNGT, enhanced response in the inferior frontal cortex of the poly-drug group was found.
9-1	1430-1433	For	_	
9-2	1434-1437	the	_	
9-3	1438-1442	GNGT	_	
9-4	1442-1443	,	_	
9-5	1444-1452	enhanced	_	
9-6	1453-1461	response	_	
9-7	1462-1464	in	_	
9-8	1465-1468	the	_	
9-9	1469-1477	inferior	_	
9-10	1478-1485	frontal	_	
9-11	1486-1492	cortex	_	
9-12	1493-1495	of	_	
9-13	1496-1499	the	_	
9-14	1500-1509	poly-drug	_	
9-15	1510-1515	group	_	
9-16	1516-1519	was	_	
9-17	1520-1525	found	_	
9-18	1525-1526	.	_	

#Text=However, there were no effects of GSK598809 on the neural network underlying response inhibition nor were there any behavioral drug effects on response inhibition.
10-1	1527-1534	However	_	
10-2	1534-1535	,	_	
10-3	1536-1541	there	_	
10-4	1542-1546	were	_	
10-5	1547-1549	no	_	
10-6	1550-1557	effects	_	
10-7	1558-1560	of	_	
10-8	1561-1570	GSK598809	_	
10-9	1571-1573	on	_	
10-10	1574-1577	the	_	
10-11	1578-1584	neural	_	
10-12	1585-1592	network	_	
10-13	1593-1603	underlying	_	
10-14	1604-1612	response	_	
10-15	1613-1623	inhibition	_	
10-16	1624-1627	nor	_	
10-17	1628-1632	were	_	
10-18	1633-1638	there	_	
10-19	1639-1642	any	_	
10-20	1643-1653	behavioral	_	
10-21	1654-1658	drug	_	
10-22	1659-1666	effects	_	
10-23	1667-1669	on	_	
10-24	1670-1678	response	_	
10-25	1679-1689	inhibition	_	
10-26	1689-1690	.	_	

#Text=GSK598809 modulated the neural network underlying reward anticipation but not response inhibition, suggesting that DRD3 antagonists may restore reward deficits in addiction.
11-1	1691-1700	GSK598809	_	
11-2	1701-1710	modulated	_	
11-3	1711-1714	the	_	
11-4	1715-1721	neural	_	
11-5	1722-1729	network	_	
11-6	1730-1740	underlying	_	
11-7	1741-1747	reward	_	
11-8	1748-1760	anticipation	_	
11-9	1761-1764	but	_	
11-10	1765-1768	not	_	
11-11	1769-1777	response	_	
11-12	1778-1788	inhibition	_	
11-13	1788-1789	,	_	
11-14	1790-1800	suggesting	_	
11-15	1801-1805	that	_	
11-16	1806-1810	DRD3	_	
11-17	1811-1822	antagonists	_	
11-18	1823-1826	may	_	
11-19	1827-1834	restore	_	
11-20	1835-1841	reward	_	
11-21	1842-1850	deficits	_	
11-22	1851-1853	in	_	
11-23	1854-1863	addiction	_	
11-24	1863-1864	.	_	

#Text=INTRODUCTION
#Text=Evidence suggests dysregulation of neurobiological networks involved in reward processing and inhibitory control contributes to the risk and maintenance of addiction and relapse during abstinence.
12-1	1865-1877	INTRODUCTION	_	
12-2	1878-1886	Evidence	_	
12-3	1887-1895	suggests	_	
12-4	1896-1909	dysregulation	_	
12-5	1910-1912	of	_	
12-6	1913-1928	neurobiological	_	
12-7	1929-1937	networks	_	
12-8	1938-1946	involved	_	
12-9	1947-1949	in	_	
12-10	1950-1956	reward	_	
12-11	1957-1967	processing	_	
12-12	1968-1971	and	_	
12-13	1972-1982	inhibitory	_	
12-14	1983-1990	control	_	
12-15	1991-2002	contributes	_	
12-16	2003-2005	to	_	
12-17	2006-2009	the	_	
12-18	2010-2014	risk	_	
12-19	2015-2018	and	_	
12-20	2019-2030	maintenance	_	
12-21	2031-2033	of	_	
12-22	2034-2043	addiction	_	
12-23	2044-2047	and	_	
12-24	2048-2055	relapse	_	
12-25	2056-2062	during	_	
12-26	2063-2073	abstinence	_	
12-27	2073-2074	.	_	

#Text=Disturbances in reward functioning involve hyporesponsivity to non-drug reward, which is associated with increased craving, drug use, and brain response to drug-related stimuli.
13-1	2075-2087	Disturbances	_	
13-2	2088-2090	in	_	
13-3	2091-2097	reward	_	
13-4	2098-2109	functioning	_	
13-5	2110-2117	involve	_	
13-6	2118-2134	hyporesponsivity	_	
13-7	2135-2137	to	_	
13-8	2138-2146	non-drug	_	
13-9	2147-2153	reward	_	
13-10	2153-2154	,	_	
13-11	2155-2160	which	_	
13-12	2161-2163	is	_	
13-13	2164-2174	associated	_	
13-14	2175-2179	with	_	
13-15	2180-2189	increased	_	
13-16	2190-2197	craving	_	
13-17	2197-2198	,	_	
13-18	2199-2203	drug	_	
13-19	2204-2207	use	_	
13-20	2207-2208	,	_	
13-21	2209-2212	and	_	
13-22	2213-2218	brain	_	
13-23	2219-2227	response	_	
13-24	2228-2230	to	_	
13-25	2231-2243	drug-related	_	
13-26	2244-2251	stimuli	_	
13-27	2251-2252	.	_	

#Text=Failures of impulse control across a range of domains have been a consistent finding in addiction and are associated with relapse. fMRI studies implicate reduced recruitment of lateral and medial prefrontal regions in impaired impulse control, although enhanced recruitment has been found in those who have successfully achieved abstinence from cocaine.
14-1	2253-2261	Failures	_	
14-2	2262-2264	of	_	
14-3	2265-2272	impulse	_	
14-4	2273-2280	control	_	
14-5	2281-2287	across	_	
14-6	2288-2289	a	_	
14-7	2290-2295	range	_	
14-8	2296-2298	of	_	
14-9	2299-2306	domains	_	
14-10	2307-2311	have	_	
14-11	2312-2316	been	_	
14-12	2317-2318	a	_	
14-13	2319-2329	consistent	_	
14-14	2330-2337	finding	_	
14-15	2338-2340	in	_	
14-16	2341-2350	addiction	_	
14-17	2351-2354	and	_	
14-18	2355-2358	are	_	
14-19	2359-2369	associated	_	
14-20	2370-2374	with	_	
14-21	2375-2382	relapse	_	
14-22	2382-2383	.	_	
14-23	2384-2388	fMRI	_	
14-24	2389-2396	studies	_	
14-25	2397-2406	implicate	_	
14-26	2407-2414	reduced	_	
14-27	2415-2426	recruitment	_	
14-28	2427-2429	of	_	
14-29	2430-2437	lateral	_	
14-30	2438-2441	and	_	
14-31	2442-2448	medial	_	
14-32	2449-2459	prefrontal	_	
14-33	2460-2467	regions	_	
14-34	2468-2470	in	_	
14-35	2471-2479	impaired	_	
14-36	2480-2487	impulse	_	
14-37	2488-2495	control	_	
14-38	2495-2496	,	_	
14-39	2497-2505	although	_	
14-40	2506-2514	enhanced	_	
14-41	2515-2526	recruitment	_	
14-42	2527-2530	has	_	
14-43	2531-2535	been	_	
14-44	2536-2541	found	_	
14-45	2542-2544	in	_	
14-46	2545-2550	those	_	
14-47	2551-2554	who	_	
14-48	2555-2559	have	_	
14-49	2560-2572	successfully	_	
14-50	2573-2581	achieved	_	
14-51	2582-2592	abstinence	_	
14-52	2593-2597	from	_	
14-53	2598-2605	cocaine	_	
14-54	2605-2606	.	_	

#Text=Abnormalities in reward and impulse control may be effects of blunted dopamine signaling in addiction.
15-1	2607-2620	Abnormalities	_	
15-2	2621-2623	in	_	
15-3	2624-2630	reward	_	
15-4	2631-2634	and	_	
15-5	2635-2642	impulse	_	
15-6	2643-2650	control	_	
15-7	2651-2654	may	_	
15-8	2655-2657	be	_	
15-9	2658-2665	effects	_	
15-10	2666-2668	of	_	
15-11	2669-2676	blunted	_	
15-12	2677-2685	dopamine	_	
15-13	2686-2695	signaling	_	
15-14	2696-2698	in	_	
15-15	2699-2708	addiction	_	
15-16	2708-2709	.	_	

#Text=Reductions in dopamine release and receptor density are associated with increased drug use and craving and may precede the development of addiction.
16-1	2710-2720	Reductions	_	
16-2	2721-2723	in	_	
16-3	2724-2732	dopamine	_	
16-4	2733-2740	release	_	
16-5	2741-2744	and	_	
16-6	2745-2753	receptor	_	
16-7	2754-2761	density	_	
16-8	2762-2765	are	_	
16-9	2766-2776	associated	_	
16-10	2777-2781	with	_	
16-11	2782-2791	increased	_	
16-12	2792-2796	drug	_	
16-13	2797-2800	use	_	
16-14	2801-2804	and	_	
16-15	2805-2812	craving	_	
16-16	2813-2816	and	_	
16-17	2817-2820	may	_	
16-18	2821-2828	precede	_	
16-19	2829-2832	the	_	
16-20	2833-2844	development	_	
16-21	2845-2847	of	_	
16-22	2848-2857	addiction	_	
16-23	2857-2858	.	_	

#Text=Dopamine has a pivotal role in reward-related behaviors, mediating reward learning and ‘incentive salience’ of reward stimuli.
17-1	2859-2867	Dopamine	_	
17-2	2868-2871	has	_	
17-3	2872-2873	a	_	
17-4	2874-2881	pivotal	_	
17-5	2882-2886	role	_	
17-6	2887-2889	in	_	
17-7	2890-2904	reward-related	_	
17-8	2905-2914	behaviors	_	
17-9	2914-2915	,	_	
17-10	2916-2925	mediating	_	
17-11	2926-2932	reward	_	
17-12	2933-2941	learning	_	
17-13	2942-2945	and	_	
17-14	2946-2947	‘	_	
17-15	2947-2956	incentive	_	
17-16	2957-2965	salience	_	
17-17	2965-2966	’	_	
17-18	2967-2969	of	_	
17-19	2970-2976	reward	_	
17-20	2977-2984	stimuli	_	
17-21	2984-2985	.	_	

#Text=Deficits in dopamine neurotransmission may impair impulse control, as low striatal D2/D3 binding is associated with increased impulsivity in rodents and humans.
18-1	2986-2994	Deficits	_	
18-2	2995-2997	in	_	
18-3	2998-3006	dopamine	_	
18-4	3007-3024	neurotransmission	_	
18-5	3025-3028	may	_	
18-6	3029-3035	impair	_	
18-7	3036-3043	impulse	_	
18-8	3044-3051	control	_	
18-9	3051-3052	,	_	
18-10	3053-3055	as	_	
18-11	3056-3059	low	_	
18-12	3060-3068	striatal	_	
18-13	3069-3071	D2	_	
18-14	3071-3072	/	_	
18-15	3072-3074	D3	_	
18-16	3075-3082	binding	_	
18-17	3083-3085	is	_	
18-18	3086-3096	associated	_	
18-19	3097-3101	with	_	
18-20	3102-3111	increased	_	
18-21	3112-3123	impulsivity	_	
18-22	3124-3126	in	_	
18-23	3127-3134	rodents	_	
18-24	3135-3138	and	_	
18-25	3139-3145	humans	_	
18-26	3145-3146	.	_	

#Text=Drugs increasing extracellular dopamine improve response inhibition in cocaine and alcohol dependence.
19-1	3147-3152	Drugs	_	
19-2	3153-3163	increasing	_	
19-3	3164-3177	extracellular	_	
19-4	3178-3186	dopamine	_	
19-5	3187-3194	improve	_	
19-6	3195-3203	response	_	
19-7	3204-3214	inhibition	_	
19-8	3215-3217	in	_	
19-9	3218-3225	cocaine	_	
19-10	3226-3229	and	_	
19-11	3230-3237	alcohol	_	
19-12	3238-3248	dependence	_	
19-13	3248-3249	.	_	

#Text=These lines of evidence suggest that increasing brain dopamine may be a useful therapeutic strategy for addiction.
20-1	3250-3255	These	_	
20-2	3256-3261	lines	_	
20-3	3262-3264	of	_	
20-4	3265-3273	evidence	_	
20-5	3274-3281	suggest	_	
20-6	3282-3286	that	_	
20-7	3287-3297	increasing	_	
20-8	3298-3303	brain	_	
20-9	3304-3312	dopamine	_	
20-10	3313-3316	may	_	
20-11	3317-3319	be	_	
20-12	3320-3321	a	_	
20-13	3322-3328	useful	_	
20-14	3329-3340	therapeutic	_	
20-15	3341-3349	strategy	_	
20-16	3350-3353	for	_	
20-17	3354-3363	addiction	_	
20-18	3363-3364	.	_	

#Text=The D3 receptor (DRD3) is preferentially expressed within ventral striatal and limbic brain regions involved in reward processing.
21-1	3365-3368	The	_	
21-2	3369-3371	D3	_	
21-3	3372-3380	receptor	_	
21-4	3381-3382	(	_	
21-5	3382-3386	DRD3	_	
21-6	3386-3387	)	_	
21-7	3388-3390	is	_	
21-8	3391-3405	preferentially	_	
21-9	3406-3415	expressed	_	
21-10	3416-3422	within	_	
21-11	3423-3430	ventral	_	
21-12	3431-3439	striatal	_	
21-13	3440-3443	and	_	
21-14	3444-3450	limbic	_	
21-15	3451-3456	brain	_	
21-16	3457-3464	regions	_	
21-17	3465-3473	involved	_	
21-18	3474-3476	in	_	
21-19	3477-3483	reward	_	
21-20	3484-3494	processing	_	
21-21	3494-3495	.	_	

#Text=In vitro studies demonstrate the highest density of DRD3s within the ventral striatum of the human brain, whereas in vivo human positron emission tomography (PET) studies demonstrated maximal DRD3 density within the ventral pallidum (VP), followed by the substantia nigra (SN) and ventral striatum (VS), with lower levels in thalamus and dorsal striatum.
22-1	3496-3498	In	_	
22-2	3499-3504	vitro	_	
22-3	3505-3512	studies	_	
22-4	3513-3524	demonstrate	_	
22-5	3525-3528	the	_	
22-6	3529-3536	highest	_	
22-7	3537-3544	density	_	
22-8	3545-3547	of	_	
22-9	3548-3553	DRD3s	_	
22-10	3554-3560	within	_	
22-11	3561-3564	the	_	
22-12	3565-3572	ventral	_	
22-13	3573-3581	striatum	_	
22-14	3582-3584	of	_	
22-15	3585-3588	the	_	
22-16	3589-3594	human	_	
22-17	3595-3600	brain	_	
22-18	3600-3601	,	_	
22-19	3602-3609	whereas	_	
22-20	3610-3612	in	_	
22-21	3613-3617	vivo	_	
22-22	3618-3623	human	_	
22-23	3624-3632	positron	_	
22-24	3633-3641	emission	_	
22-25	3642-3652	tomography	_	
22-26	3653-3654	(	_	
22-27	3654-3657	PET	_	
22-28	3657-3658	)	_	
22-29	3659-3666	studies	_	
22-30	3667-3679	demonstrated	_	
22-31	3680-3687	maximal	_	
22-32	3688-3692	DRD3	_	
22-33	3693-3700	density	_	
22-34	3701-3707	within	_	
22-35	3708-3711	the	_	
22-36	3712-3719	ventral	_	
22-37	3720-3728	pallidum	_	
22-38	3729-3730	(	_	
22-39	3730-3732	VP	_	
22-40	3732-3733	)	_	
22-41	3733-3734	,	_	
22-42	3735-3743	followed	_	
22-43	3744-3746	by	_	
22-44	3747-3750	the	_	
22-45	3751-3761	substantia	_	
22-46	3762-3767	nigra	_	
22-47	3768-3769	(	_	
22-48	3769-3771	SN	_	
22-49	3771-3772	)	_	
22-50	3773-3776	and	_	
22-51	3777-3784	ventral	_	
22-52	3785-3793	striatum	_	
22-53	3794-3795	(	_	
22-54	3795-3797	VS	_	
22-55	3797-3798	)	_	
22-56	3798-3799	,	_	
22-57	3800-3804	with	_	
22-58	3805-3810	lower	_	
22-59	3811-3817	levels	_	
22-60	3818-3820	in	_	
22-61	3821-3829	thalamus	_	
22-62	3830-3833	and	_	
22-63	3834-3840	dorsal	_	
22-64	3841-3849	striatum	_	
22-65	3849-3850	.	_	

#Text=Exposure to drugs of abuse results in upregulation of DRD3 in rodent models of addiction.
23-1	3851-3859	Exposure	_	
23-2	3860-3862	to	_	
23-3	3863-3868	drugs	_	
23-4	3869-3871	of	_	
23-5	3872-3877	abuse	_	
23-6	3878-3885	results	_	
23-7	3886-3888	in	_	
23-8	3889-3901	upregulation	_	
23-9	3902-3904	of	_	
23-10	3905-3909	DRD3	_	
23-11	3910-3912	in	_	
23-12	3913-3919	rodent	_	
23-13	3920-3926	models	_	
23-14	3927-3929	of	_	
23-15	3930-3939	addiction	_	
23-16	3939-3940	.	_	

#Text=Upregulated DRD3 density has been found within the VS and SN in a postmortem study of cocaine dependence while upregulated nigral DRD3s correlated positively with impulsivity and risky decision making in stimulant dependence.
24-1	3941-3952	Upregulated	_	
24-2	3953-3957	DRD3	_	
24-3	3958-3965	density	_	
24-4	3966-3969	has	_	
24-5	3970-3974	been	_	
24-6	3975-3980	found	_	
24-7	3981-3987	within	_	
24-8	3988-3991	the	_	
24-9	3992-3994	VS	_	
24-10	3995-3998	and	_	
24-11	3999-4001	SN	_	
24-12	4002-4004	in	_	
24-13	4005-4006	a	_	
24-14	4007-4017	postmortem	_	
24-15	4018-4023	study	_	
24-16	4024-4026	of	_	
24-17	4027-4034	cocaine	_	
24-18	4035-4045	dependence	_	
24-19	4046-4051	while	_	
24-20	4052-4063	upregulated	_	
24-21	4064-4070	nigral	_	
24-22	4071-4076	DRD3s	_	
24-23	4077-4087	correlated	_	
24-24	4088-4098	positively	_	
24-25	4099-4103	with	_	
24-26	4104-4115	impulsivity	_	
24-27	4116-4119	and	_	
24-28	4120-4125	risky	_	
24-29	4126-4134	decision	_	
24-30	4135-4141	making	_	
24-31	4142-4144	in	_	
24-32	4145-4154	stimulant	_	
24-33	4155-4165	dependence	_	
24-34	4165-4166	.	_	

#Text=Trends for upregulated ventral pallidal DRD3 have been found in both alcohol dependence and heavy stimulant use.
25-1	4167-4173	Trends	_	
25-2	4174-4177	for	_	
25-3	4178-4189	upregulated	_	
25-4	4190-4197	ventral	_	
25-5	4198-4206	pallidal	_	
25-6	4207-4211	DRD3	_	
25-7	4212-4216	have	_	
25-8	4217-4221	been	_	
25-9	4222-4227	found	_	
25-10	4228-4230	in	_	
25-11	4231-4235	both	_	
25-12	4236-4243	alcohol	_	
25-13	4244-4254	dependence	_	
25-14	4255-4258	and	_	
25-15	4259-4264	heavy	_	
25-16	4265-4274	stimulant	_	
25-17	4275-4278	use	_	
25-18	4278-4279	.	_	

#Text=Consequently, there is much interest in this receptor as a target for drug therapy.
26-1	4280-4292	Consequently	_	
26-2	4292-4293	,	_	
26-3	4294-4299	there	_	
26-4	4300-4302	is	_	
26-5	4303-4307	much	_	
26-6	4308-4316	interest	_	
26-7	4317-4319	in	_	
26-8	4320-4324	this	_	
26-9	4325-4333	receptor	_	
26-10	4334-4336	as	_	
26-11	4337-4338	a	_	
26-12	4339-4345	target	_	
26-13	4346-4349	for	_	
26-14	4350-4354	drug	_	
26-15	4355-4362	therapy	_	
26-16	4362-4363	.	_	

#Text=DRD3 antagonists have shown promise in preclinical studies, reducing self-administration, cue-induced drug-seeking, and conditioned place preference.
27-1	4364-4368	DRD3	_	
27-2	4369-4380	antagonists	_	
27-3	4381-4385	have	_	
27-4	4386-4391	shown	_	
27-5	4392-4399	promise	_	
27-6	4400-4402	in	_	
27-7	4403-4414	preclinical	_	
27-8	4415-4422	studies	_	
27-9	4422-4423	,	_	
27-10	4424-4432	reducing	_	
27-11	4433-4452	self-administration	_	
27-12	4452-4453	,	_	
27-13	4454-4465	cue-induced	_	
27-14	4466-4478	drug-seeking	_	
27-15	4478-4479	,	_	
27-16	4480-4483	and	_	
27-17	4484-4495	conditioned	_	
27-18	4496-4501	place	_	
27-19	4502-4512	preference	_	
27-20	4512-4513	.	_	

#Text=In clinical populations, the novel DRD3 antagonist GSK598809 transiently reduced craving in nicotine dependence and attentional bias for food cues in low restrained eaters.
28-1	4514-4516	In	_	
28-2	4517-4525	clinical	_	
28-3	4526-4537	populations	_	
28-4	4537-4538	,	_	
28-5	4539-4542	the	_	
28-6	4543-4548	novel	_	
28-7	4549-4553	DRD3	_	
28-8	4554-4564	antagonist	_	
28-9	4565-4574	GSK598809	_	
28-10	4575-4586	transiently	_	
28-11	4587-4594	reduced	_	
28-12	4595-4602	craving	_	
28-13	4603-4605	in	_	
28-14	4606-4614	nicotine	_	
28-15	4615-4625	dependence	_	
28-16	4626-4629	and	_	
28-17	4630-4641	attentional	_	
28-18	4642-4646	bias	_	
28-19	4647-4650	for	_	
28-20	4651-4655	food	_	
28-21	4656-4660	cues	_	
28-22	4661-4663	in	_	
28-23	4664-4667	low	_	
28-24	4668-4678	restrained	_	
28-25	4679-4685	eaters	_	
28-26	4685-4686	.	_	

#Text=The exact mechanism by which DRD3 antagonists achieve these effects is currently unknown, although there is evidence that the DRD3 is an autoreceptor controlling the synthesis and release of dopamine.
29-1	4687-4690	The	_	
29-2	4691-4696	exact	_	
29-3	4697-4706	mechanism	_	
29-4	4707-4709	by	_	
29-5	4710-4715	which	_	
29-6	4716-4720	DRD3	_	
29-7	4721-4732	antagonists	_	
29-8	4733-4740	achieve	_	
29-9	4741-4746	these	_	
29-10	4747-4754	effects	_	
29-11	4755-4757	is	_	
29-12	4758-4767	currently	_	
29-13	4768-4775	unknown	_	
29-14	4775-4776	,	_	
29-15	4777-4785	although	_	
29-16	4786-4791	there	_	
29-17	4792-4794	is	_	
29-18	4795-4803	evidence	_	
29-19	4804-4808	that	_	
29-20	4809-4812	the	_	
29-21	4813-4817	DRD3	_	
29-22	4818-4820	is	_	
29-23	4821-4823	an	_	
29-24	4824-4836	autoreceptor	_	
29-25	4837-4848	controlling	_	
29-26	4849-4852	the	_	
29-27	4853-4862	synthesis	_	
29-28	4863-4866	and	_	
29-29	4867-4874	release	_	
29-30	4875-4877	of	_	
29-31	4878-4886	dopamine	_	
29-32	4886-4887	.	_	

#Text=Blockade of DRD3 with GSK598809 may therefore increase extra-synaptic dopamine.
30-1	4888-4896	Blockade	_	
30-2	4897-4899	of	_	
30-3	4900-4904	DRD3	_	
30-4	4905-4909	with	_	
30-5	4910-4919	GSK598809	_	
30-6	4920-4923	may	_	
30-7	4924-4933	therefore	_	
30-8	4934-4942	increase	_	
30-9	4943-4957	extra-synaptic	_	
30-10	4958-4966	dopamine	_	
30-11	4966-4967	.	_	

#Text=The ICCAM Platform study is a multicenter research study that aimed to (1) identify brain networks underlying addiction to alcohol, cocaine, and opiates and relapse vulnerability and (2) identify potential new treatments for addiction based on their ability to modulate these networks.
31-1	4968-4971	The	_	
31-2	4972-4977	ICCAM	_	
31-3	4978-4986	Platform	_	
31-4	4987-4992	study	_	
31-5	4993-4995	is	_	
31-6	4996-4997	a	_	
31-7	4998-5009	multicenter	_	
31-8	5010-5018	research	_	
31-9	5019-5024	study	_	
31-10	5025-5029	that	_	
31-11	5030-5035	aimed	_	
31-12	5036-5038	to	_	
31-13	5039-5040	(	_	
31-14	5040-5041	1	_	
31-15	5041-5042	)	_	
31-16	5043-5051	identify	_	
31-17	5052-5057	brain	_	
31-18	5058-5066	networks	_	
31-19	5067-5077	underlying	_	
31-20	5078-5087	addiction	_	
31-21	5088-5090	to	_	
31-22	5091-5098	alcohol	_	
31-23	5098-5099	,	_	
31-24	5100-5107	cocaine	_	
31-25	5107-5108	,	_	
31-26	5109-5112	and	_	
31-27	5113-5120	opiates	_	
31-28	5121-5124	and	_	
31-29	5125-5132	relapse	_	
31-30	5133-5146	vulnerability	_	
31-31	5147-5150	and	_	
31-32	5151-5152	(	_	
31-33	5152-5153	2	_	
31-34	5153-5154	)	_	
31-35	5155-5163	identify	_	
31-36	5164-5173	potential	_	
31-37	5174-5177	new	_	
31-38	5178-5188	treatments	_	
31-39	5189-5192	for	_	
31-40	5193-5202	addiction	_	
31-41	5203-5208	based	_	
31-42	5209-5211	on	_	
31-43	5212-5217	their	_	
31-44	5218-5225	ability	_	
31-45	5226-5228	to	_	
31-46	5229-5237	modulate	_	
31-47	5238-5243	these	_	
31-48	5244-5252	networks	_	
31-49	5252-5253	.	_	

#Text=Here we present the effects of GSK598809 on networks underlying the anticipation of reward, using the monetary incentive delay task (MIDT) and response inhibition using the Go/No-Go task (GNGT).
32-1	5254-5258	Here	_	
32-2	5259-5261	we	_	
32-3	5262-5269	present	_	
32-4	5270-5273	the	_	
32-5	5274-5281	effects	_	
32-6	5282-5284	of	_	
32-7	5285-5294	GSK598809	_	
32-8	5295-5297	on	_	
32-9	5298-5306	networks	_	
32-10	5307-5317	underlying	_	
32-11	5318-5321	the	_	
32-12	5322-5334	anticipation	_	
32-13	5335-5337	of	_	
32-14	5338-5344	reward	_	
32-15	5344-5345	,	_	
32-16	5346-5351	using	_	
32-17	5352-5355	the	_	
32-18	5356-5364	monetary	_	
32-19	5365-5374	incentive	_	
32-20	5375-5380	delay	_	
32-21	5381-5385	task	_	
32-22	5386-5387	(	_	
32-23	5387-5391	MIDT	_	
32-24	5391-5392	)	_	
32-25	5393-5396	and	_	
32-26	5397-5405	response	_	
32-27	5406-5416	inhibition	_	
32-28	5417-5422	using	_	
32-29	5423-5426	the	_	
32-30	5427-5429	Go	_	
32-31	5429-5430	/	_	
32-32	5430-5435	No-Go	_	
32-33	5436-5440	task	_	
32-34	5441-5442	(	_	
32-35	5442-5446	GNGT	_	
32-36	5446-5447	)	_	
32-37	5447-5448	.	_	

#Text=We hypothesized that reward and inhibitory control disturbances would be found in abstinent drug-dependent individuals and that GSK598809 would mitigate such disturbances.
33-1	5449-5451	We	_	
33-2	5452-5464	hypothesized	_	
33-3	5465-5469	that	_	
33-4	5470-5476	reward	_	
33-5	5477-5480	and	_	
33-6	5481-5491	inhibitory	_	
33-7	5492-5499	control	_	
33-8	5500-5512	disturbances	_	
33-9	5513-5518	would	_	
33-10	5519-5521	be	_	
33-11	5522-5527	found	_	
33-12	5528-5530	in	_	
33-13	5531-5540	abstinent	_	
33-14	5541-5555	drug-dependent	_	
33-15	5556-5567	individuals	_	
33-16	5568-5571	and	_	
33-17	5572-5576	that	_	
33-18	5577-5586	GSK598809	_	
33-19	5587-5592	would	_	
33-20	5593-5601	mitigate	_	
33-21	5602-5606	such	_	
33-22	5607-5619	disturbances	_	
33-23	5619-5620	.	_	

#Text=MATERIALS AND METHODS
#Text=Participants
#Text=Participants were recruited as part of the ICCAM multicenter study.
34-1	5621-5630	MATERIALS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
34-2	5631-5634	AND	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
34-3	5635-5642	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod[10]	
34-4	5643-5655	Participants	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-5	5656-5668	Participants	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-6	5669-5673	were	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-7	5674-5683	recruited	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-8	5684-5686	as	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-9	5687-5691	part	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-10	5692-5694	of	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-11	5695-5698	the	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-12	5699-5704	ICCAM	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-13	5705-5716	multicenter	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-14	5717-5722	study	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
34-15	5722-5723	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	

#Text=Detailed description of recruitment and participant characteristics are described elsewhere.
35-1	5724-5732	Detailed	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-2	5733-5744	description	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-3	5745-5747	of	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-4	5748-5759	recruitment	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-5	5760-5763	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-6	5764-5775	participant	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-7	5776-5791	characteristics	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-8	5792-5795	are	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-9	5796-5805	described	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-10	5806-5815	elsewhere	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
35-11	5815-5816	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	

#Text=Briefly, substance-dependent individuals were recruited according to the following criteria: aged 20–64 years, meeting DSM-IV (American Psychiatric Association, 2000) criteria for current or prior alcohol, cocaine or opiate dependence, abstinent for at least 4 weeks, free from any current primary axis-1 mental health disorder, no history of severe enduring mental illness, no psychoactive medications, no serious physical health problems, no neurological disease, and no contraindications for MRI scanning.
36-1	5817-5824	Briefly	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-2	5824-5825	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-3	5826-5845	substance-dependent	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
36-4	5846-5857	individuals	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[12]	
36-5	5858-5862	were	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-6	5863-5872	recruited	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-7	5873-5882	according	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-8	5883-5885	to	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-9	5886-5889	the	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-10	5890-5899	following	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-11	5900-5908	criteria	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-12	5908-5909	:	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-13	5910-5914	aged	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-14	5915-5917	20	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-15	5917-5918	–	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-16	5918-5920	64	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-17	5921-5926	years	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-18	5926-5927	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-19	5928-5935	meeting	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-20	5936-5942	DSM-IV	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-21	5943-5944	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-22	5944-5952	American	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-23	5953-5964	Psychiatric	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-24	5965-5976	Association	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-25	5976-5977	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-26	5978-5982	2000	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-27	5982-5983	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-28	5984-5992	criteria	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-29	5993-5996	for	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-30	5997-6004	current	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-31	6005-6007	or	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-32	6008-6013	prior	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-33	6014-6021	alcohol	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-34	6021-6022	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-35	6023-6030	cocaine	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-36	6031-6033	or	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-37	6034-6040	opiate	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-38	6041-6051	dependence	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-39	6051-6052	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-40	6053-6062	abstinent	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-41	6063-6066	for	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-42	6067-6069	at	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-43	6070-6075	least	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-44	6076-6077	4	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-45	6078-6083	weeks	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-46	6083-6084	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-47	6085-6089	free	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-48	6090-6094	from	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-49	6095-6098	any	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-50	6099-6106	current	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-51	6107-6114	primary	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-52	6115-6119	axis	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-53	6119-6120	-	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-54	6120-6121	1	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-55	6122-6128	mental	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-56	6129-6135	health	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-57	6136-6144	disorder	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-58	6144-6145	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-59	6146-6148	no	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-60	6149-6156	history	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-61	6157-6159	of	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-62	6160-6166	severe	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-63	6167-6175	enduring	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-64	6176-6182	mental	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-65	6183-6190	illness	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-66	6190-6191	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-67	6192-6194	no	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-68	6195-6207	psychoactive	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-69	6208-6219	medications	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-70	6219-6220	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-71	6221-6223	no	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-72	6224-6231	serious	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-73	6232-6240	physical	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-74	6241-6247	health	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-75	6248-6256	problems	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-76	6256-6257	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-77	6258-6260	no	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-78	6261-6273	neurological	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-79	6274-6281	disease	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-80	6281-6282	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-81	6283-6286	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-82	6287-6289	no	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-83	6290-6307	contraindications	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-84	6308-6311	for	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-85	6312-6315	MRI	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-86	6316-6324	scanning	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
36-87	6324-6325	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	

#Text=Healthy controls (HC) were recruited according to the same criteria except that they had no current or history of dependence to any drug except nicotine.
37-1	6326-6333	Healthy	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
37-2	6334-6342	controls	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
37-3	6343-6344	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
37-4	6344-6346	HC	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
37-5	6346-6347	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]	
37-6	6348-6352	were	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-7	6353-6362	recruited	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-8	6363-6372	according	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-9	6373-6375	to	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-10	6376-6379	the	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-11	6380-6384	same	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-12	6385-6393	criteria	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-13	6394-6400	except	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-14	6401-6405	that	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-15	6406-6410	they	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-16	6411-6414	had	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-17	6415-6417	no	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-18	6418-6425	current	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-19	6426-6428	or	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-20	6429-6436	history	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-21	6437-6439	of	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-22	6440-6450	dependence	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-23	6451-6453	to	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-24	6454-6457	any	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-25	6458-6462	drug	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-26	6463-6469	except	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-27	6470-6478	nicotine	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
37-28	6478-6479	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	

#Text=Eighty-eight participants completed both placebo and GSK598809 sessions: a HC group (n=35), an abstinent alcohol-dependent (AD) (n=20) and an abstinent poly-drug-dependent (PD) group (n=33).
38-1	6480-6492	Eighty-eight	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-2	6493-6505	participants	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-3	6506-6515	completed	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-4	6516-6520	both	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-5	6521-6528	placebo	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-6	6529-6532	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-7	6533-6542	GSK598809	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-8	6543-6551	sessions	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-9	6551-6552	:	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-10	6553-6554	a	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
38-11	6555-6557	HC	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
38-12	6558-6563	group	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
38-13	6564-6565	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-14	6565-6566	n	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-15	6566-6567	=	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-16	6567-6569	35	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-17	6569-6570	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-18	6570-6571	,	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-19	6572-6574	an	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-20	6575-6584	abstinent	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[15]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
38-21	6585-6602	alcohol-dependent	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[15]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
38-22	6603-6604	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[15]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
38-23	6604-6606	AD	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[15]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
38-24	6606-6607	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[15]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[16]	
38-25	6608-6609	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-26	6609-6610	n	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-27	6610-6611	=	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-28	6611-6613	20	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-29	6613-6614	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-30	6615-6618	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-31	6619-6621	an	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-32	6622-6631	abstinent	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[18]	
38-33	6632-6651	poly-drug-dependent	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[18]	
38-34	6652-6653	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[18]	
38-35	6653-6655	PD	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[18]	
38-36	6655-6656	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[18]	
38-37	6657-6662	group	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[17]|http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[18]	
38-38	6663-6664	(	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-39	6664-6665	n	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-40	6665-6666	=	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-41	6666-6668	33	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-42	6668-6669	)	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	
38-43	6669-6670	.	http://www.case.edu/ProvCaRe/provcare#StudyMethod[11]	

#Text=Five people were excluded from the MID analysis, and 14 from the GNG analysis leaving final Ns of 83 and 74, respectively (see Supplementary Materials for details).
39-1	6671-6675	Five	_	
39-2	6676-6682	people	_	
39-3	6683-6687	were	_	
39-4	6688-6696	excluded	_	
39-5	6697-6701	from	_	
39-6	6702-6705	the	_	
39-7	6706-6709	MID	_	
39-8	6710-6718	analysis	_	
39-9	6718-6719	,	_	
39-10	6720-6723	and	_	
39-11	6724-6726	14	_	
39-12	6727-6731	from	_	
39-13	6732-6735	the	_	
39-14	6736-6739	GNG	_	
39-15	6740-6748	analysis	_	
39-16	6749-6756	leaving	_	
39-17	6757-6762	final	_	
39-18	6763-6765	Ns	_	
39-19	6766-6768	of	_	
39-20	6769-6771	83	_	
39-21	6772-6775	and	_	
39-22	6776-6778	74	_	
39-23	6778-6779	,	_	
39-24	6780-6792	respectively	_	
39-25	6793-6794	(	_	
39-26	6794-6797	see	_	
39-27	6798-6811	Supplementary	_	
39-28	6812-6821	Materials	_	
39-29	6822-6825	for	_	
39-30	6826-6833	details	_	
39-31	6833-6834	)	_	
39-32	6834-6835	.	_	

#Text=The HC group was matched with the AD and PD groups for age, sex, smoking status, and handedness and additionally with the AD group, but not the PD group, for IQ and years of education (see Supplementary Tables S1 and S2).
40-1	6836-6839	The	_	
40-2	6840-6842	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
40-3	6843-6848	group	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
40-4	6849-6852	was	_	
40-5	6853-6860	matched	_	
40-6	6861-6865	with	_	
40-7	6866-6869	the	_	
40-8	6870-6872	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
40-9	6873-6876	and	_	
40-10	6877-6879	PD	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[20]	
40-11	6880-6886	groups	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[20]	
40-12	6887-6890	for	_	
40-13	6891-6894	age	_	
40-14	6894-6895	,	_	
40-15	6896-6899	sex	_	
40-16	6899-6900	,	_	
40-17	6901-6908	smoking	_	
40-18	6909-6915	status	_	
40-19	6915-6916	,	_	
40-20	6917-6920	and	_	
40-21	6921-6931	handedness	_	
40-22	6932-6935	and	_	
40-23	6936-6948	additionally	_	
40-24	6949-6953	with	_	
40-25	6954-6957	the	_	
40-26	6958-6960	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[21]	
40-27	6961-6966	group	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[21]	
40-28	6966-6967	,	_	
40-29	6968-6971	but	_	
40-30	6972-6975	not	_	
40-31	6976-6979	the	_	
40-32	6980-6982	PD	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[22]	
40-33	6983-6988	group	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[22]	
40-34	6988-6989	,	_	
40-35	6990-6993	for	_	
40-36	6994-6996	IQ	_	
40-37	6997-7000	and	_	
40-38	7001-7006	years	_	
40-39	7007-7009	of	_	
40-40	7010-7019	education	_	
40-41	7020-7021	(	_	
40-42	7021-7024	see	_	
40-43	7025-7038	Supplementary	_	
40-44	7039-7045	Tables	_	
40-45	7046-7048	S1	_	
40-46	7049-7052	and	_	
40-47	7053-7055	S2	_	
40-48	7055-7056	)	_	
40-49	7056-7057	.	_	

#Text=AD and PD groups differed significantly for age for the MID analysis, with a trend for a difference for the GNG analysis (p=0.06).
41-1	7058-7060	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
41-2	7061-7064	and	_	
41-3	7065-7067	PD	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[23]	
41-4	7068-7074	groups	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceAbuse[23]	
41-5	7075-7083	differed	_	
41-6	7084-7097	significantly	_	
41-7	7098-7101	for	_	
41-8	7102-7105	age	_	
41-9	7106-7109	for	_	
41-10	7110-7113	the	_	
41-11	7114-7117	MID	_	
41-12	7118-7126	analysis	_	
41-13	7126-7127	,	_	
41-14	7128-7132	with	_	
41-15	7133-7134	a	_	
41-16	7135-7140	trend	_	
41-17	7141-7144	for	_	
41-18	7145-7146	a	_	
41-19	7147-7157	difference	_	
41-20	7158-7161	for	_	
41-21	7162-7165	the	_	
41-22	7166-7169	GNG	_	
41-23	7170-7178	analysis	_	
41-24	7179-7180	(	_	
41-25	7180-7181	p	_	
41-26	7181-7182	=	_	
41-27	7182-7186	0.06	_	
41-28	7186-7187	)	_	
41-29	7187-7188	.	_	

#Text=Procedures and Tasks
#Text=Procedures are described in detail elsewhere.
42-1	7189-7199	Procedures	_	
42-2	7200-7203	and	_	
42-3	7204-7209	Tasks	_	
42-4	7210-7220	Procedures	_	
42-5	7221-7224	are	_	
42-6	7225-7234	described	_	
42-7	7235-7237	in	_	
42-8	7238-7244	detail	_	
42-9	7245-7254	elsewhere	_	
42-10	7254-7255	.	_	

#Text=Briefly, the ICCAM study involved five separate scanning sessions (one screening, including fMRI scanning to familiarize participants with the scanner environment and tasks, and four drug testing sessions).
43-1	7256-7263	Briefly	_	
43-2	7263-7264	,	_	
43-3	7265-7268	the	_	
43-4	7269-7274	ICCAM	_	
43-5	7275-7280	study	_	
43-6	7281-7289	involved	_	
43-7	7290-7294	five	_	
43-8	7295-7303	separate	_	
43-9	7304-7312	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
43-10	7313-7321	sessions	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[24]	
43-11	7322-7323	(	_	
43-12	7323-7326	one	_	
43-13	7327-7336	screening	_	
43-14	7336-7337	,	_	
43-15	7338-7347	including	_	
43-16	7348-7352	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
43-17	7353-7361	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
43-18	7362-7364	to	_	
43-19	7365-7376	familiarize	_	
43-20	7377-7389	participants	_	
43-21	7390-7394	with	_	
43-22	7395-7398	the	_	
43-23	7399-7406	scanner	_	
43-24	7407-7418	environment	_	
43-25	7419-7422	and	_	
43-26	7423-7428	tasks	_	
43-27	7428-7429	,	_	
43-28	7430-7433	and	_	
43-29	7434-7438	four	_	
43-30	7439-7443	drug	_	
43-31	7444-7451	testing	_	
43-32	7452-7460	sessions	_	
43-33	7460-7461	)	_	
43-34	7461-7462	.	_	

#Text=Placebo and GSK598809 (60 mg) were administered in a double-blind manner with a crossover design.
44-1	7463-7470	Placebo	_	
44-2	7471-7474	and	_	
44-3	7475-7484	GSK598809	_	
44-4	7485-7486	(	_	
44-5	7486-7488	60	_	
44-6	7489-7491	mg	_	
44-7	7491-7492	)	_	
44-8	7493-7497	were	_	
44-9	7498-7510	administered	_	
44-10	7511-7513	in	_	
44-11	7514-7515	a	_	
44-12	7516-7528	double-blind	_	
44-13	7529-7535	manner	_	
44-14	7536-7540	with	_	
44-15	7541-7542	a	_	
44-16	7543-7552	crossover	_	
44-17	7553-7559	design	_	
44-18	7559-7560	.	_	

#Text=Owing to concerns over study dropout and loss of placebo data, a weighted randomization was used with the placebo session administered in study session 2 or 3, whereas GSK598809 was administered in session 4 or 5 (with the other two sessions testing other drugs as part of the ICCAM platform).
45-1	7561-7566	Owing	_	
45-2	7567-7569	to	_	
45-3	7570-7578	concerns	_	
45-4	7579-7583	over	_	
45-5	7584-7589	study	_	
45-6	7590-7597	dropout	_	
45-7	7598-7601	and	_	
45-8	7602-7606	loss	_	
45-9	7607-7609	of	_	
45-10	7610-7617	placebo	_	
45-11	7618-7622	data	_	
45-12	7622-7623	,	_	
45-13	7624-7625	a	_	
45-14	7626-7634	weighted	_	
45-15	7635-7648	randomization	_	
45-16	7649-7652	was	_	
45-17	7653-7657	used	_	
45-18	7658-7662	with	_	
45-19	7663-7666	the	_	
45-20	7667-7674	placebo	_	
45-21	7675-7682	session	_	
45-22	7683-7695	administered	_	
45-23	7696-7698	in	_	
45-24	7699-7704	study	_	
45-25	7705-7712	session	_	
45-26	7713-7714	2	_	
45-27	7715-7717	or	_	
45-28	7718-7719	3	_	
45-29	7719-7720	,	_	
45-30	7721-7728	whereas	_	
45-31	7729-7738	GSK598809	_	
45-32	7739-7742	was	_	
45-33	7743-7755	administered	_	
45-34	7756-7758	in	_	
45-35	7759-7766	session	_	
45-36	7767-7768	4	_	
45-37	7769-7771	or	_	
45-38	7772-7773	5	_	
45-39	7774-7775	(	_	
45-40	7775-7779	with	_	
45-41	7780-7783	the	_	
45-42	7784-7789	other	_	
45-43	7790-7793	two	_	
45-44	7794-7802	sessions	_	
45-45	7803-7810	testing	_	
45-46	7811-7816	other	_	
45-47	7817-7822	drugs	_	
45-48	7823-7825	as	_	
45-49	7826-7830	part	_	
45-50	7831-7833	of	_	
45-51	7834-7837	the	_	
45-52	7838-7843	ICCAM	_	
45-53	7844-7852	platform	_	
45-54	7852-7853	)	_	
45-55	7853-7854	.	_	

#Text=The mean (SD) inter-session interval between placebo and GSK598809 sessions was 34.39 days (40.91) (MIDT) and 36.15 days (42.72) (GNGT), with no difference between groups; MID (F(2.80)=0.25, p=0.78), GNG (F(2,71)=0.03, p=0.98).
46-1	7855-7858	The	_	
46-2	7859-7863	mean	_	
46-3	7864-7865	(	_	
46-4	7865-7867	SD	_	
46-5	7867-7868	)	_	
46-6	7869-7882	inter-session	_	
46-7	7883-7891	interval	_	
46-8	7892-7899	between	_	
46-9	7900-7907	placebo	_	
46-10	7908-7911	and	_	
46-11	7912-7921	GSK598809	_	
46-12	7922-7930	sessions	_	
46-13	7931-7934	was	_	
46-14	7935-7940	34.39	_	
46-15	7941-7945	days	_	
46-16	7946-7947	(	_	
46-17	7947-7952	40.91	_	
46-18	7952-7953	)	_	
46-19	7954-7955	(	_	
46-20	7955-7959	MIDT	_	
46-21	7959-7960	)	_	
46-22	7961-7964	and	_	
46-23	7965-7970	36.15	_	
46-24	7971-7975	days	_	
46-25	7976-7977	(	_	
46-26	7977-7982	42.72	_	
46-27	7982-7983	)	_	
46-28	7984-7985	(	_	
46-29	7985-7989	GNGT	_	
46-30	7989-7990	)	_	
46-31	7990-7991	,	_	
46-32	7992-7996	with	_	
46-33	7997-7999	no	_	
46-34	8000-8010	difference	_	
46-35	8011-8018	between	_	
46-36	8019-8025	groups	_	
46-37	8025-8026	;	_	
46-38	8027-8030	MID	_	
46-39	8031-8032	(	_	
46-40	8032-8033	F	_	
46-41	8033-8034	(	_	
46-42	8034-8038	2.80	_	
46-43	8038-8039	)	_	
46-44	8039-8040	=	_	
46-45	8040-8044	0.25	_	
46-46	8044-8045	,	_	
46-47	8046-8047	p	_	
46-48	8047-8048	=	_	
46-49	8048-8052	0.78	_	
46-50	8052-8053	)	_	
46-51	8053-8054	,	_	
46-52	8055-8058	GNG	_	
46-53	8059-8060	(	_	
46-54	8060-8061	F	_	
46-55	8061-8062	(	_	
46-56	8062-8066	2,71	_	
46-57	8066-8067	)	_	
46-58	8067-8068	=	_	
46-59	8068-8072	0.03	_	
46-60	8072-8073	,	_	
46-61	8074-8075	p	_	
46-62	8075-8076	=	_	
46-63	8076-8080	0.98	_	
46-64	8080-8081	)	_	
46-65	8081-8082	.	_	

#Text=Scans occurred 2 h after administration of drug or placebo and tasks were practiced before scanning.
47-1	8083-8088	Scans	_	
47-2	8089-8097	occurred	_	
47-3	8098-8099	2	_	
47-4	8100-8101	h	_	
47-5	8102-8107	after	_	
47-6	8108-8122	administration	_	
47-7	8123-8125	of	_	
47-8	8126-8130	drug	_	
47-9	8131-8133	or	_	
47-10	8134-8141	placebo	_	
47-11	8142-8145	and	_	
47-12	8146-8151	tasks	_	
47-13	8152-8156	were	_	
47-14	8157-8166	practiced	_	
47-15	8167-8173	before	_	
47-16	8174-8182	scanning	_	
47-17	8182-8183	.	_	

#Text=All participants had an alcohol breathalyzer reading of 0.0%.
48-1	8184-8187	All	_	
48-2	8188-8200	participants	_	
48-3	8201-8204	had	_	
48-4	8205-8207	an	_	
48-5	8208-8215	alcohol	_	
48-6	8216-8228	breathalyzer	_	
48-7	8229-8236	reading	_	
48-8	8237-8239	of	_	
48-9	8240-8244	0.0%	_	
48-10	8244-8245	.	_	

#Text=Participants were urine screened.
49-1	8246-8258	Participants	_	
49-2	8259-8263	were	_	
49-3	8264-8269	urine	_	
49-4	8270-8278	screened	_	
49-5	8278-8279	.	_	

#Text=A positive test for cannabis was allowed owing to its long half-life provided there was no use in the previous week.
50-1	8280-8281	A	_	
50-2	8282-8290	positive	_	
50-3	8291-8295	test	_	
50-4	8296-8299	for	_	
50-5	8300-8308	cannabis	_	
50-6	8309-8312	was	_	
50-7	8313-8320	allowed	_	
50-8	8321-8326	owing	_	
50-9	8327-8329	to	_	
50-10	8330-8333	its	_	
50-11	8334-8338	long	_	
50-12	8339-8348	half-life	_	
50-13	8349-8357	provided	_	
50-14	8358-8363	there	_	
50-15	8364-8367	was	_	
50-16	8368-8370	no	_	
50-17	8371-8374	use	_	
50-18	8375-8377	in	_	
50-19	8378-8381	the	_	
50-20	8382-8390	previous	_	
50-21	8391-8395	week	_	
50-22	8395-8396	.	_	

#Text=Participants tested negative for all other drugs, with two allowed exceptions (see Supplementary Materials).
51-1	8397-8409	Participants	_	
51-2	8410-8416	tested	_	
51-3	8417-8425	negative	_	
51-4	8426-8429	for	_	
51-5	8430-8433	all	_	
51-6	8434-8439	other	_	
51-7	8440-8445	drugs	_	
51-8	8445-8446	,	_	
51-9	8447-8451	with	_	
51-10	8452-8455	two	_	
51-11	8456-8463	allowed	_	
51-12	8464-8474	exceptions	_	
51-13	8475-8476	(	_	
51-14	8476-8479	see	_	
51-15	8480-8493	Supplementary	_	
51-16	8494-8503	Materials	_	
51-17	8503-8504	)	_	
51-18	8504-8505	.	_	

#Text=Tasks
#Text=Both the MIDT and GNGT are described in detail within Supplementary Materials.
52-1	8506-8511	Tasks	_	
52-2	8512-8516	Both	_	
52-3	8517-8520	the	_	
52-4	8521-8525	MIDT	_	
52-5	8526-8529	and	_	
52-6	8530-8534	GNGT	_	
52-7	8535-8538	are	_	
52-8	8539-8548	described	_	
52-9	8549-8551	in	_	
52-10	8552-8558	detail	_	
52-11	8559-8565	within	_	
52-12	8566-8579	Supplementary	_	
52-13	8580-8589	Materials	_	
52-14	8589-8590	.	_	

#Text=The MIDT was modified from and was designed to probe reward sensitivity.
53-1	8591-8594	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-2	8595-8599	MIDT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-3	8600-8603	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-4	8604-8612	modified	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-5	8613-8617	from	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-6	8618-8621	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-7	8622-8625	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-8	8626-8634	designed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-9	8635-8637	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-10	8638-8643	probe	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-11	8644-8650	reward	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-12	8651-8662	sensitivity	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	
53-13	8662-8663	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[26]	

#Text=Participants could win or lose money (or neither win nor lose) depending upon how quickly they reacted to a target stimulus that was predicted by a win, loss, or neutral cue.
54-1	8664-8676	Participants	_	
54-2	8677-8682	could	_	
54-3	8683-8686	win	_	
54-4	8687-8689	or	_	
54-5	8690-8694	lose	_	
54-6	8695-8700	money	_	
54-7	8701-8702	(	_	
54-8	8702-8704	or	_	
54-9	8705-8712	neither	_	
54-10	8713-8716	win	_	
54-11	8717-8720	nor	_	
54-12	8721-8725	lose	_	
54-13	8725-8726	)	_	
54-14	8727-8736	depending	_	
54-15	8737-8741	upon	_	
54-16	8742-8745	how	_	
54-17	8746-8753	quickly	_	
54-18	8754-8758	they	_	
54-19	8759-8766	reacted	_	
54-20	8767-8769	to	_	
54-21	8770-8771	a	_	
54-22	8772-8778	target	_	
54-23	8779-8787	stimulus	_	
54-24	8788-8792	that	_	
54-25	8793-8796	was	_	
54-26	8797-8806	predicted	_	
54-27	8807-8809	by	_	
54-28	8810-8811	a	_	
54-29	8812-8815	win	_	
54-30	8815-8816	,	_	
54-31	8817-8821	loss	_	
54-32	8821-8822	,	_	
54-33	8823-8825	or	_	
54-34	8826-8833	neutral	_	
54-35	8834-8837	cue	_	
54-36	8837-8838	.	_	

#Text=The task was designed such that win accuracy would be 66% and £10 would be won at each session.
55-1	8839-8842	The	_	
55-2	8843-8847	task	_	
55-3	8848-8851	was	_	
55-4	8852-8860	designed	_	
55-5	8861-8865	such	_	
55-6	8866-8870	that	_	
55-7	8871-8874	win	_	
55-8	8875-8883	accuracy	_	
55-9	8884-8889	would	_	
55-10	8890-8892	be	_	
55-11	8893-8896	66%	_	
55-12	8897-8900	and	_	
55-13	8901-8904	£10	_	
55-14	8905-8910	would	_	
55-15	8911-8913	be	_	
55-16	8914-8917	won	_	
55-17	8918-8920	at	_	
55-18	8921-8925	each	_	
55-19	8926-8933	session	_	
55-20	8933-8934	.	_	

#Text=The GNGT was an event-related task adapted from, consisting of a series of letter Xs and letter Ys.
56-1	8935-8938	The	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-2	8939-8943	GNGT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-3	8944-8947	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-4	8948-8950	an	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-5	8951-8964	event-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-6	8965-8969	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-7	8970-8977	adapted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-8	8978-8982	from	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-9	8982-8983	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-10	8984-8994	consisting	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-11	8995-8997	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-12	8998-8999	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-13	9000-9006	series	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-14	9007-9009	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-15	9010-9016	letter	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-16	9017-9019	Xs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-17	9020-9023	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-18	9024-9030	letter	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-19	9031-9033	Ys	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
56-20	9033-9034	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	

#Text=Participants were instructed to respond as fast as they could to each letter (Go trial) except when the letter was the same as the previous letter (No-Go trial).
57-1	9035-9047	Participants	_	
57-2	9048-9052	were	_	
57-3	9053-9063	instructed	_	
57-4	9064-9066	to	_	
57-5	9067-9074	respond	_	
57-6	9075-9077	as	_	
57-7	9078-9082	fast	_	
57-8	9083-9085	as	_	
57-9	9086-9090	they	_	
57-10	9091-9096	could	_	
57-11	9097-9099	to	_	
57-12	9100-9104	each	_	
57-13	9105-9111	letter	_	
57-14	9112-9113	(	_	
57-15	9113-9115	Go	_	
57-16	9116-9121	trial	_	
57-17	9121-9122	)	_	
57-18	9123-9129	except	_	
57-19	9130-9134	when	_	
57-20	9135-9138	the	_	
57-21	9139-9145	letter	_	
57-22	9146-9149	was	_	
57-23	9150-9153	the	_	
57-24	9154-9158	same	_	
57-25	9159-9161	as	_	
57-26	9162-9165	the	_	
57-27	9166-9174	previous	_	
57-28	9175-9181	letter	_	
57-29	9182-9183	(	_	
57-30	9183-9188	No-Go	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[28]	
57-31	9189-9194	trial	http://maven.renci.org/NeuroBridge/neurobridge#GoNoGoTask[28]	
57-32	9194-9195	)	_	
57-33	9195-9196	.	_	

#Text=Analysis of Behavioral Data
#Text=For the MIDT, reward-neutral reaction time (RT) was analyzed.
58-1	9197-9205	Analysis	_	
58-2	9206-9208	of	_	
58-3	9209-9219	Behavioral	_	
58-4	9220-9224	Data	_	
58-5	9225-9228	For	_	
58-6	9229-9232	the	_	
58-7	9233-9237	MIDT	_	
58-8	9237-9238	,	_	
58-9	9239-9253	reward-neutral	_	
58-10	9254-9262	reaction	_	
58-11	9263-9267	time	_	
58-12	9268-9269	(	_	
58-13	9269-9271	RT	_	
58-14	9271-9272	)	_	
58-15	9273-9276	was	_	
58-16	9277-9285	analyzed	_	
58-17	9285-9286	.	_	

#Text=For the GNGT, percentage accuracy for Go trials and No-Go trials and RT for Go trials were analyzed.
59-1	9287-9290	For	_	
59-2	9291-9294	the	_	
59-3	9295-9299	GNGT	_	
59-4	9299-9300	,	_	
59-5	9301-9311	percentage	_	
59-6	9312-9320	accuracy	_	
59-7	9321-9324	for	_	
59-8	9325-9327	Go	_	
59-9	9328-9334	trials	_	
59-10	9335-9338	and	_	
59-11	9339-9344	No-Go	_	
59-12	9345-9351	trials	_	
59-13	9352-9355	and	_	
59-14	9356-9358	RT	_	
59-15	9359-9362	for	_	
59-16	9363-9365	Go	_	
59-17	9366-9372	trials	_	
59-18	9373-9377	were	_	
59-19	9378-9386	analyzed	_	
59-20	9386-9387	.	_	

#Text=All analyses used mixed ANOVAs with drug session as the within-subject factor and group as the between-subject factor.
60-1	9388-9391	All	_	
60-2	9392-9400	analyses	_	
60-3	9401-9405	used	_	
60-4	9406-9411	mixed	_	
60-5	9412-9418	ANOVAs	_	
60-6	9419-9423	with	_	
60-7	9424-9428	drug	_	
60-8	9429-9436	session	_	
60-9	9437-9439	as	_	
60-10	9440-9443	the	_	
60-11	9444-9458	within-subject	_	
60-12	9459-9465	factor	_	
60-13	9466-9469	and	_	
60-14	9470-9475	group	_	
60-15	9476-9478	as	_	
60-16	9479-9482	the	_	
60-17	9483-9498	between-subject	_	
60-18	9499-9505	factor	_	
60-19	9505-9506	.	_	

#Text=Age was included as a mean-adjusted covariate in all analyses.
61-1	9507-9510	Age	_	
61-2	9511-9514	was	_	
61-3	9515-9523	included	_	
61-4	9524-9526	as	_	
61-5	9527-9528	a	_	
61-6	9529-9542	mean-adjusted	_	
61-7	9543-9552	covariate	_	
61-8	9553-9555	in	_	
61-9	9556-9559	all	_	
61-10	9560-9568	analyses	_	
61-11	9568-9569	.	_	

#Text=Analysis of fMRI Data
#Text=Details of data acquisition and preprocessing are in Supplementary Materials.
62-1	9570-9578	Analysis	_	
62-2	9579-9581	of	_	
62-3	9582-9586	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[29]	
62-4	9587-9591	Data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[29]	
62-5	9592-9599	Details	_	
62-6	9600-9602	of	_	
62-7	9603-9607	data	_	
62-8	9608-9619	acquisition	_	
62-9	9620-9623	and	_	
62-10	9624-9637	preprocessing	_	
62-11	9638-9641	are	_	
62-12	9642-9644	in	_	
62-13	9645-9658	Supplementary	_	
62-14	9659-9668	Materials	_	
62-15	9668-9669	.	_	

#Text=For the MIDT, analysis focused on the ‘cue and anticipation’ phase and was modeled as a mini-block beginning at the cue onset and ending at the onset of the target stimulus (see Supplementary Materials for details).
63-1	9670-9673	For	_	
63-2	9674-9677	the	_	
63-3	9678-9682	MIDT	_	
63-4	9682-9683	,	_	
63-5	9684-9692	analysis	_	
63-6	9693-9700	focused	_	
63-7	9701-9703	on	_	
63-8	9704-9707	the	_	
63-9	9708-9709	‘	_	
63-10	9709-9712	cue	_	
63-11	9713-9716	and	_	
63-12	9717-9729	anticipation	_	
63-13	9729-9730	’	_	
63-14	9731-9736	phase	_	
63-15	9737-9740	and	_	
63-16	9741-9744	was	_	
63-17	9745-9752	modeled	_	
63-18	9753-9755	as	_	
63-19	9756-9757	a	_	
63-20	9758-9768	mini-block	_	
63-21	9769-9778	beginning	_	
63-22	9779-9781	at	_	
63-23	9782-9785	the	_	
63-24	9786-9789	cue	_	
63-25	9790-9795	onset	_	
63-26	9796-9799	and	_	
63-27	9800-9806	ending	_	
63-28	9807-9809	at	_	
63-29	9810-9813	the	_	
63-30	9814-9819	onset	_	
63-31	9820-9822	of	_	
63-32	9823-9826	the	_	
63-33	9827-9833	target	_	
63-34	9834-9842	stimulus	_	
63-35	9843-9844	(	_	
63-36	9844-9847	see	_	
63-37	9848-9861	Supplementary	_	
63-38	9862-9871	Materials	_	
63-39	9872-9875	for	_	
63-40	9876-9883	details	_	
63-41	9883-9884	)	_	
63-42	9884-9885	.	_	

#Text=The contrast of interest is the average of the ‘reward cue anticipation’ compared with ‘neutral cue anticipation’ across both runs.
64-1	9886-9889	The	_	
64-2	9890-9898	contrast	_	
64-3	9899-9901	of	_	
64-4	9902-9910	interest	_	
64-5	9911-9913	is	_	
64-6	9914-9917	the	_	
64-7	9918-9925	average	_	
64-8	9926-9928	of	_	
64-9	9929-9932	the	_	
64-10	9933-9934	‘	_	
64-11	9934-9940	reward	_	
64-12	9941-9944	cue	_	
64-13	9945-9957	anticipation	_	
64-14	9957-9958	’	_	
64-15	9959-9967	compared	_	
64-16	9968-9972	with	_	
64-17	9973-9974	‘	_	
64-18	9974-9981	neutral	_	
64-19	9982-9985	cue	_	
64-20	9986-9998	anticipation	_	
64-21	9998-9999	’	_	
64-22	10000-10006	across	_	
64-23	10007-10011	both	_	
64-24	10012-10016	runs	_	
64-25	10016-10017	.	_	

#Text=For the GNGT, successful inhibitions of No-Go trials (‘stops’) and unsuccessful No-Gos (‘errors’) were modeled against an implicit baseline of Go trials.
65-1	10018-10021	For	_	
65-2	10022-10025	the	_	
65-3	10026-10030	GNGT	_	
65-4	10030-10031	,	_	
65-5	10032-10042	successful	_	
65-6	10043-10054	inhibitions	_	
65-7	10055-10057	of	_	
65-8	10058-10063	No-Go	_	
65-9	10064-10070	trials	_	
65-10	10071-10072	(	_	
65-11	10072-10073	‘	_	
65-12	10073-10078	stops	_	
65-13	10078-10079	’	_	
65-14	10079-10080	)	_	
65-15	10081-10084	and	_	
65-16	10085-10097	unsuccessful	_	
65-17	10098-10104	No-Gos	_	
65-18	10105-10106	(	_	
65-19	10106-10107	‘	_	
65-20	10107-10113	errors	_	
65-21	10113-10114	’	_	
65-22	10114-10115	)	_	
65-23	10116-10120	were	_	
65-24	10121-10128	modeled	_	
65-25	10129-10136	against	_	
65-26	10137-10139	an	_	
65-27	10140-10148	implicit	_	
65-28	10149-10157	baseline	_	
65-29	10158-10160	of	_	
65-30	10161-10163	Go	_	
65-31	10164-10170	trials	_	
65-32	10170-10171	.	_	

#Text=Stops that were preceded by a Go trial that also did not have a response were considered ‘fake inhibitions’ and were modeled separately as conditions of no-interest.
66-1	10172-10177	Stops	_	
66-2	10178-10182	that	_	
66-3	10183-10187	were	_	
66-4	10188-10196	preceded	_	
66-5	10197-10199	by	_	
66-6	10200-10201	a	_	
66-7	10202-10204	Go	_	
66-8	10205-10210	trial	_	
66-9	10211-10215	that	_	
66-10	10216-10220	also	_	
66-11	10221-10224	did	_	
66-12	10225-10228	not	_	
66-13	10229-10233	have	_	
66-14	10234-10235	a	_	
66-15	10236-10244	response	_	
66-16	10245-10249	were	_	
66-17	10250-10260	considered	_	
66-18	10261-10262	‘	_	
66-19	10262-10266	fake	_	
66-20	10267-10278	inhibitions	_	
66-21	10278-10279	’	_	
66-22	10280-10283	and	_	
66-23	10284-10288	were	_	
66-24	10289-10296	modeled	_	
66-25	10297-10307	separately	_	
66-26	10308-10310	as	_	
66-27	10311-10321	conditions	_	
66-28	10322-10324	of	_	
66-29	10325-10336	no-interest	_	
66-30	10336-10337	.	_	

#Text=The task was powered to look at ‘stops’ rather than ‘errors’, therefore only the ‘stops>go’ contrast is explored further.
67-1	10338-10341	The	_	
67-2	10342-10346	task	_	
67-3	10347-10350	was	_	
67-4	10351-10358	powered	_	
67-5	10359-10361	to	_	
67-6	10362-10366	look	_	
67-7	10367-10369	at	_	
67-8	10370-10371	‘	_	
67-9	10371-10376	stops	_	
67-10	10376-10377	’	_	
67-11	10378-10384	rather	_	
67-12	10385-10389	than	_	
67-13	10390-10391	‘	_	
67-14	10391-10397	errors	_	
67-15	10397-10398	’	_	
67-16	10398-10399	,	_	
67-17	10400-10409	therefore	_	
67-18	10410-10414	only	_	
67-19	10415-10418	the	_	
67-20	10419-10420	‘	_	
67-21	10420-10425	stops	_	
67-22	10425-10426	>	_	
67-23	10426-10428	go	_	
67-24	10428-10429	’	_	
67-25	10430-10438	contrast	_	
67-26	10439-10441	is	_	
67-27	10442-10450	explored	_	
67-28	10451-10458	further	_	
67-29	10458-10459	.	_	

#Text=Realignment parameters and movement outliers (scan-to-scan displacement of >3 mm) were added to the models as nuisance regressors.
68-1	10460-10471	Realignment	_	
68-2	10472-10482	parameters	_	
68-3	10483-10486	and	_	
68-4	10487-10495	movement	_	
68-5	10496-10504	outliers	_	
68-6	10505-10506	(	_	
68-7	10506-10518	scan-to-scan	_	
68-8	10519-10531	displacement	_	
68-9	10532-10534	of	_	
68-10	10535-10536	>	_	
68-11	10536-10537	3	_	
68-12	10538-10540	mm	_	
68-13	10540-10541	)	_	
68-14	10542-10546	were	_	
68-15	10547-10552	added	_	
68-16	10553-10555	to	_	
68-17	10556-10559	the	_	
68-18	10560-10566	models	_	
68-19	10567-10569	as	_	
68-20	10570-10578	nuisance	_	
68-21	10579-10589	regressors	_	
68-22	10589-10590	.	_	

#Text=A region of interest (ROI) approach was used.
69-1	10591-10592	A	_	
69-2	10593-10599	region	_	
69-3	10600-10602	of	_	
69-4	10603-10611	interest	_	
69-5	10612-10613	(	_	
69-6	10613-10616	ROI	_	
69-7	10616-10617	)	_	
69-8	10618-10626	approach	_	
69-9	10627-10630	was	_	
69-10	10631-10635	used	_	
69-11	10635-10636	.	_	

#Text=ROIs of the VS, VP, and SN were chosen for the MIDT owing to their key roles in reward processing and evidence of abnormalities within these regions in addiction.
70-1	10637-10641	ROIs	_	
70-2	10642-10644	of	_	
70-3	10645-10648	the	_	
70-4	10649-10651	VS	_	
70-5	10651-10652	,	_	
70-6	10653-10655	VP	_	
70-7	10655-10656	,	_	
70-8	10657-10660	and	_	
70-9	10661-10663	SN	_	
70-10	10664-10668	were	_	
70-11	10669-10675	chosen	_	
70-12	10676-10679	for	_	
70-13	10680-10683	the	_	
70-14	10684-10688	MIDT	_	
70-15	10689-10694	owing	_	
70-16	10695-10697	to	_	
70-17	10698-10703	their	_	
70-18	10704-10707	key	_	
70-19	10708-10713	roles	_	
70-20	10714-10716	in	_	
70-21	10717-10723	reward	_	
70-22	10724-10734	processing	_	
70-23	10735-10738	and	_	
70-24	10739-10747	evidence	_	
70-25	10748-10750	of	_	
70-26	10751-10764	abnormalities	_	
70-27	10765-10771	within	_	
70-28	10772-10777	these	_	
70-29	10778-10785	regions	_	
70-30	10786-10788	in	_	
70-31	10789-10798	addiction	_	
70-32	10798-10799	.	_	

#Text=Additionally, as reviewed above, these regions are particularly rich in DRD3s and therefore are potential targets for GSK598809 effects.
71-1	10800-10812	Additionally	_	
71-2	10812-10813	,	_	
71-3	10814-10816	as	_	
71-4	10817-10825	reviewed	_	
71-5	10826-10831	above	_	
71-6	10831-10832	,	_	
71-7	10833-10838	these	_	
71-8	10839-10846	regions	_	
71-9	10847-10850	are	_	
71-10	10851-10863	particularly	_	
71-11	10864-10868	rich	_	
71-12	10869-10871	in	_	
71-13	10872-10877	DRD3s	_	
71-14	10878-10881	and	_	
71-15	10882-10891	therefore	_	
71-16	10892-10895	are	_	
71-17	10896-10905	potential	_	
71-18	10906-10913	targets	_	
71-19	10914-10917	for	_	
71-20	10918-10927	GSK598809	_	
71-21	10928-10935	effects	_	
71-22	10935-10936	.	_	

#Text=For the GNGT, bilateral inferior frontal gyri (IFG) and anterior cingulate cortex were chosen owing to their key role in motor inhibition and abnormal recruitment in addiction.
72-1	10937-10940	For	_	
72-2	10941-10944	the	_	
72-3	10945-10949	GNGT	_	
72-4	10949-10950	,	_	
72-5	10951-10960	bilateral	_	
72-6	10961-10969	inferior	_	
72-7	10970-10977	frontal	_	
72-8	10978-10982	gyri	_	
72-9	10983-10984	(	_	
72-10	10984-10987	IFG	_	
72-11	10987-10988	)	_	
72-12	10989-10992	and	_	
72-13	10993-11001	anterior	_	
72-14	11002-11011	cingulate	_	
72-15	11012-11018	cortex	_	
72-16	11019-11023	were	_	
72-17	11024-11030	chosen	_	
72-18	11031-11036	owing	_	
72-19	11037-11039	to	_	
72-20	11040-11045	their	_	
72-21	11046-11049	key	_	
72-22	11050-11054	role	_	
72-23	11055-11057	in	_	
72-24	11058-11063	motor	_	
72-25	11064-11074	inhibition	_	
72-26	11075-11078	and	_	
72-27	11079-11087	abnormal	_	
72-28	11088-11099	recruitment	_	
72-29	11100-11102	in	_	
72-30	11103-11112	addiction	_	
72-31	11112-11113	.	_	

#Text=While not key ROIs for this task, exploratory investigations were also carried out with the DRD3-rich regions of VS, VP, and SN.
73-1	11114-11119	While	_	
73-2	11120-11123	not	_	
73-3	11124-11127	key	_	
73-4	11128-11132	ROIs	_	
73-5	11133-11136	for	_	
73-6	11137-11141	this	_	
73-7	11142-11146	task	_	
73-8	11146-11147	,	_	
73-9	11148-11159	exploratory	_	
73-10	11160-11174	investigations	_	
73-11	11175-11179	were	_	
73-12	11180-11184	also	_	
73-13	11185-11192	carried	_	
73-14	11193-11196	out	_	
73-15	11197-11201	with	_	
73-16	11202-11205	the	_	
73-17	11206-11210	DRD3	_	
73-18	11210-11211	-	_	
73-19	11211-11215	rich	_	
73-20	11216-11223	regions	_	
73-21	11224-11226	of	_	
73-22	11227-11229	VS	_	
73-23	11229-11230	,	_	
73-24	11231-11233	VP	_	
73-25	11233-11234	,	_	
73-26	11235-11238	and	_	
73-27	11239-11241	SN	_	
73-28	11241-11242	.	_	

#Text=Mean reward-neutral (MID) and stop-go (GNG) contrast estimates were extracted from the relevant ROIs for each participant and entered into mixed ANOVAs (see Supplementary Materials for details).
74-1	11243-11247	Mean	_	
74-2	11248-11262	reward-neutral	_	
74-3	11263-11264	(	_	
74-4	11264-11267	MID	_	
74-5	11267-11268	)	_	
74-6	11269-11272	and	_	
74-7	11273-11280	stop-go	_	
74-8	11281-11282	(	_	
74-9	11282-11285	GNG	_	
74-10	11285-11286	)	_	
74-11	11287-11295	contrast	_	
74-12	11296-11305	estimates	_	
74-13	11306-11310	were	_	
74-14	11311-11320	extracted	_	
74-15	11321-11325	from	_	
74-16	11326-11329	the	_	
74-17	11330-11338	relevant	_	
74-18	11339-11343	ROIs	_	
74-19	11344-11347	for	_	
74-20	11348-11352	each	_	
74-21	11353-11364	participant	_	
74-22	11365-11368	and	_	
74-23	11369-11376	entered	_	
74-24	11377-11381	into	_	
74-25	11382-11387	mixed	_	
74-26	11388-11394	ANOVAs	_	
74-27	11395-11396	(	_	
74-28	11396-11399	see	_	
74-29	11400-11413	Supplementary	_	
74-30	11414-11423	Materials	_	
74-31	11424-11427	for	_	
74-32	11428-11435	details	_	
74-33	11435-11436	)	_	
74-34	11436-11437	.	_	

#Text=A Bonferroni’s correction for the three regions investigated for each task was applied, with significance set at p<0.017.
75-1	11438-11439	A	_	
75-2	11440-11450	Bonferroni	_	
75-3	11450-11451	’	_	
75-4	11451-11452	s	_	
75-5	11453-11463	correction	_	
75-6	11464-11467	for	_	
75-7	11468-11471	the	_	
75-8	11472-11477	three	_	
75-9	11478-11485	regions	_	
75-10	11486-11498	investigated	_	
75-11	11499-11502	for	_	
75-12	11503-11507	each	_	
75-13	11508-11512	task	_	
75-14	11513-11516	was	_	
75-15	11517-11524	applied	_	
75-16	11524-11525	,	_	
75-17	11526-11530	with	_	
75-18	11531-11543	significance	_	
75-19	11544-11547	set	_	
75-20	11548-11550	at	_	
75-21	11551-11552	p	_	
75-22	11552-11553	<	_	
75-23	11553-11558	0.017	_	
75-24	11558-11559	.	_	

#Text=Additional exploratory whole-brain investigations were carried out using a voxel-wise threshold of p<0.05, Family-Wise Error Corrected (see Figure 1 for ROIs and Supplementary Materials for further details).
76-1	11560-11570	Additional	_	
76-2	11571-11582	exploratory	_	
76-3	11583-11594	whole-brain	_	
76-4	11595-11609	investigations	_	
76-5	11610-11614	were	_	
76-6	11615-11622	carried	_	
76-7	11623-11626	out	_	
76-8	11627-11632	using	_	
76-9	11633-11634	a	_	
76-10	11635-11645	voxel-wise	_	
76-11	11646-11655	threshold	_	
76-12	11656-11658	of	_	
76-13	11659-11660	p	_	
76-14	11660-11661	<	_	
76-15	11661-11665	0.05	_	
76-16	11665-11666	,	_	
76-17	11667-11678	Family-Wise	_	
76-18	11679-11684	Error	_	
76-19	11685-11694	Corrected	_	
76-20	11695-11696	(	_	
76-21	11696-11699	see	_	
76-22	11700-11706	Figure	_	
76-23	11707-11708	1	_	
76-24	11709-11712	for	_	
76-25	11713-11717	ROIs	_	
76-26	11718-11721	and	_	
76-27	11722-11735	Supplementary	_	
76-28	11736-11745	Materials	_	
76-29	11746-11749	for	_	
76-30	11750-11757	further	_	
76-31	11758-11765	details	_	
76-32	11765-11766	)	_	
76-33	11766-11767	.	_	

#Text=Correlational analyses were additionally carried out to investigate the relationships between ROI brain response and performance, reward and impulsivity variables, ROI brain response and duration of abstinence, and drug effects on ROI response and performance (see Supplementary Materials for details).
77-1	11768-11781	Correlational	_	
77-2	11782-11790	analyses	_	
77-3	11791-11795	were	_	
77-4	11796-11808	additionally	_	
77-5	11809-11816	carried	_	
77-6	11817-11820	out	_	
77-7	11821-11823	to	_	
77-8	11824-11835	investigate	_	
77-9	11836-11839	the	_	
77-10	11840-11853	relationships	_	
77-11	11854-11861	between	_	
77-12	11862-11865	ROI	_	
77-13	11866-11871	brain	_	
77-14	11872-11880	response	_	
77-15	11881-11884	and	_	
77-16	11885-11896	performance	_	
77-17	11896-11897	,	_	
77-18	11898-11904	reward	_	
77-19	11905-11908	and	_	
77-20	11909-11920	impulsivity	_	
77-21	11921-11930	variables	_	
77-22	11930-11931	,	_	
77-23	11932-11935	ROI	_	
77-24	11936-11941	brain	_	
77-25	11942-11950	response	_	
77-26	11951-11954	and	_	
77-27	11955-11963	duration	_	
77-28	11964-11966	of	_	
77-29	11967-11977	abstinence	_	
77-30	11977-11978	,	_	
77-31	11979-11982	and	_	
77-32	11983-11987	drug	_	
77-33	11988-11995	effects	_	
77-34	11996-11998	on	_	
77-35	11999-12002	ROI	_	
77-36	12003-12011	response	_	
77-37	12012-12015	and	_	
77-38	12016-12027	performance	_	
77-39	12028-12029	(	_	
77-40	12029-12032	see	_	
77-41	12033-12046	Supplementary	_	
77-42	12047-12056	Materials	_	
77-43	12057-12060	for	_	
77-44	12061-12068	details	_	
77-45	12068-12069	)	_	
77-46	12069-12070	.	_	

#Text=Twenty-nine analyses were carried out and Bonferroni-corrected significance was set at p<0.0017.
78-1	12071-12082	Twenty-nine	_	
78-2	12083-12091	analyses	_	
78-3	12092-12096	were	_	
78-4	12097-12104	carried	_	
78-5	12105-12108	out	_	
78-6	12109-12112	and	_	
78-7	12113-12133	Bonferroni-corrected	_	
78-8	12134-12146	significance	_	
78-9	12147-12150	was	_	
78-10	12151-12154	set	_	
78-11	12155-12157	at	_	
78-12	12158-12159	p	_	
78-13	12159-12160	<	_	
78-14	12160-12166	0.0017	_	
78-15	12166-12167	.	_	

#Text=RESULTS
#Text=MID Behavioral
#Text=There were no significant drug or group effects or interactions for MID performance (see Supplementary Figure S1).
79-1	12168-12175	RESULTS	_	
79-2	12176-12179	MID	_	
79-3	12180-12190	Behavioral	_	
79-4	12191-12196	There	_	
79-5	12197-12201	were	_	
79-6	12202-12204	no	_	
79-7	12205-12216	significant	_	
79-8	12217-12221	drug	_	
79-9	12222-12224	or	_	
79-10	12225-12230	group	_	
79-11	12231-12238	effects	_	
79-12	12239-12241	or	_	
79-13	12242-12254	interactions	_	
79-14	12255-12258	for	_	
79-15	12259-12262	MID	_	
79-16	12263-12274	performance	_	
79-17	12275-12276	(	_	
79-18	12276-12279	see	_	
79-19	12280-12293	Supplementary	_	
79-20	12294-12300	Figure	_	
79-21	12301-12303	S1	_	
79-22	12303-12304	)	_	
79-23	12304-12305	.	_	

#Text=MID fMRI
#Text=Effect of task
#Text=The reward-neutral contrast for each group for both the placebo and GSK598809 conditions revealed a highly significant network of activation, including the VP, VS, and SN, in line with previous studies.
80-1	12306-12309	MID	_	
80-2	12310-12314	fMRI	_	
80-3	12315-12321	Effect	_	
80-4	12322-12324	of	_	
80-5	12325-12329	task	_	
80-6	12330-12333	The	_	
80-7	12334-12348	reward-neutral	_	
80-8	12349-12357	contrast	_	
80-9	12358-12361	for	_	
80-10	12362-12366	each	_	
80-11	12367-12372	group	_	
80-12	12373-12376	for	_	
80-13	12377-12381	both	_	
80-14	12382-12385	the	_	
80-15	12386-12393	placebo	_	
80-16	12394-12397	and	_	
80-17	12398-12407	GSK598809	_	
80-18	12408-12418	conditions	_	
80-19	12419-12427	revealed	_	
80-20	12428-12429	a	_	
80-21	12430-12436	highly	_	
80-22	12437-12448	significant	_	
80-23	12449-12456	network	_	
80-24	12457-12459	of	_	
80-25	12460-12470	activation	_	
80-26	12470-12471	,	_	
80-27	12472-12481	including	_	
80-28	12482-12485	the	_	
80-29	12486-12488	VP	_	
80-30	12488-12489	,	_	
80-31	12490-12492	VS	_	
80-32	12492-12493	,	_	
80-33	12494-12497	and	_	
80-34	12498-12500	SN	_	
80-35	12500-12501	,	_	
80-36	12502-12504	in	_	
80-37	12505-12509	line	_	
80-38	12510-12514	with	_	
80-39	12515-12523	previous	_	
80-40	12524-12531	studies	_	
80-41	12531-12532	.	_	

#Text=See Supplementary Figure S3.
81-1	12533-12536	See	_	
81-2	12537-12550	Supplementary	_	
81-3	12551-12557	Figure	_	
81-4	12558-12560	S3	_	
81-5	12560-12561	.	_	

#Text=Effects of group and drug: whole-brain analysis
#Text=Mixed ANOVAs demonstrated a significant main effect of drug within the left VP, caudate, and cerebellum (Table 1 and Supplementary Figure S5).
82-1	12562-12569	Effects	_	
82-2	12570-12572	of	_	
82-3	12573-12578	group	_	
82-4	12579-12582	and	_	
82-5	12583-12587	drug	_	
82-6	12587-12588	:	_	
82-7	12589-12600	whole-brain	_	
82-8	12601-12609	analysis	_	
82-9	12610-12615	Mixed	_	
82-10	12616-12622	ANOVAs	_	
82-11	12623-12635	demonstrated	_	
82-12	12636-12637	a	_	
82-13	12638-12649	significant	_	
82-14	12650-12654	main	_	
82-15	12655-12661	effect	_	
82-16	12662-12664	of	_	
82-17	12665-12669	drug	_	
82-18	12670-12676	within	_	
82-19	12677-12680	the	_	
82-20	12681-12685	left	_	
82-21	12686-12688	VP	_	
82-22	12688-12689	,	_	
82-23	12690-12697	caudate	_	
82-24	12697-12698	,	_	
82-25	12699-12702	and	_	
82-26	12703-12713	cerebellum	_	
82-27	12714-12715	(	_	
82-28	12715-12720	Table	_	
82-29	12721-12722	1	_	
82-30	12723-12726	and	_	
82-31	12727-12740	Supplementary	_	
82-32	12741-12747	Figure	_	
82-33	12748-12750	S5	_	
82-34	12750-12751	)	_	
82-35	12751-12752	.	_	

#Text=These effects appear to be driven by increased reward-neutral anticipation response in the GSK598809 session compared with the placebo session, in particular for the AD group and to a lesser extent the PD group.
83-1	12753-12758	These	_	
83-2	12759-12766	effects	_	
83-3	12767-12773	appear	_	
83-4	12774-12776	to	_	
83-5	12777-12779	be	_	
83-6	12780-12786	driven	_	
83-7	12787-12789	by	_	
83-8	12790-12799	increased	_	
83-9	12800-12814	reward-neutral	_	
83-10	12815-12827	anticipation	_	
83-11	12828-12836	response	_	
83-12	12837-12839	in	_	
83-13	12840-12843	the	_	
83-14	12844-12853	GSK598809	_	
83-15	12854-12861	session	_	
83-16	12862-12870	compared	_	
83-17	12871-12875	with	_	
83-18	12876-12879	the	_	
83-19	12880-12887	placebo	_	
83-20	12888-12895	session	_	
83-21	12895-12896	,	_	
83-22	12897-12899	in	_	
83-23	12900-12910	particular	_	
83-24	12911-12914	for	_	
83-25	12915-12918	the	_	
83-26	12919-12921	AD	_	
83-27	12922-12927	group	_	
83-28	12928-12931	and	_	
83-29	12932-12934	to	_	
83-30	12935-12936	a	_	
83-31	12937-12943	lesser	_	
83-32	12944-12950	extent	_	
83-33	12951-12954	the	_	
83-34	12955-12957	PD	_	
83-35	12958-12963	group	_	
83-36	12963-12964	.	_	

#Text=However, these apparent interactions were not significant.
84-1	12965-12972	However	_	
84-2	12972-12973	,	_	
84-3	12974-12979	these	_	
84-4	12980-12988	apparent	_	
84-5	12989-13001	interactions	_	
84-6	13002-13006	were	_	
84-7	13007-13010	not	_	
84-8	13011-13022	significant	_	
84-9	13022-13023	.	_	

#Text=A significant effect of drug was also observed in the right middle frontal gyrus (corresponding to the dorsolateral prefrontal cortex (DLPFC), see Table 1 and Supplementary Figure S3), which was driven by a significant group-by-drug session interaction.
85-1	13024-13025	A	_	
85-2	13026-13037	significant	_	
85-3	13038-13044	effect	_	
85-4	13045-13047	of	_	
85-5	13048-13052	drug	_	
85-6	13053-13056	was	_	
85-7	13057-13061	also	_	
85-8	13062-13070	observed	_	
85-9	13071-13073	in	_	
85-10	13074-13077	the	_	
85-11	13078-13083	right	_	
85-12	13084-13090	middle	_	
85-13	13091-13098	frontal	_	
85-14	13099-13104	gyrus	_	
85-15	13105-13106	(	_	
85-16	13106-13119	corresponding	_	
85-17	13120-13122	to	_	
85-18	13123-13126	the	_	
85-19	13127-13139	dorsolateral	_	
85-20	13140-13150	prefrontal	_	
85-21	13151-13157	cortex	_	
85-22	13158-13159	(	_	
85-23	13159-13164	DLPFC	_	
85-24	13164-13165	)	_	
85-25	13165-13166	,	_	
85-26	13167-13170	see	_	
85-27	13171-13176	Table	_	
85-28	13177-13178	1	_	
85-29	13179-13182	and	_	
85-30	13183-13196	Supplementary	_	
85-31	13197-13203	Figure	_	
85-32	13204-13206	S3	_	
85-33	13206-13207	)	_	
85-34	13207-13208	,	_	
85-35	13209-13214	which	_	
85-36	13215-13218	was	_	
85-37	13219-13225	driven	_	
85-38	13226-13228	by	_	
85-39	13229-13230	a	_	
85-40	13231-13242	significant	_	
85-41	13243-13256	group-by-drug	_	
85-42	13257-13264	session	_	
85-43	13265-13276	interaction	_	
85-44	13276-13277	.	_	

#Text=GSK598809 increases reward-neutral BOLD response to a greater degree in the AD group compared with both the HC and PD groups.
86-1	13278-13287	GSK598809	_	
86-2	13288-13297	increases	_	
86-3	13298-13312	reward-neutral	_	
86-4	13313-13317	BOLD	_	
86-5	13318-13326	response	_	
86-6	13327-13329	to	_	
86-7	13330-13331	a	_	
86-8	13332-13339	greater	_	
86-9	13340-13346	degree	_	
86-10	13347-13349	in	_	
86-11	13350-13353	the	_	
86-12	13354-13356	AD	_	
86-13	13357-13362	group	_	
86-14	13363-13371	compared	_	
86-15	13372-13376	with	_	
86-16	13377-13381	both	_	
86-17	13382-13385	the	_	
86-18	13386-13388	HC	_	
86-19	13389-13392	and	_	
86-20	13393-13395	PD	_	
86-21	13396-13402	groups	_	
86-22	13402-13403	.	_	

#Text=ROI analysis
#Text=Mixed ANOVAs demonstrated a main effect of drug within the VS (p=0.005), VP (p<0.001), and SN (p=0.009) (Table 1).
87-1	13404-13407	ROI	_	
87-2	13408-13416	analysis	_	
87-3	13417-13422	Mixed	_	
87-4	13423-13429	ANOVAs	_	
87-5	13430-13442	demonstrated	_	
87-6	13443-13444	a	_	
87-7	13445-13449	main	_	
87-8	13450-13456	effect	_	
87-9	13457-13459	of	_	
87-10	13460-13464	drug	_	
87-11	13465-13471	within	_	
87-12	13472-13475	the	_	
87-13	13476-13478	VS	_	
87-14	13479-13480	(	_	
87-15	13480-13481	p	_	
87-16	13481-13482	=	_	
87-17	13482-13487	0.005	_	
87-18	13487-13488	)	_	
87-19	13488-13489	,	_	
87-20	13490-13492	VP	_	
87-21	13493-13494	(	_	
87-22	13494-13495	p	_	
87-23	13495-13496	<	_	
87-24	13496-13501	0.001	_	
87-25	13501-13502	)	_	
87-26	13502-13503	,	_	
87-27	13504-13507	and	_	
87-28	13508-13510	SN	_	
87-29	13511-13512	(	_	
87-30	13512-13513	p	_	
87-31	13513-13514	=	_	
87-32	13514-13519	0.009	_	
87-33	13519-13520	)	_	
87-34	13521-13522	(	_	
87-35	13522-13527	Table	_	
87-36	13528-13529	1	_	
87-37	13529-13530	)	_	
87-38	13530-13531	.	_	

#Text=These effects are due to increased reward-neutral BOLD response in the GSK598809 session compared with the placebo session (Figure 2).
88-1	13532-13537	These	_	
88-2	13538-13545	effects	_	
88-3	13546-13549	are	_	
88-4	13550-13553	due	_	
88-5	13554-13556	to	_	
88-6	13557-13566	increased	_	
88-7	13567-13581	reward-neutral	_	
88-8	13582-13586	BOLD	_	
88-9	13587-13595	response	_	
88-10	13596-13598	in	_	
88-11	13599-13602	the	_	
88-12	13603-13612	GSK598809	_	
88-13	13613-13620	session	_	
88-14	13621-13629	compared	_	
88-15	13630-13634	with	_	
88-16	13635-13638	the	_	
88-17	13639-13646	placebo	_	
88-18	13647-13654	session	_	
88-19	13655-13656	(	_	
88-20	13656-13662	Figure	_	
88-21	13663-13664	2	_	
88-22	13664-13665	)	_	
88-23	13665-13666	.	_	

#Text=Although these effects appear to be mainly driven by the dependent groups in each ROI, only a trend for a drug-by-group interaction was found and only in the VP (p=0.041, Table 1).
89-1	13667-13675	Although	_	
89-2	13676-13681	these	_	
89-3	13682-13689	effects	_	
89-4	13690-13696	appear	_	
89-5	13697-13699	to	_	
89-6	13700-13702	be	_	
89-7	13703-13709	mainly	_	
89-8	13710-13716	driven	_	
89-9	13717-13719	by	_	
89-10	13720-13723	the	_	
89-11	13724-13733	dependent	_	
89-12	13734-13740	groups	_	
89-13	13741-13743	in	_	
89-14	13744-13748	each	_	
89-15	13749-13752	ROI	_	
89-16	13752-13753	,	_	
89-17	13754-13758	only	_	
89-18	13759-13760	a	_	
89-19	13761-13766	trend	_	
89-20	13767-13770	for	_	
89-21	13771-13772	a	_	
89-22	13773-13786	drug-by-group	_	
89-23	13787-13798	interaction	_	
89-24	13799-13802	was	_	
89-25	13803-13808	found	_	
89-26	13809-13812	and	_	
89-27	13813-13817	only	_	
89-28	13818-13820	in	_	
89-29	13821-13824	the	_	
89-30	13825-13827	VP	_	
89-31	13828-13829	(	_	
89-32	13829-13830	p	_	
89-33	13830-13831	=	_	
89-34	13831-13836	0.041	_	
89-35	13836-13837	,	_	
89-36	13838-13843	Table	_	
89-37	13844-13845	1	_	
89-38	13845-13846	)	_	
89-39	13846-13847	.	_	

#Text=Post hoc paired t-tests revealed a significant effect of GSK598809 on VP reward-neutral BOLD response within the AD group (p<0.001) and PD group (p=0.003) but not the HC group (p=0.145).
90-1	13848-13852	Post	_	
90-2	13853-13856	hoc	_	
90-3	13857-13863	paired	_	
90-4	13864-13871	t-tests	_	
90-5	13872-13880	revealed	_	
90-6	13881-13882	a	_	
90-7	13883-13894	significant	_	
90-8	13895-13901	effect	_	
90-9	13902-13904	of	_	
90-10	13905-13914	GSK598809	_	
90-11	13915-13917	on	_	
90-12	13918-13920	VP	_	
90-13	13921-13935	reward-neutral	_	
90-14	13936-13940	BOLD	_	
90-15	13941-13949	response	_	
90-16	13950-13956	within	_	
90-17	13957-13960	the	_	
90-18	13961-13963	AD	_	
90-19	13964-13969	group	_	
90-20	13970-13971	(	_	
90-21	13971-13972	p	_	
90-22	13972-13973	<	_	
90-23	13973-13978	0.001	_	
90-24	13978-13979	)	_	
90-25	13980-13983	and	_	
90-26	13984-13986	PD	_	
90-27	13987-13992	group	_	
90-28	13993-13994	(	_	
90-29	13994-13995	p	_	
90-30	13995-13996	=	_	
90-31	13996-14001	0.003	_	
90-32	14001-14002	)	_	
90-33	14003-14006	but	_	
90-34	14007-14010	not	_	
90-35	14011-14014	the	_	
90-36	14015-14017	HC	_	
90-37	14018-14023	group	_	
90-38	14024-14025	(	_	
90-39	14025-14026	p	_	
90-40	14026-14027	=	_	
90-41	14027-14032	0.145	_	
90-42	14032-14033	)	_	
90-43	14033-14034	.	_	

#Text=No significant main effects of group were found although trends were found within the VS and SN (p=0.048 and 0.042, respectively).
91-1	14035-14037	No	_	
91-2	14038-14049	significant	_	
91-3	14050-14054	main	_	
91-4	14055-14062	effects	_	
91-5	14063-14065	of	_	
91-6	14066-14071	group	_	
91-7	14072-14076	were	_	
91-8	14077-14082	found	_	
91-9	14083-14091	although	_	
91-10	14092-14098	trends	_	
91-11	14099-14103	were	_	
91-12	14104-14109	found	_	
91-13	14110-14116	within	_	
91-14	14117-14120	the	_	
91-15	14121-14123	VS	_	
91-16	14124-14127	and	_	
91-17	14128-14130	SN	_	
91-18	14131-14132	(	_	
91-19	14132-14133	p	_	
91-20	14133-14134	=	_	
91-21	14134-14139	0.048	_	
91-22	14140-14143	and	_	
91-23	14144-14149	0.042	_	
91-24	14149-14150	,	_	
91-25	14151-14163	respectively	_	
91-26	14163-14164	)	_	
91-27	14164-14165	.	_	

#Text=Figure 2 suggests that these effects were driven by blunting occurring within the placebo condition of the PD group.
92-1	14166-14172	Figure	_	
92-2	14173-14174	2	_	
92-3	14175-14183	suggests	_	
92-4	14184-14188	that	_	
92-5	14189-14194	these	_	
92-6	14195-14202	effects	_	
92-7	14203-14207	were	_	
92-8	14208-14214	driven	_	
92-9	14215-14217	by	_	
92-10	14218-14226	blunting	_	
92-11	14227-14236	occurring	_	
92-12	14237-14243	within	_	
92-13	14244-14247	the	_	
92-14	14248-14255	placebo	_	
92-15	14256-14265	condition	_	
92-16	14266-14268	of	_	
92-17	14269-14272	the	_	
92-18	14273-14275	PD	_	
92-19	14276-14281	group	_	
92-20	14281-14282	.	_	

#Text=Exploratory post hoc investigations carried out with the placebo session data only demonstrated a significant main effect of group in the VS (F(2,79)=5.03, p=0.009, PD<HC) and a trend for a significant blunting in the SN that just fell short of Bonferroni-corrected significance, (F(2,79)=5.03, p=0.022, PD<HC).
93-1	14283-14294	Exploratory	_	
93-2	14295-14299	post	_	
93-3	14300-14303	hoc	_	
93-4	14304-14318	investigations	_	
93-5	14319-14326	carried	_	
93-6	14327-14330	out	_	
93-7	14331-14335	with	_	
93-8	14336-14339	the	_	
93-9	14340-14347	placebo	_	
93-10	14348-14355	session	_	
93-11	14356-14360	data	_	
93-12	14361-14365	only	_	
93-13	14366-14378	demonstrated	_	
93-14	14379-14380	a	_	
93-15	14381-14392	significant	_	
93-16	14393-14397	main	_	
93-17	14398-14404	effect	_	
93-18	14405-14407	of	_	
93-19	14408-14413	group	_	
93-20	14414-14416	in	_	
93-21	14417-14420	the	_	
93-22	14421-14423	VS	_	
93-23	14424-14425	(	_	
93-24	14425-14426	F	_	
93-25	14426-14427	(	_	
93-26	14427-14431	2,79	_	
93-27	14431-14432	)	_	
93-28	14432-14433	=	_	
93-29	14433-14437	5.03	_	
93-30	14437-14438	,	_	
93-31	14439-14440	p	_	
93-32	14440-14441	=	_	
93-33	14441-14446	0.009	_	
93-34	14446-14447	,	_	
93-35	14448-14450	PD	_	
93-36	14450-14451	<	_	
93-37	14451-14453	HC	_	
93-38	14453-14454	)	_	
93-39	14455-14458	and	_	
93-40	14459-14460	a	_	
93-41	14461-14466	trend	_	
93-42	14467-14470	for	_	
93-43	14471-14472	a	_	
93-44	14473-14484	significant	_	
93-45	14485-14493	blunting	_	
93-46	14494-14496	in	_	
93-47	14497-14500	the	_	
93-48	14501-14503	SN	_	
93-49	14504-14508	that	_	
93-50	14509-14513	just	_	
93-51	14514-14518	fell	_	
93-52	14519-14524	short	_	
93-53	14525-14527	of	_	
93-54	14528-14548	Bonferroni-corrected	_	
93-55	14549-14561	significance	_	
93-56	14561-14562	,	_	
93-57	14563-14564	(	_	
93-58	14564-14565	F	_	
93-59	14565-14566	(	_	
93-60	14566-14570	2,79	_	
93-61	14570-14571	)	_	
93-62	14571-14572	=	_	
93-63	14572-14576	5.03	_	
93-64	14576-14577	,	_	
93-65	14578-14579	p	_	
93-66	14579-14580	=	_	
93-67	14580-14585	0.022	_	
93-68	14585-14586	,	_	
93-69	14587-14589	PD	_	
93-70	14589-14590	<	_	
93-71	14590-14592	HC	_	
93-72	14592-14593	)	_	
93-73	14593-14594	.	_	

#Text=Post hoc tests revealed no difference or trends between AD and HC or AD and PD.
94-1	14595-14599	Post	_	
94-2	14600-14603	hoc	_	
94-3	14604-14609	tests	_	
94-4	14610-14618	revealed	_	
94-5	14619-14621	no	_	
94-6	14622-14632	difference	_	
94-7	14633-14635	or	_	
94-8	14636-14642	trends	_	
94-9	14643-14650	between	_	
94-10	14651-14653	AD	_	
94-11	14654-14657	and	_	
94-12	14658-14660	HC	_	
94-13	14661-14663	or	_	
94-14	14664-14666	AD	_	
94-15	14667-14670	and	_	
94-16	14671-14673	PD	_	
94-17	14673-14674	.	_	

#Text=No group effects or trends emerged for corresponding analysis of the GSK598809 session.
95-1	14675-14677	No	_	
95-2	14678-14683	group	_	
95-3	14684-14691	effects	_	
95-4	14692-14694	or	_	
95-5	14695-14701	trends	_	
95-6	14702-14709	emerged	_	
95-7	14710-14713	for	_	
95-8	14714-14727	corresponding	_	
95-9	14728-14736	analysis	_	
95-10	14737-14739	of	_	
95-11	14740-14743	the	_	
95-12	14744-14753	GSK598809	_	
95-13	14754-14761	session	_	
95-14	14761-14762	.	_	

#Text=Additional exploratory investigations were carried out within the ROIs, separating the groups by primary drug of dependence (see Supplementary Materials).
96-1	14763-14773	Additional	_	
96-2	14774-14785	exploratory	_	
96-3	14786-14800	investigations	_	
96-4	14801-14805	were	_	
96-5	14806-14813	carried	_	
96-6	14814-14817	out	_	
96-7	14818-14824	within	_	
96-8	14825-14828	the	_	
96-9	14829-14833	ROIs	_	
96-10	14833-14834	,	_	
96-11	14835-14845	separating	_	
96-12	14846-14849	the	_	
96-13	14850-14856	groups	_	
96-14	14857-14859	by	_	
96-15	14860-14867	primary	_	
96-16	14868-14872	drug	_	
96-17	14873-14875	of	_	
96-18	14876-14886	dependence	_	
96-19	14887-14888	(	_	
96-20	14888-14891	see	_	
96-21	14892-14905	Supplementary	_	
96-22	14906-14915	Materials	_	
96-23	14915-14916	)	_	
96-24	14916-14917	.	_	

#Text=This suggested that drug effects were driven by participants with a primary alcohol but not opiate dependence (see Supplementary Figure S7).
97-1	14918-14922	This	_	
97-2	14923-14932	suggested	_	
97-3	14933-14937	that	_	
97-4	14938-14942	drug	_	
97-5	14943-14950	effects	_	
97-6	14951-14955	were	_	
97-7	14956-14962	driven	_	
97-8	14963-14965	by	_	
97-9	14966-14978	participants	_	
97-10	14979-14983	with	_	
97-11	14984-14985	a	_	
97-12	14986-14993	primary	_	
97-13	14994-15001	alcohol	_	
97-14	15002-15005	but	_	
97-15	15006-15009	not	_	
97-16	15010-15016	opiate	_	
97-17	15017-15027	dependence	_	
97-18	15028-15029	(	_	
97-19	15029-15032	see	_	
97-20	15033-15046	Supplementary	_	
97-21	15047-15053	Figure	_	
97-22	15054-15056	S7	_	
97-23	15056-15057	)	_	
97-24	15057-15058	.	_	

#Text=Investigations into primary cocaine dependence were not carried out owing to small numbers.
98-1	15059-15073	Investigations	_	
98-2	15074-15078	into	_	
98-3	15079-15086	primary	_	
98-4	15087-15094	cocaine	_	
98-5	15095-15105	dependence	_	
98-6	15106-15110	were	_	
98-7	15111-15114	not	_	
98-8	15115-15122	carried	_	
98-9	15123-15126	out	_	
98-10	15127-15132	owing	_	
98-11	15133-15135	to	_	
98-12	15136-15141	small	_	
98-13	15142-15149	numbers	_	
98-14	15149-15150	.	_	

#Text=GNG Behavioral
#Text=There were no significant drug or group effects or interactions for GNG performance (see Supplementary Figure S1).
99-1	15151-15154	GNG	_	
99-2	15155-15165	Behavioral	_	
99-3	15166-15171	There	_	
99-4	15172-15176	were	_	
99-5	15177-15179	no	_	
99-6	15180-15191	significant	_	
99-7	15192-15196	drug	_	
99-8	15197-15199	or	_	
99-9	15200-15205	group	_	
99-10	15206-15213	effects	_	
99-11	15214-15216	or	_	
99-12	15217-15229	interactions	_	
99-13	15230-15233	for	_	
99-14	15234-15237	GNG	_	
99-15	15238-15249	performance	_	
99-16	15250-15251	(	_	
99-17	15251-15254	see	_	
99-18	15255-15268	Supplementary	_	
99-19	15269-15275	Figure	_	
99-20	15276-15278	S1	_	
99-21	15278-15279	)	_	
99-22	15279-15280	.	_	

#Text=GNG fMRI—Effect of Task
#Text=The stops>go contrast for each group for both the placebo and GSK598809 conditions revealed a highly significant network of activation, in line with previous studies using this task.
100-1	15281-15284	GNG	_	
100-2	15285-15296	fMRI—Effect	_	
100-3	15297-15299	of	_	
100-4	15300-15304	Task	_	
100-5	15305-15308	The	_	
100-6	15309-15314	stops	_	
100-7	15314-15315	>	_	
100-8	15315-15317	go	_	
100-9	15318-15326	contrast	_	
100-10	15327-15330	for	_	
100-11	15331-15335	each	_	
100-12	15336-15341	group	_	
100-13	15342-15345	for	_	
100-14	15346-15350	both	_	
100-15	15351-15354	the	_	
100-16	15355-15362	placebo	_	
100-17	15363-15366	and	_	
100-18	15367-15376	GSK598809	_	
100-19	15377-15387	conditions	_	
100-20	15388-15396	revealed	_	
100-21	15397-15398	a	_	
100-22	15399-15405	highly	_	
100-23	15406-15417	significant	_	
100-24	15418-15425	network	_	
100-25	15426-15428	of	_	
100-26	15429-15439	activation	_	
100-27	15439-15440	,	_	
100-28	15441-15443	in	_	
100-29	15444-15448	line	_	
100-30	15449-15453	with	_	
100-31	15454-15462	previous	_	
100-32	15463-15470	studies	_	
100-33	15471-15476	using	_	
100-34	15477-15481	this	_	
100-35	15482-15486	task	_	
100-36	15486-15487	.	_	

#Text=See Supplementary Figure S4.
101-1	15488-15491	See	_	
101-2	15492-15505	Supplementary	_	
101-3	15506-15512	Figure	_	
101-4	15513-15515	S4	_	
101-5	15515-15516	.	_	

#Text=Effects of group and drug: whole-brain analysis
#Text=Whole-brain analyses using mixed ANOVAs revealed a significant group effect within the left cerebral peduncle region of the midbrain owing to increased activation in the AD group (Supplementary Figure S6).
102-1	15517-15524	Effects	_	
102-2	15525-15527	of	_	
102-3	15528-15533	group	_	
102-4	15534-15537	and	_	
102-5	15538-15542	drug	_	
102-6	15542-15543	:	_	
102-7	15544-15555	whole-brain	_	
102-8	15556-15564	analysis	_	
102-9	15565-15576	Whole-brain	_	
102-10	15577-15585	analyses	_	
102-11	15586-15591	using	_	
102-12	15592-15597	mixed	_	
102-13	15598-15604	ANOVAs	_	
102-14	15605-15613	revealed	_	
102-15	15614-15615	a	_	
102-16	15616-15627	significant	_	
102-17	15628-15633	group	_	
102-18	15634-15640	effect	_	
102-19	15641-15647	within	_	
102-20	15648-15651	the	_	
102-21	15652-15656	left	_	
102-22	15657-15665	cerebral	_	
102-23	15666-15674	peduncle	_	
102-24	15675-15681	region	_	
102-25	15682-15684	of	_	
102-26	15685-15688	the	_	
102-27	15689-15697	midbrain	_	
102-28	15698-15703	owing	_	
102-29	15704-15706	to	_	
102-30	15707-15716	increased	_	
102-31	15717-15727	activation	_	
102-32	15728-15730	in	_	
102-33	15731-15734	the	_	
102-34	15735-15737	AD	_	
102-35	15738-15743	group	_	
102-36	15744-15745	(	_	
102-37	15745-15758	Supplementary	_	
102-38	15759-15765	Figure	_	
102-39	15766-15768	S6	_	
102-40	15768-15769	)	_	
102-41	15769-15770	.	_	

#Text=No drug effects or interactions were found.
103-1	15771-15773	No	_	
103-2	15774-15778	drug	_	
103-3	15779-15786	effects	_	
103-4	15787-15789	or	_	
103-5	15790-15802	interactions	_	
103-6	15803-15807	were	_	
103-7	15808-15813	found	_	
103-8	15813-15814	.	_	

#Text=ROI analysis
#Text=There was no effect of GSK598809 in any of the ROIs.
104-1	15815-15818	ROI	_	
104-2	15819-15827	analysis	_	
104-3	15828-15833	There	_	
104-4	15834-15837	was	_	
104-5	15838-15840	no	_	
104-6	15841-15847	effect	_	
104-7	15848-15850	of	_	
104-8	15851-15860	GSK598809	_	
104-9	15861-15863	in	_	
104-10	15864-15867	any	_	
104-11	15868-15870	of	_	
104-12	15871-15874	the	_	
104-13	15875-15879	ROIs	_	
104-14	15879-15880	.	_	

#Text=A main effect of group was found in the right IFG (F(2,)=4.71, p=0.012), and at trend level in the left IFG (p=0.024), driven by hyperactivation in the PD compared with the HC group (p=0.016).
105-1	15881-15882	A	_	
105-2	15883-15887	main	_	
105-3	15888-15894	effect	_	
105-4	15895-15897	of	_	
105-5	15898-15903	group	_	
105-6	15904-15907	was	_	
105-7	15908-15913	found	_	
105-8	15914-15916	in	_	
105-9	15917-15920	the	_	
105-10	15921-15926	right	_	
105-11	15927-15930	IFG	_	
105-12	15931-15932	(	_	
105-13	15932-15933	F	_	
105-14	15933-15934	(	_	
105-15	15934-15935	2	_	
105-16	15935-15936	,	_	
105-17	15936-15937	)	_	
105-18	15937-15938	=	_	
105-19	15938-15942	4.71	_	
105-20	15942-15943	,	_	
105-21	15944-15945	p	_	
105-22	15945-15946	=	_	
105-23	15946-15951	0.012	_	
105-24	15951-15952	)	_	
105-25	15952-15953	,	_	
105-26	15954-15957	and	_	
105-27	15958-15960	at	_	
105-28	15961-15966	trend	_	
105-29	15967-15972	level	_	
105-30	15973-15975	in	_	
105-31	15976-15979	the	_	
105-32	15980-15984	left	_	
105-33	15985-15988	IFG	_	
105-34	15989-15990	(	_	
105-35	15990-15991	p	_	
105-36	15991-15992	=	_	
105-37	15992-15997	0.024	_	
105-38	15997-15998	)	_	
105-39	15998-15999	,	_	
105-40	16000-16006	driven	_	
105-41	16007-16009	by	_	
105-42	16010-16025	hyperactivation	_	
105-43	16026-16028	in	_	
105-44	16029-16032	the	_	
105-45	16033-16035	PD	_	
105-46	16036-16044	compared	_	
105-47	16045-16049	with	_	
105-48	16050-16053	the	_	
105-49	16054-16056	HC	_	
105-50	16057-16062	group	_	
105-51	16063-16064	(	_	
105-52	16064-16065	p	_	
105-53	16065-16066	=	_	
105-54	16066-16071	0.016	_	
105-55	16071-16072	)	_	
105-56	16072-16073	.	_	

#Text=See Figure 3.
106-1	16074-16077	See	_	
106-2	16078-16084	Figure	_	
106-3	16085-16086	3	_	
106-4	16086-16087	.	_	

#Text=Exploratory analysis revealed no significant effects of GSK598809 in DRD3-rich regions (VS, VP, SN).
107-1	16088-16099	Exploratory	_	
107-2	16100-16108	analysis	_	
107-3	16109-16117	revealed	_	
107-4	16118-16120	no	_	
107-5	16121-16132	significant	_	
107-6	16133-16140	effects	_	
107-7	16141-16143	of	_	
107-8	16144-16153	GSK598809	_	
107-9	16154-16156	in	_	
107-10	16157-16161	DRD3	_	
107-11	16161-16162	-	_	
107-12	16162-16166	rich	_	
107-13	16167-16174	regions	_	
107-14	16175-16176	(	_	
107-15	16176-16178	VS	_	
107-16	16178-16179	,	_	
107-17	16180-16182	VP	_	
107-18	16182-16183	,	_	
107-19	16184-16186	SN	_	
107-20	16186-16187	)	_	
107-21	16187-16188	.	_	

#Text=Correlational Analyses
#Text=Ventral striatal ROI activation during the placebo condition for the MIDT, in all participants, correlated with impulsivity measured by the Barratt Impulsivity Scale (BIS) (r=−0.368, p=0.001) but not the reward responsivity subscale of the BISBAS (Supplementary Table S4).
108-1	16189-16202	Correlational	_	
108-2	16203-16211	Analyses	_	
108-3	16212-16219	Ventral	_	
108-4	16220-16228	striatal	_	
108-5	16229-16232	ROI	_	
108-6	16233-16243	activation	_	
108-7	16244-16250	during	_	
108-8	16251-16254	the	_	
108-9	16255-16262	placebo	_	
108-10	16263-16272	condition	_	
108-11	16273-16276	for	_	
108-12	16277-16280	the	_	
108-13	16281-16285	MIDT	_	
108-14	16285-16286	,	_	
108-15	16287-16289	in	_	
108-16	16290-16293	all	_	
108-17	16294-16306	participants	_	
108-18	16306-16307	,	_	
108-19	16308-16318	correlated	_	
108-20	16319-16323	with	_	
108-21	16324-16335	impulsivity	_	
108-22	16336-16344	measured	_	
108-23	16345-16347	by	_	
108-24	16348-16351	the	_	
108-25	16352-16359	Barratt	_	
108-26	16360-16371	Impulsivity	_	
108-27	16372-16377	Scale	_	
108-28	16378-16379	(	_	
108-29	16379-16382	BIS	_	
108-30	16382-16383	)	_	
108-31	16384-16385	(	_	
108-32	16385-16386	r	_	
108-33	16386-16387	=	_	
108-34	16387-16388	−	_	
108-35	16388-16393	0.368	_	
108-36	16393-16394	,	_	
108-37	16395-16396	p	_	
108-38	16396-16397	=	_	
108-39	16397-16402	0.001	_	
108-40	16402-16403	)	_	
108-41	16404-16407	but	_	
108-42	16408-16411	not	_	
108-43	16412-16415	the	_	
108-44	16416-16422	reward	_	
108-45	16423-16435	responsivity	_	
108-46	16436-16444	subscale	_	
108-47	16445-16447	of	_	
108-48	16448-16451	the	_	
108-49	16452-16458	BISBAS	_	
108-50	16459-16460	(	_	
108-51	16460-16473	Supplementary	_	
108-52	16474-16479	Table	_	
108-53	16480-16482	S4	_	
108-54	16482-16483	)	_	
108-55	16483-16484	.	_	

#Text=To rule out the possibility of this negative association being primarily driven by group differences, an additional correlation was carried out within the healthy control group only, which supported this negative relationship (r=−0.372, p=0.033).
109-1	16485-16487	To	_	
109-2	16488-16492	rule	_	
109-3	16493-16496	out	_	
109-4	16497-16500	the	_	
109-5	16501-16512	possibility	_	
109-6	16513-16515	of	_	
109-7	16516-16520	this	_	
109-8	16521-16529	negative	_	
109-9	16530-16541	association	_	
109-10	16542-16547	being	_	
109-11	16548-16557	primarily	_	
109-12	16558-16564	driven	_	
109-13	16565-16567	by	_	
109-14	16568-16573	group	_	
109-15	16574-16585	differences	_	
109-16	16585-16586	,	_	
109-17	16587-16589	an	_	
109-18	16590-16600	additional	_	
109-19	16601-16612	correlation	_	
109-20	16613-16616	was	_	
109-21	16617-16624	carried	_	
109-22	16625-16628	out	_	
109-23	16629-16635	within	_	
109-24	16636-16639	the	_	
109-25	16640-16647	healthy	_	
109-26	16648-16655	control	_	
109-27	16656-16661	group	_	
109-28	16662-16666	only	_	
109-29	16666-16667	,	_	
109-30	16668-16673	which	_	
109-31	16674-16683	supported	_	
109-32	16684-16688	this	_	
109-33	16689-16697	negative	_	
109-34	16698-16710	relationship	_	
109-35	16711-16712	(	_	
109-36	16712-16713	r	_	
109-37	16713-16714	=	_	
109-38	16714-16715	−	_	
109-39	16715-16720	0.372	_	
109-40	16720-16721	,	_	
109-41	16722-16723	p	_	
109-42	16723-16724	=	_	
109-43	16724-16729	0.033	_	
109-44	16729-16730	)	_	
109-45	16730-16731	.	_	

#Text=No correlations were found with any of the GNG ROIs (Supplementary Table S3 and S4).
110-1	16732-16734	No	_	
110-2	16735-16747	correlations	_	
110-3	16748-16752	were	_	
110-4	16753-16758	found	_	
110-5	16759-16763	with	_	
110-6	16764-16767	any	_	
110-7	16768-16770	of	_	
110-8	16771-16774	the	_	
110-9	16775-16778	GNG	_	
110-10	16779-16783	ROIs	_	
110-11	16784-16785	(	_	
110-12	16785-16798	Supplementary	_	
110-13	16799-16804	Table	_	
110-14	16805-16807	S3	_	
110-15	16808-16811	and	_	
110-16	16812-16814	S4	_	
110-17	16814-16815	)	_	
110-18	16815-16816	.	_	

#Text=No relationships were found between the MID and GNGT ROI activation or fMRI and questionnaire behavioral measures (Supplementary Table S4) or with duration of abstinence (Supplementary Table S5).
111-1	16817-16819	No	_	
111-2	16820-16833	relationships	_	
111-3	16834-16838	were	_	
111-4	16839-16844	found	_	
111-5	16845-16852	between	_	
111-6	16853-16856	the	_	
111-7	16857-16860	MID	_	
111-8	16861-16864	and	_	
111-9	16865-16869	GNGT	_	
111-10	16870-16873	ROI	_	
111-11	16874-16884	activation	_	
111-12	16885-16887	or	_	
111-13	16888-16892	fMRI	_	
111-14	16893-16896	and	_	
111-15	16897-16910	questionnaire	_	
111-16	16911-16921	behavioral	_	
111-17	16922-16930	measures	_	
111-18	16931-16932	(	_	
111-19	16932-16945	Supplementary	_	
111-20	16946-16951	Table	_	
111-21	16952-16954	S4	_	
111-22	16954-16955	)	_	
111-23	16956-16958	or	_	
111-24	16959-16963	with	_	
111-25	16964-16972	duration	_	
111-26	16973-16975	of	_	
111-27	16976-16986	abstinence	_	
111-28	16987-16988	(	_	
111-29	16988-17001	Supplementary	_	
111-30	17002-17007	Table	_	
111-31	17008-17010	S5	_	
111-32	17010-17011	)	_	
111-33	17011-17012	.	_	

#Text=No relationship was found between the effect of GSK598809 on VP activation and MID performance (Supplementary Table S6).
112-1	17013-17015	No	_	
112-2	17016-17028	relationship	_	
112-3	17029-17032	was	_	
112-4	17033-17038	found	_	
112-5	17039-17046	between	_	
112-6	17047-17050	the	_	
112-7	17051-17057	effect	_	
112-8	17058-17060	of	_	
112-9	17061-17070	GSK598809	_	
112-10	17071-17073	on	_	
112-11	17074-17076	VP	_	
112-12	17077-17087	activation	_	
112-13	17088-17091	and	_	
112-14	17092-17095	MID	_	
112-15	17096-17107	performance	_	
112-16	17108-17109	(	_	
112-17	17109-17122	Supplementary	_	
112-18	17123-17128	Table	_	
112-19	17129-17131	S6	_	
112-20	17131-17132	)	_	
112-21	17132-17133	.	_	

#Text=DISCUSSION
#Text=This study aimed to investigate the effects of the selective DRD3 antagonist GSK598809 on networks involved in the anticipation of reward and response inhibition.
113-1	17134-17144	DISCUSSION	_	
113-2	17145-17149	This	_	
113-3	17150-17155	study	_	
113-4	17156-17161	aimed	_	
113-5	17162-17164	to	_	
113-6	17165-17176	investigate	_	
113-7	17177-17180	the	_	
113-8	17181-17188	effects	_	
113-9	17189-17191	of	_	
113-10	17192-17195	the	_	
113-11	17196-17205	selective	_	
113-12	17206-17210	DRD3	_	
113-13	17211-17221	antagonist	_	
113-14	17222-17231	GSK598809	_	
113-15	17232-17234	on	_	
113-16	17235-17243	networks	_	
113-17	17244-17252	involved	_	
113-18	17253-17255	in	_	
113-19	17256-17259	the	_	
113-20	17260-17272	anticipation	_	
113-21	17273-17275	of	_	
113-22	17276-17282	reward	_	
113-23	17283-17286	and	_	
113-24	17287-17295	response	_	
113-25	17296-17306	inhibition	_	
113-26	17306-17307	.	_	

#Text=The main findings were that GSK598809 significantly increased reward-neutral reward anticipatory responses for the MIDT but had no effects on brain response during response inhibition.
114-1	17308-17311	The	_	
114-2	17312-17316	main	_	
114-3	17317-17325	findings	_	
114-4	17326-17330	were	_	
114-5	17331-17335	that	_	
114-6	17336-17345	GSK598809	_	
114-7	17346-17359	significantly	_	
114-8	17360-17369	increased	_	
114-9	17370-17384	reward-neutral	_	
114-10	17385-17391	reward	_	
114-11	17392-17404	anticipatory	_	
114-12	17405-17414	responses	_	
114-13	17415-17418	for	_	
114-14	17419-17422	the	_	
114-15	17423-17427	MIDT	_	
114-16	17428-17431	but	_	
114-17	17432-17435	had	_	
114-18	17436-17438	no	_	
114-19	17439-17446	effects	_	
114-20	17447-17449	on	_	
114-21	17450-17455	brain	_	
114-22	17456-17464	response	_	
114-23	17465-17471	during	_	
114-24	17472-17480	response	_	
114-25	17481-17491	inhibition	_	
114-26	17491-17492	.	_	

#Text=Group effects were found for both tasks, although in opposite directions.
115-1	17493-17498	Group	_	
115-2	17499-17506	effects	_	
115-3	17507-17511	were	_	
115-4	17512-17517	found	_	
115-5	17518-17521	for	_	
115-6	17522-17526	both	_	
115-7	17527-17532	tasks	_	
115-8	17532-17533	,	_	
115-9	17534-17542	although	_	
115-10	17543-17545	in	_	
115-11	17546-17554	opposite	_	
115-12	17555-17565	directions	_	
115-13	17565-17566	.	_	

#Text=Blunting of the VS in the PD group and DLPFC response in the AD group was found for the MIDT under placebo.
116-1	17567-17575	Blunting	_	
116-2	17576-17578	of	_	
116-3	17579-17582	the	_	
116-4	17583-17585	VS	_	
116-5	17586-17588	in	_	
116-6	17589-17592	the	_	
116-7	17593-17595	PD	_	
116-8	17596-17601	group	_	
116-9	17602-17605	and	_	
116-10	17606-17611	DLPFC	_	
116-11	17612-17620	response	_	
116-12	17621-17623	in	_	
116-13	17624-17627	the	_	
116-14	17628-17630	AD	_	
116-15	17631-17636	group	_	
116-16	17637-17640	was	_	
116-17	17641-17646	found	_	
116-18	17647-17650	for	_	
116-19	17651-17654	the	_	
116-20	17655-17659	MIDT	_	
116-21	17660-17665	under	_	
116-22	17666-17673	placebo	_	
116-23	17673-17674	.	_	

#Text=Enhanced inferior frontal response in the PD group and enhanced midbrain response in the AD group was found for the GNGT.
117-1	17675-17683	Enhanced	_	
117-2	17684-17692	inferior	_	
117-3	17693-17700	frontal	_	
117-4	17701-17709	response	_	
117-5	17710-17712	in	_	
117-6	17713-17716	the	_	
117-7	17717-17719	PD	_	
117-8	17720-17725	group	_	
117-9	17726-17729	and	_	
117-10	17730-17738	enhanced	_	
117-11	17739-17747	midbrain	_	
117-12	17748-17756	response	_	
117-13	17757-17759	in	_	
117-14	17760-17763	the	_	
117-15	17764-17766	AD	_	
117-16	17767-17772	group	_	
117-17	17773-17776	was	_	
117-18	17777-17782	found	_	
117-19	17783-17786	for	_	
117-20	17787-17790	the	_	
117-21	17791-17795	GNGT	_	
117-22	17795-17796	.	_	

#Text=There were no effects of either drug or group on task performance, therefore all reported differences in BOLD response occur in the context of normal performance.
118-1	17797-17802	There	_	
118-2	17803-17807	were	_	
118-3	17808-17810	no	_	
118-4	17811-17818	effects	_	
118-5	17819-17821	of	_	
118-6	17822-17828	either	_	
118-7	17829-17833	drug	_	
118-8	17834-17836	or	_	
118-9	17837-17842	group	_	
118-10	17843-17845	on	_	
118-11	17846-17850	task	_	
118-12	17851-17862	performance	_	
118-13	17862-17863	,	_	
118-14	17864-17873	therefore	_	
118-15	17874-17877	all	_	
118-16	17878-17886	reported	_	
118-17	17887-17898	differences	_	
118-18	17899-17901	in	_	
118-19	17902-17906	BOLD	_	
118-20	17907-17915	response	_	
118-21	17916-17921	occur	_	
118-22	17922-17924	in	_	
118-23	17925-17928	the	_	
118-24	17929-17936	context	_	
118-25	17937-17939	of	_	
118-26	17940-17946	normal	_	
118-27	17947-17958	performance	_	
118-28	17958-17959	.	_	

#Text=MID
#Text=Deficits in ventral striatal reward-related signaling are hypothesized to confer vulnerability to addiction and relapse.
119-1	17960-17963	MID	_	
119-2	17964-17972	Deficits	_	
119-3	17973-17975	in	_	
119-4	17976-17983	ventral	_	
119-5	17984-17992	striatal	_	
119-6	17993-18007	reward-related	_	
119-7	18008-18017	signaling	_	
119-8	18018-18021	are	_	
119-9	18022-18034	hypothesized	_	
119-10	18035-18037	to	_	
119-11	18038-18044	confer	_	
119-12	18045-18058	vulnerability	_	
119-13	18059-18061	to	_	
119-14	18062-18071	addiction	_	
119-15	18072-18075	and	_	
119-16	18076-18083	relapse	_	
119-17	18083-18084	.	_	

#Text=We found blunted ventral striatal response in the PD group, and an overall negative correlation between VS response and impulsivity.
120-1	18085-18087	We	_	
120-2	18088-18093	found	_	
120-3	18094-18101	blunted	_	
120-4	18102-18109	ventral	_	
120-5	18110-18118	striatal	_	
120-6	18119-18127	response	_	
120-7	18128-18130	in	_	
120-8	18131-18134	the	_	
120-9	18135-18137	PD	_	
120-10	18138-18143	group	_	
120-11	18143-18144	,	_	
120-12	18145-18148	and	_	
120-13	18149-18151	an	_	
120-14	18152-18159	overall	_	
120-15	18160-18168	negative	_	
120-16	18169-18180	correlation	_	
120-17	18181-18188	between	_	
120-18	18189-18191	VS	_	
120-19	18192-18200	response	_	
120-20	18201-18204	and	_	
120-21	18205-18216	impulsivity	_	
120-22	18216-18217	.	_	

#Text=Reduced MID VS response associated with increased impulsivity has been previously demonstrated in alcohol dependence, therefore our finding adds to a growing literature supporting the reward deficiency hypothesis of addiction.
121-1	18218-18225	Reduced	_	
121-2	18226-18229	MID	_	
121-3	18230-18232	VS	_	
121-4	18233-18241	response	_	
121-5	18242-18252	associated	_	
121-6	18253-18257	with	_	
121-7	18258-18267	increased	_	
121-8	18268-18279	impulsivity	_	
121-9	18280-18283	has	_	
121-10	18284-18288	been	_	
121-11	18289-18299	previously	_	
121-12	18300-18312	demonstrated	_	
121-13	18313-18315	in	_	
121-14	18316-18323	alcohol	_	
121-15	18324-18334	dependence	_	
121-16	18334-18335	,	_	
121-17	18336-18345	therefore	_	
121-18	18346-18349	our	_	
121-19	18350-18357	finding	_	
121-20	18358-18362	adds	_	
121-21	18363-18365	to	_	
121-22	18366-18367	a	_	
121-23	18368-18375	growing	_	
121-24	18376-18386	literature	_	
121-25	18387-18397	supporting	_	
121-26	18398-18401	the	_	
121-27	18402-18408	reward	_	
121-28	18409-18419	deficiency	_	
121-29	18420-18430	hypothesis	_	
121-30	18431-18433	of	_	
121-31	18434-18443	addiction	_	
121-32	18443-18444	.	_	

#Text=In contrast to the studies above, we did not find significant blunting in the AD group.
122-1	18445-18447	In	_	
122-2	18448-18456	contrast	_	
122-3	18457-18459	to	_	
122-4	18460-18463	the	_	
122-5	18464-18471	studies	_	
122-6	18472-18477	above	_	
122-7	18477-18478	,	_	
122-8	18479-18481	we	_	
122-9	18482-18485	did	_	
122-10	18486-18489	not	_	
122-11	18490-18494	find	_	
122-12	18495-18506	significant	_	
122-13	18507-18515	blunting	_	
122-14	18516-18518	in	_	
122-15	18519-18522	the	_	
122-16	18523-18525	AD	_	
122-17	18526-18531	group	_	
122-18	18531-18532	.	_	

#Text=This could suggest recovery with long-term abstinence in our cohort; however, we did not find a significant association between the length of abstinence and ventral striatal response in the AD group, perhaps owing to small sample size.
123-1	18533-18537	This	_	
123-2	18538-18543	could	_	
123-3	18544-18551	suggest	_	
123-4	18552-18560	recovery	_	
123-5	18561-18565	with	_	
123-6	18566-18575	long-term	_	
123-7	18576-18586	abstinence	_	
123-8	18587-18589	in	_	
123-9	18590-18593	our	_	
123-10	18594-18600	cohort	_	
123-11	18600-18601	;	_	
123-12	18602-18609	however	_	
123-13	18609-18610	,	_	
123-14	18611-18613	we	_	
123-15	18614-18617	did	_	
123-16	18618-18621	not	_	
123-17	18622-18626	find	_	
123-18	18627-18628	a	_	
123-19	18629-18640	significant	_	
123-20	18641-18652	association	_	
123-21	18653-18660	between	_	
123-22	18661-18664	the	_	
123-23	18665-18671	length	_	
123-24	18672-18674	of	_	
123-25	18675-18685	abstinence	_	
123-26	18686-18689	and	_	
123-27	18690-18697	ventral	_	
123-28	18698-18706	striatal	_	
123-29	18707-18715	response	_	
123-30	18716-18718	in	_	
123-31	18719-18722	the	_	
123-32	18723-18725	AD	_	
123-33	18726-18731	group	_	
123-34	18731-18732	,	_	
123-35	18733-18740	perhaps	_	
123-36	18741-18746	owing	_	
123-37	18747-18749	to	_	
123-38	18750-18755	small	_	
123-39	18756-18762	sample	_	
123-40	18763-18767	size	_	
123-41	18767-18768	.	_	

#Text=There was a general restorative or enhancing effect of GSK598809 on reward anticipatory BOLD response.
124-1	18769-18774	There	_	
124-2	18775-18778	was	_	
124-3	18779-18780	a	_	
124-4	18781-18788	general	_	
124-5	18789-18800	restorative	_	
124-6	18801-18803	or	_	
124-7	18804-18813	enhancing	_	
124-8	18814-18820	effect	_	
124-9	18821-18823	of	_	
124-10	18824-18833	GSK598809	_	
124-11	18834-18836	on	_	
124-12	18837-18843	reward	_	
124-13	18844-18856	anticipatory	_	
124-14	18857-18861	BOLD	_	
124-15	18862-18870	response	_	
124-16	18870-18871	.	_	

#Text=This finding is in line with evidence suggesting that D3 receptors may act as autoreceptors, inhibiting dopamine synthesis and release.
125-1	18872-18876	This	_	
125-2	18877-18884	finding	_	
125-3	18885-18887	is	_	
125-4	18888-18890	in	_	
125-5	18891-18895	line	_	
125-6	18896-18900	with	_	
125-7	18901-18909	evidence	_	
125-8	18910-18920	suggesting	_	
125-9	18921-18925	that	_	
125-10	18926-18928	D3	_	
125-11	18929-18938	receptors	_	
125-12	18939-18942	may	_	
125-13	18943-18946	act	_	
125-14	18947-18949	as	_	
125-15	18950-18963	autoreceptors	_	
125-16	18963-18964	,	_	
125-17	18965-18975	inhibiting	_	
125-18	18976-18984	dopamine	_	
125-19	18985-18994	synthesis	_	
125-20	18995-18998	and	_	
125-21	18999-19006	release	_	
125-22	19006-19007	.	_	

#Text=It has been hypothesized that tonic extracellular dopamine may inhibit phasic dopamine reward signaling via actions on autoreceptors.
126-1	19008-19010	It	_	
126-2	19011-19014	has	_	
126-3	19015-19019	been	_	
126-4	19020-19032	hypothesized	_	
126-5	19033-19037	that	_	
126-6	19038-19043	tonic	_	
126-7	19044-19057	extracellular	_	
126-8	19058-19066	dopamine	_	
126-9	19067-19070	may	_	
126-10	19071-19078	inhibit	_	
126-11	19079-19085	phasic	_	
126-12	19086-19094	dopamine	_	
126-13	19095-19101	reward	_	
126-14	19102-19111	signaling	_	
126-15	19112-19115	via	_	
126-16	19116-19123	actions	_	
126-17	19124-19126	on	_	
126-18	19127-19140	autoreceptors	_	
126-19	19140-19141	.	_	

#Text=This may explain the opposing effects on MID reward anticipatory BOLD response of GSK598809 and amphetamine, which releases dopamine.
127-1	19142-19146	This	_	
127-2	19147-19150	may	_	
127-3	19151-19158	explain	_	
127-4	19159-19162	the	_	
127-5	19163-19171	opposing	_	
127-6	19172-19179	effects	_	
127-7	19180-19182	on	_	
127-8	19183-19186	MID	_	
127-9	19187-19193	reward	_	
127-10	19194-19206	anticipatory	_	
127-11	19207-19211	BOLD	_	
127-12	19212-19220	response	_	
127-13	19221-19223	of	_	
127-14	19224-19233	GSK598809	_	
127-15	19234-19237	and	_	
127-16	19238-19249	amphetamine	_	
127-17	19249-19250	,	_	
127-18	19251-19256	which	_	
127-19	19257-19265	releases	_	
127-20	19266-19274	dopamine	_	
127-21	19274-19275	.	_	

#Text=Amphetamine increases tonic dopamine levels but decreasesreward anticipatory BOLD response.
128-1	19276-19287	Amphetamine	_	
128-2	19288-19297	increases	_	
128-3	19298-19303	tonic	_	
128-4	19304-19312	dopamine	_	
128-5	19313-19319	levels	_	
128-6	19320-19323	but	_	
128-7	19324-19339	decreasesreward	_	
128-8	19340-19352	anticipatory	_	
128-9	19353-19357	BOLD	_	
128-10	19358-19366	response	_	
128-11	19366-19367	.	_	

#Text=In contrast, by blocking D3 autoreceptors, GSK598809 may enhance phasic dopamine reward signaling and reward anticipatory BOLD response.
129-1	19368-19370	In	_	
129-2	19371-19379	contrast	_	
129-3	19379-19380	,	_	
129-4	19381-19383	by	_	
129-5	19384-19392	blocking	_	
129-6	19393-19395	D3	_	
129-7	19396-19409	autoreceptors	_	
129-8	19409-19410	,	_	
129-9	19411-19420	GSK598809	_	
129-10	19421-19424	may	_	
129-11	19425-19432	enhance	_	
129-12	19433-19439	phasic	_	
129-13	19440-19448	dopamine	_	
129-14	19449-19455	reward	_	
129-15	19456-19465	signaling	_	
129-16	19466-19469	and	_	
129-17	19470-19476	reward	_	
129-18	19477-19489	anticipatory	_	
129-19	19490-19494	BOLD	_	
129-20	19495-19503	response	_	
129-21	19503-19504	.	_	

#Text=This reward enhancing effect of dopamine autoreceptor blockade is supported by a recent study demonstrating low doses of the D2/D3 antagonist amisulpride (chosen to result in preferential autoreceptor blockade) increased MID reward responsivity in depressed patients.
130-1	19505-19509	This	_	
130-2	19510-19516	reward	_	
130-3	19517-19526	enhancing	_	
130-4	19527-19533	effect	_	
130-5	19534-19536	of	_	
130-6	19537-19545	dopamine	_	
130-7	19546-19558	autoreceptor	_	
130-8	19559-19567	blockade	_	
130-9	19568-19570	is	_	
130-10	19571-19580	supported	_	
130-11	19581-19583	by	_	
130-12	19584-19585	a	_	
130-13	19586-19592	recent	_	
130-14	19593-19598	study	_	
130-15	19599-19612	demonstrating	_	
130-16	19613-19616	low	_	
130-17	19617-19622	doses	_	
130-18	19623-19625	of	_	
130-19	19626-19629	the	_	
130-20	19630-19632	D2	_	
130-21	19632-19633	/	_	
130-22	19633-19635	D3	_	
130-23	19636-19646	antagonist	_	
130-24	19647-19658	amisulpride	_	
130-25	19659-19660	(	_	
130-26	19660-19666	chosen	_	
130-27	19667-19669	to	_	
130-28	19670-19676	result	_	
130-29	19677-19679	in	_	
130-30	19680-19692	preferential	_	
130-31	19693-19705	autoreceptor	_	
130-32	19706-19714	blockade	_	
130-33	19714-19715	)	_	
130-34	19716-19725	increased	_	
130-35	19726-19729	MID	_	
130-36	19730-19736	reward	_	
130-37	19737-19749	responsivity	_	
130-38	19750-19752	in	_	
130-39	19753-19762	depressed	_	
130-40	19763-19771	patients	_	
130-41	19771-19772	.	_	

#Text=Despite these BOLD enhancing effects of GSK598809, no behavioral effects were found.
131-1	19773-19780	Despite	_	
131-2	19781-19786	these	_	
131-3	19787-19791	BOLD	_	
131-4	19792-19801	enhancing	_	
131-5	19802-19809	effects	_	
131-6	19810-19812	of	_	
131-7	19813-19822	GSK598809	_	
131-8	19822-19823	,	_	
131-9	19824-19826	no	_	
131-10	19827-19837	behavioral	_	
131-11	19838-19845	effects	_	
131-12	19846-19850	were	_	
131-13	19851-19856	found	_	
131-14	19856-19857	.	_	

#Text=This may reflect ceiling effects as the behavioral requirements of the MIDT are very simple—reaction times were unimpaired in the placebo condition, suggesting that participants were already performing at maximum capacity for a speeded motor response.
132-1	19858-19862	This	_	
132-2	19863-19866	may	_	
132-3	19867-19874	reflect	_	
132-4	19875-19882	ceiling	_	
132-5	19883-19890	effects	_	
132-6	19891-19893	as	_	
132-7	19894-19897	the	_	
132-8	19898-19908	behavioral	_	
132-9	19909-19921	requirements	_	
132-10	19922-19924	of	_	
132-11	19925-19928	the	_	
132-12	19929-19933	MIDT	_	
132-13	19934-19937	are	_	
132-14	19938-19942	very	_	
132-15	19943-19958	simple—reaction	_	
132-16	19959-19964	times	_	
132-17	19965-19969	were	_	
132-18	19970-19980	unimpaired	_	
132-19	19981-19983	in	_	
132-20	19984-19987	the	_	
132-21	19988-19995	placebo	_	
132-22	19996-20005	condition	_	
132-23	20005-20006	,	_	
132-24	20007-20017	suggesting	_	
132-25	20018-20022	that	_	
132-26	20023-20035	participants	_	
132-27	20036-20040	were	_	
132-28	20041-20048	already	_	
132-29	20049-20059	performing	_	
132-30	20060-20062	at	_	
132-31	20063-20070	maximum	_	
132-32	20071-20079	capacity	_	
132-33	20080-20083	for	_	
132-34	20084-20085	a	_	
132-35	20086-20093	speeded	_	
132-36	20094-20099	motor	_	
132-37	20100-20108	response	_	
132-38	20108-20109	.	_	

#Text=Furthermore, 60 mg of GSK598809 results in only partial D3 blockade, therefore behavioral effects may emerge with increasing dose.
133-1	20110-20121	Furthermore	_	
133-2	20121-20122	,	_	
133-3	20123-20125	60	_	
133-4	20126-20128	mg	_	
133-5	20129-20131	of	_	
133-6	20132-20141	GSK598809	_	
133-7	20142-20149	results	_	
133-8	20150-20152	in	_	
133-9	20153-20157	only	_	
133-10	20158-20165	partial	_	
133-11	20166-20168	D3	_	
133-12	20169-20177	blockade	_	
133-13	20177-20178	,	_	
133-14	20179-20188	therefore	_	
133-15	20189-20199	behavioral	_	
133-16	20200-20207	effects	_	
133-17	20208-20211	may	_	
133-18	20212-20218	emerge	_	
133-19	20219-20223	with	_	
133-20	20224-20234	increasing	_	
133-21	20235-20239	dose	_	
133-22	20239-20240	.	_	

#Text=Although no significant drug-by-group interactions were found, the effects of GSK598809 appeared to be largely driven by effects within the abstinent drug-dependent groups rather than controls (especially within the DRD3-rich VP where a strong trend to an interaction was observed).
134-1	20241-20249	Although	_	
134-2	20250-20252	no	_	
134-3	20253-20264	significant	_	
134-4	20265-20278	drug-by-group	_	
134-5	20279-20291	interactions	_	
134-6	20292-20296	were	_	
134-7	20297-20302	found	_	
134-8	20302-20303	,	_	
134-9	20304-20307	the	_	
134-10	20308-20315	effects	_	
134-11	20316-20318	of	_	
134-12	20319-20328	GSK598809	_	
134-13	20329-20337	appeared	_	
134-14	20338-20340	to	_	
134-15	20341-20343	be	_	
134-16	20344-20351	largely	_	
134-17	20352-20358	driven	_	
134-18	20359-20361	by	_	
134-19	20362-20369	effects	_	
134-20	20370-20376	within	_	
134-21	20377-20380	the	_	
134-22	20381-20390	abstinent	_	
134-23	20391-20405	drug-dependent	_	
134-24	20406-20412	groups	_	
134-25	20413-20419	rather	_	
134-26	20420-20424	than	_	
134-27	20425-20433	controls	_	
134-28	20434-20435	(	_	
134-29	20435-20445	especially	_	
134-30	20446-20452	within	_	
134-31	20453-20456	the	_	
134-32	20457-20461	DRD3	_	
134-33	20461-20462	-	_	
134-34	20462-20466	rich	_	
134-35	20467-20469	VP	_	
134-36	20470-20475	where	_	
134-37	20476-20477	a	_	
134-38	20478-20484	strong	_	
134-39	20485-20490	trend	_	
134-40	20491-20493	to	_	
134-41	20494-20496	an	_	
134-42	20497-20508	interaction	_	
134-43	20509-20512	was	_	
134-44	20513-20521	observed	_	
134-45	20521-20522	)	_	
134-46	20522-20523	.	_	

#Text=These patterns may be due to upregulation of DRD3s in stimulant and alcohol dependence and evidence of enhanced dopamine autoreceptor actions in response to chronic exposure to alcohol.
135-1	20524-20529	These	_	
135-2	20530-20538	patterns	_	
135-3	20539-20542	may	_	
135-4	20543-20545	be	_	
135-5	20546-20549	due	_	
135-6	20550-20552	to	_	
135-7	20553-20565	upregulation	_	
135-8	20566-20568	of	_	
135-9	20569-20574	DRD3s	_	
135-10	20575-20577	in	_	
135-11	20578-20587	stimulant	_	
135-12	20588-20591	and	_	
135-13	20592-20599	alcohol	_	
135-14	20600-20610	dependence	_	
135-15	20611-20614	and	_	
135-16	20615-20623	evidence	_	
135-17	20624-20626	of	_	
135-18	20627-20635	enhanced	_	
135-19	20636-20644	dopamine	_	
135-20	20645-20657	autoreceptor	_	
135-21	20658-20665	actions	_	
135-22	20666-20668	in	_	
135-23	20669-20677	response	_	
135-24	20678-20680	to	_	
135-25	20681-20688	chronic	_	
135-26	20689-20697	exposure	_	
135-27	20698-20700	to	_	
135-28	20701-20708	alcohol	_	
135-29	20708-20709	.	_	

#Text=While requiring replication in a larger sample, exploratory investigations raised the intriguing possibility that GSK598809 may be relatively ineffective in opiate dependence.
136-1	20710-20715	While	_	
136-2	20716-20725	requiring	_	
136-3	20726-20737	replication	_	
136-4	20738-20740	in	_	
136-5	20741-20742	a	_	
136-6	20743-20749	larger	_	
136-7	20750-20756	sample	_	
136-8	20756-20757	,	_	
136-9	20758-20769	exploratory	_	
136-10	20770-20784	investigations	_	
136-11	20785-20791	raised	_	
136-12	20792-20795	the	_	
136-13	20796-20806	intriguing	_	
136-14	20807-20818	possibility	_	
136-15	20819-20823	that	_	
136-16	20824-20833	GSK598809	_	
136-17	20834-20837	may	_	
136-18	20838-20840	be	_	
136-19	20841-20851	relatively	_	
136-20	20852-20863	ineffective	_	
136-21	20864-20866	in	_	
136-22	20867-20873	opiate	_	
136-23	20874-20884	dependence	_	
136-24	20884-20885	.	_	

#Text=At the time of writing, we were unable to find any published studies on DRD3 density in human opiate addicts.
137-1	20886-20888	At	_	
137-2	20889-20892	the	_	
137-3	20893-20897	time	_	
137-4	20898-20900	of	_	
137-5	20901-20908	writing	_	
137-6	20908-20909	,	_	
137-7	20910-20912	we	_	
137-8	20913-20917	were	_	
137-9	20918-20924	unable	_	
137-10	20925-20927	to	_	
137-11	20928-20932	find	_	
137-12	20933-20936	any	_	
137-13	20937-20946	published	_	
137-14	20947-20954	studies	_	
137-15	20955-20957	on	_	
137-16	20958-20962	DRD3	_	
137-17	20963-20970	density	_	
137-18	20971-20973	in	_	
137-19	20974-20979	human	_	
137-20	20980-20986	opiate	_	
137-21	20987-20994	addicts	_	
137-22	20994-20995	.	_	

#Text=However, in contrast to the increases in DRD3 expression in rodents after alcohol and cocaine exposure, a very recent study demonstrated that heroin exposure decreased DRD3 expression, possibly explaining the apparent reduced efficacy of GSK598809 in those with a primary opiate dependence.
138-1	20996-21003	However	_	
138-2	21003-21004	,	_	
138-3	21005-21007	in	_	
138-4	21008-21016	contrast	_	
138-5	21017-21019	to	_	
138-6	21020-21023	the	_	
138-7	21024-21033	increases	_	
138-8	21034-21036	in	_	
138-9	21037-21041	DRD3	_	
138-10	21042-21052	expression	_	
138-11	21053-21055	in	_	
138-12	21056-21063	rodents	_	
138-13	21064-21069	after	_	
138-14	21070-21077	alcohol	_	
138-15	21078-21081	and	_	
138-16	21082-21089	cocaine	_	
138-17	21090-21098	exposure	_	
138-18	21098-21099	,	_	
138-19	21100-21101	a	_	
138-20	21102-21106	very	_	
138-21	21107-21113	recent	_	
138-22	21114-21119	study	_	
138-23	21120-21132	demonstrated	_	
138-24	21133-21137	that	_	
138-25	21138-21144	heroin	_	
138-26	21145-21153	exposure	_	
138-27	21154-21163	decreased	_	
138-28	21164-21168	DRD3	_	
138-29	21169-21179	expression	_	
138-30	21179-21180	,	_	
138-31	21181-21189	possibly	_	
138-32	21190-21200	explaining	_	
138-33	21201-21204	the	_	
138-34	21205-21213	apparent	_	
138-35	21214-21221	reduced	_	
138-36	21222-21230	efficacy	_	
138-37	21231-21233	of	_	
138-38	21234-21243	GSK598809	_	
138-39	21244-21246	in	_	
138-40	21247-21252	those	_	
138-41	21253-21257	with	_	
138-42	21258-21259	a	_	
138-43	21260-21267	primary	_	
138-44	21268-21274	opiate	_	
138-45	21275-21285	dependence	_	
138-46	21285-21286	.	_	

#Text=In addition to effects within DRD3-rich regions, whole-brain analyses revealed effects within the caudate, cerebellum, and DLPFC.
139-1	21287-21289	In	_	
139-2	21290-21298	addition	_	
139-3	21299-21301	to	_	
139-4	21302-21309	effects	_	
139-5	21310-21316	within	_	
139-6	21317-21321	DRD3	_	
139-7	21321-21322	-	_	
139-8	21322-21326	rich	_	
139-9	21327-21334	regions	_	
139-10	21334-21335	,	_	
139-11	21336-21347	whole-brain	_	
139-12	21348-21356	analyses	_	
139-13	21357-21365	revealed	_	
139-14	21366-21373	effects	_	
139-15	21374-21380	within	_	
139-16	21381-21384	the	_	
139-17	21385-21392	caudate	_	
139-18	21392-21393	,	_	
139-19	21394-21404	cerebellum	_	
139-20	21404-21405	,	_	
139-21	21406-21409	and	_	
139-22	21410-21415	DLPFC	_	
139-23	21415-21416	.	_	

#Text=In vivo PET studies do not report high DRD3 levels within these regions.
140-1	21417-21419	In	_	
140-2	21420-21424	vivo	_	
140-3	21425-21428	PET	_	
140-4	21429-21436	studies	_	
140-5	21437-21439	do	_	
140-6	21440-21443	not	_	
140-7	21444-21450	report	_	
140-8	21451-21455	high	_	
140-9	21456-21460	DRD3	_	
140-10	21461-21467	levels	_	
140-11	21468-21474	within	_	
140-12	21475-21480	these	_	
140-13	21481-21488	regions	_	
140-14	21488-21489	.	_	

#Text=An enhanced MIDT reward anticipatory caudate response was also found with DRD3 receptor blocking doses of amisulpride.
141-1	21490-21492	An	_	
141-2	21493-21501	enhanced	_	
141-3	21502-21506	MIDT	_	
141-4	21507-21513	reward	_	
141-5	21514-21526	anticipatory	_	
141-6	21527-21534	caudate	_	
141-7	21535-21543	response	_	
141-8	21544-21547	was	_	
141-9	21548-21552	also	_	
141-10	21553-21558	found	_	
141-11	21559-21563	with	_	
141-12	21564-21568	DRD3	_	
141-13	21569-21577	receptor	_	
141-14	21578-21586	blocking	_	
141-15	21587-21592	doses	_	
141-16	21593-21595	of	_	
141-17	21596-21607	amisulpride	_	
141-18	21607-21608	.	_	

#Text=There is evidence supporting the caudate, lateral prefrontal regions, and cerebellum to be important regions mediating the integration of motivation with goal-directed behavior.
142-1	21609-21614	There	_	
142-2	21615-21617	is	_	
142-3	21618-21626	evidence	_	
142-4	21627-21637	supporting	_	
142-5	21638-21641	the	_	
142-6	21642-21649	caudate	_	
142-7	21649-21650	,	_	
142-8	21651-21658	lateral	_	
142-9	21659-21669	prefrontal	_	
142-10	21670-21677	regions	_	
142-11	21677-21678	,	_	
142-12	21679-21682	and	_	
142-13	21683-21693	cerebellum	_	
142-14	21694-21696	to	_	
142-15	21697-21699	be	_	
142-16	21700-21709	important	_	
142-17	21710-21717	regions	_	
142-18	21718-21727	mediating	_	
142-19	21728-21731	the	_	
142-20	21732-21743	integration	_	
142-21	21744-21746	of	_	
142-22	21747-21757	motivation	_	
142-23	21758-21762	with	_	
142-24	21763-21776	goal-directed	_	
142-25	21777-21785	behavior	_	
142-26	21785-21786	.	_	

#Text=Enhanced activation within these regions may therefore be a downstream consequence of GSK598809’s effects on the VS and VP, regions critically involved in incentive motivation.
143-1	21787-21795	Enhanced	_	
143-2	21796-21806	activation	_	
143-3	21807-21813	within	_	
143-4	21814-21819	these	_	
143-5	21820-21827	regions	_	
143-6	21828-21831	may	_	
143-7	21832-21841	therefore	_	
143-8	21842-21844	be	_	
143-9	21845-21846	a	_	
143-10	21847-21857	downstream	_	
143-11	21858-21869	consequence	_	
143-12	21870-21872	of	_	
143-13	21873-21882	GSK598809	_	
143-14	21882-21883	’	_	
143-15	21883-21884	s	_	
143-16	21885-21892	effects	_	
143-17	21893-21895	on	_	
143-18	21896-21899	the	_	
143-19	21900-21902	VS	_	
143-20	21903-21906	and	_	
143-21	21907-21909	VP	_	
143-22	21909-21910	,	_	
143-23	21911-21918	regions	_	
143-24	21919-21929	critically	_	
143-25	21930-21938	involved	_	
143-26	21939-21941	in	_	
143-27	21942-21951	incentive	_	
143-28	21952-21962	motivation	_	
143-29	21962-21963	.	_	

#Text=Together, these findings suggest hypofunctioning of reward signaling in substance dependence.
144-1	21964-21972	Together	_	
144-2	21972-21973	,	_	
144-3	21974-21979	these	_	
144-4	21980-21988	findings	_	
144-5	21989-21996	suggest	_	
144-6	21997-22012	hypofunctioning	_	
144-7	22013-22015	of	_	
144-8	22016-22022	reward	_	
144-9	22023-22032	signaling	_	
144-10	22033-22035	in	_	
144-11	22036-22045	substance	_	
144-12	22046-22056	dependence	_	
144-13	22056-22057	.	_	

#Text=Evidence suggests, in alcohol and stimulant dependence, that this may be caused, in part, by excessive D3 autoreceptor inhibition of dopamine systems.
145-1	22058-22066	Evidence	_	
145-2	22067-22075	suggests	_	
145-3	22075-22076	,	_	
145-4	22077-22079	in	_	
145-5	22080-22087	alcohol	_	
145-6	22088-22091	and	_	
145-7	22092-22101	stimulant	_	
145-8	22102-22112	dependence	_	
145-9	22112-22113	,	_	
145-10	22114-22118	that	_	
145-11	22119-22123	this	_	
145-12	22124-22127	may	_	
145-13	22128-22130	be	_	
145-14	22131-22137	caused	_	
145-15	22137-22138	,	_	
145-16	22139-22141	in	_	
145-17	22142-22146	part	_	
145-18	22146-22147	,	_	
145-19	22148-22150	by	_	
145-20	22151-22160	excessive	_	
145-21	22161-22163	D3	_	
145-22	22164-22176	autoreceptor	_	
145-23	22177-22187	inhibition	_	
145-24	22188-22190	of	_	
145-25	22191-22199	dopamine	_	
145-26	22200-22207	systems	_	
145-27	22207-22208	.	_	

#Text=GSK898809 may ameliorate reward deficits by disinhibiting these systems.
146-1	22209-22218	GSK898809	_	
146-2	22219-22222	may	_	
146-3	22223-22233	ameliorate	_	
146-4	22234-22240	reward	_	
146-5	22241-22249	deficits	_	
146-6	22250-22252	by	_	
146-7	22253-22266	disinhibiting	_	
146-8	22267-22272	these	_	
146-9	22273-22280	systems	_	
146-10	22280-22281	.	_	

#Text=GNG
#Text=In contrast to GNG studies demonstrating prefrontal hypoactivation and impaired response inhibition in current dependence, we found hyperactivation of lateral prefrontal regions (PD group) or midbrain (AD group) together with unimpaired behavioral performance.
147-1	22282-22285	GNG	_	
147-2	22286-22288	In	_	
147-3	22289-22297	contrast	_	
147-4	22298-22300	to	_	
147-5	22301-22304	GNG	_	
147-6	22305-22312	studies	_	
147-7	22313-22326	demonstrating	_	
147-8	22327-22337	prefrontal	_	
147-9	22338-22352	hypoactivation	_	
147-10	22353-22356	and	_	
147-11	22357-22365	impaired	_	
147-12	22366-22374	response	_	
147-13	22375-22385	inhibition	_	
147-14	22386-22388	in	_	
147-15	22389-22396	current	_	
147-16	22397-22407	dependence	_	
147-17	22407-22408	,	_	
147-18	22409-22411	we	_	
147-19	22412-22417	found	_	
147-20	22418-22433	hyperactivation	_	
147-21	22434-22436	of	_	
147-22	22437-22444	lateral	_	
147-23	22445-22455	prefrontal	_	
147-24	22456-22463	regions	_	
147-25	22464-22465	(	_	
147-26	22465-22467	PD	_	
147-27	22468-22473	group	_	
147-28	22473-22474	)	_	
147-29	22475-22477	or	_	
147-30	22478-22486	midbrain	_	
147-31	22487-22488	(	_	
147-32	22488-22490	AD	_	
147-33	22491-22496	group	_	
147-34	22496-22497	)	_	
147-35	22498-22506	together	_	
147-36	22507-22511	with	_	
147-37	22512-22522	unimpaired	_	
147-38	22523-22533	behavioral	_	
147-39	22534-22545	performance	_	
147-40	22545-22546	.	_	

#Text=Our results are consistent with two other studies in cocaine and alcohol abstinence.
148-1	22547-22550	Our	_	
148-2	22551-22558	results	_	
148-3	22559-22562	are	_	
148-4	22563-22573	consistent	_	
148-5	22574-22578	with	_	
148-6	22579-22582	two	_	
148-7	22583-22588	other	_	
148-8	22589-22596	studies	_	
148-9	22597-22599	in	_	
148-10	22600-22607	cocaine	_	
148-11	22608-22611	and	_	
148-12	22612-22619	alcohol	_	
148-13	22620-22630	abstinence	_	
148-14	22630-22631	.	_	

#Text=They perhaps reflect recovery of prefrontal structure and function in successful abstinence owing to cessation of drug use and cognitive control practices.
149-1	22632-22636	They	_	
149-2	22637-22644	perhaps	_	
149-3	22645-22652	reflect	_	
149-4	22653-22661	recovery	_	
149-5	22662-22664	of	_	
149-6	22665-22675	prefrontal	_	
149-7	22676-22685	structure	_	
149-8	22686-22689	and	_	
149-9	22690-22698	function	_	
149-10	22699-22701	in	_	
149-11	22702-22712	successful	_	
149-12	22713-22723	abstinence	_	
149-13	22724-22729	owing	_	
149-14	22730-22732	to	_	
149-15	22733-22742	cessation	_	
149-16	22743-22745	of	_	
149-17	22746-22750	drug	_	
149-18	22751-22754	use	_	
149-19	22755-22758	and	_	
149-20	22759-22768	cognitive	_	
149-21	22769-22776	control	_	
149-22	22777-22786	practices	_	
149-23	22786-22787	.	_	

#Text=Whether this hyperactivation, which is also found in relatives of alcohol patients, is protective for relapse or an addiction vulnerability marker is unknown.
150-1	22788-22795	Whether	_	
150-2	22796-22800	this	_	
150-3	22801-22816	hyperactivation	_	
150-4	22816-22817	,	_	
150-5	22818-22823	which	_	
150-6	22824-22826	is	_	
150-7	22827-22831	also	_	
150-8	22832-22837	found	_	
150-9	22838-22840	in	_	
150-10	22841-22850	relatives	_	
150-11	22851-22853	of	_	
150-12	22854-22861	alcohol	_	
150-13	22862-22870	patients	_	
150-14	22870-22871	,	_	
150-15	22872-22874	is	_	
150-16	22875-22885	protective	_	
150-17	22886-22889	for	_	
150-18	22890-22897	relapse	_	
150-19	22898-22900	or	_	
150-20	22901-22903	an	_	
150-21	22904-22913	addiction	_	
150-22	22914-22927	vulnerability	_	
150-23	22928-22934	marker	_	
150-24	22935-22937	is	_	
150-25	22938-22945	unknown	_	
150-26	22945-22946	.	_	

#Text=However, fMRI hyperactivation during cognitive tasks has been reported in detoxified alcohol-dependent participants who subsequently abstained but not in those who relapsed, supporting the notion that prefrontal hyperactivation may be protective.
151-1	22947-22954	However	_	
151-2	22954-22955	,	_	
151-3	22956-22960	fMRI	_	
151-4	22961-22976	hyperactivation	_	
151-5	22977-22983	during	_	
151-6	22984-22993	cognitive	_	
151-7	22994-22999	tasks	_	
151-8	23000-23003	has	_	
151-9	23004-23008	been	_	
151-10	23009-23017	reported	_	
151-11	23018-23020	in	_	
151-12	23021-23031	detoxified	_	
151-13	23032-23049	alcohol-dependent	_	
151-14	23050-23062	participants	_	
151-15	23063-23066	who	_	
151-16	23067-23079	subsequently	_	
151-17	23080-23089	abstained	_	
151-18	23090-23093	but	_	
151-19	23094-23097	not	_	
151-20	23098-23100	in	_	
151-21	23101-23106	those	_	
151-22	23107-23110	who	_	
151-23	23111-23119	relapsed	_	
151-24	23119-23120	,	_	
151-25	23121-23131	supporting	_	
151-26	23132-23135	the	_	
151-27	23136-23142	notion	_	
151-28	23143-23147	that	_	
151-29	23148-23158	prefrontal	_	
151-30	23159-23174	hyperactivation	_	
151-31	23175-23178	may	_	
151-32	23179-23181	be	_	
151-33	23182-23192	protective	_	
151-34	23192-23193	.	_	

#Text=Despite previous studies suggesting a link between overexpression of DRD3s and increased impulsivity as measured by questionnaire, we found no evidence to suggest GSK598809-modulated performance or neuronal response of the network underlying response inhibition.
152-1	23194-23201	Despite	_	
152-2	23202-23210	previous	_	
152-3	23211-23218	studies	_	
152-4	23219-23229	suggesting	_	
152-5	23230-23231	a	_	
152-6	23232-23236	link	_	
152-7	23237-23244	between	_	
152-8	23245-23259	overexpression	_	
152-9	23260-23262	of	_	
152-10	23263-23268	DRD3s	_	
152-11	23269-23272	and	_	
152-12	23273-23282	increased	_	
152-13	23283-23294	impulsivity	_	
152-14	23295-23297	as	_	
152-15	23298-23306	measured	_	
152-16	23307-23309	by	_	
152-17	23310-23323	questionnaire	_	
152-18	23323-23324	,	_	
152-19	23325-23327	we	_	
152-20	23328-23333	found	_	
152-21	23334-23336	no	_	
152-22	23337-23345	evidence	_	
152-23	23346-23348	to	_	
152-24	23349-23356	suggest	_	
152-25	23357-23366	GSK598809	_	
152-26	23366-23367	-	_	
152-27	23367-23376	modulated	_	
152-28	23377-23388	performance	_	
152-29	23389-23391	or	_	
152-30	23392-23400	neuronal	_	
152-31	23401-23409	response	_	
152-32	23410-23412	of	_	
152-33	23413-23416	the	_	
152-34	23417-23424	network	_	
152-35	23425-23435	underlying	_	
152-36	23436-23444	response	_	
152-37	23445-23455	inhibition	_	
152-38	23455-23456	.	_	

#Text=This may be due to the multifaceted nature of impulsivity, with DRD3s affecting some impulsivity measures but not response inhibition as measured here.
153-1	23457-23461	This	_	
153-2	23462-23465	may	_	
153-3	23466-23468	be	_	
153-4	23469-23472	due	_	
153-5	23473-23475	to	_	
153-6	23476-23479	the	_	
153-7	23480-23492	multifaceted	_	
153-8	23493-23499	nature	_	
153-9	23500-23502	of	_	
153-10	23503-23514	impulsivity	_	
153-11	23514-23515	,	_	
153-12	23516-23520	with	_	
153-13	23521-23526	DRD3s	_	
153-14	23527-23536	affecting	_	
153-15	23537-23541	some	_	
153-16	23542-23553	impulsivity	_	
153-17	23554-23562	measures	_	
153-18	23563-23566	but	_	
153-19	23567-23570	not	_	
153-20	23571-23579	response	_	
153-21	23580-23590	inhibition	_	
153-22	23591-23593	as	_	
153-23	23594-23602	measured	_	
153-24	23603-23607	here	_	
153-25	23607-23608	.	_	

#Text=We found no association between a questionnaire measure of impulsivity and GNG brain response or performance.
154-1	23609-23611	We	_	
154-2	23612-23617	found	_	
154-3	23618-23620	no	_	
154-4	23621-23632	association	_	
154-5	23633-23640	between	_	
154-6	23641-23642	a	_	
154-7	23643-23656	questionnaire	_	
154-8	23657-23664	measure	_	
154-9	23665-23667	of	_	
154-10	23668-23679	impulsivity	_	
154-11	23680-23683	and	_	
154-12	23684-23687	GNG	_	
154-13	23688-23693	brain	_	
154-14	23694-23702	response	_	
154-15	23703-23705	or	_	
154-16	23706-23717	performance	_	
154-17	23717-23718	.	_	

#Text=Furthermore, while mood-related impulsivity correlates more strongly with D2/D3 binding in the ventral rather than dorsal striatum in pathological gamblers, response inhibition correlates with receptor binding in the dorsal (where DRD3 density is low) but not the VS.
155-1	23719-23730	Furthermore	_	
155-2	23730-23731	,	_	
155-3	23732-23737	while	_	
155-4	23738-23750	mood-related	_	
155-5	23751-23762	impulsivity	_	
155-6	23763-23773	correlates	_	
155-7	23774-23778	more	_	
155-8	23779-23787	strongly	_	
155-9	23788-23792	with	_	
155-10	23793-23795	D2	_	
155-11	23795-23796	/	_	
155-12	23796-23798	D3	_	
155-13	23799-23806	binding	_	
155-14	23807-23809	in	_	
155-15	23810-23813	the	_	
155-16	23814-23821	ventral	_	
155-17	23822-23828	rather	_	
155-18	23829-23833	than	_	
155-19	23834-23840	dorsal	_	
155-20	23841-23849	striatum	_	
155-21	23850-23852	in	_	
155-22	23853-23865	pathological	_	
155-23	23866-23874	gamblers	_	
155-24	23874-23875	,	_	
155-25	23876-23884	response	_	
155-26	23885-23895	inhibition	_	
155-27	23896-23906	correlates	_	
155-28	23907-23911	with	_	
155-29	23912-23920	receptor	_	
155-30	23921-23928	binding	_	
155-31	23929-23931	in	_	
155-32	23932-23935	the	_	
155-33	23936-23942	dorsal	_	
155-34	23943-23944	(	_	
155-35	23944-23949	where	_	
155-36	23950-23954	DRD3	_	
155-37	23955-23962	density	_	
155-38	23963-23965	is	_	
155-39	23966-23969	low	_	
155-40	23969-23970	)	_	
155-41	23971-23974	but	_	
155-42	23975-23978	not	_	
155-43	23979-23982	the	_	
155-44	23983-23985	VS	_	
155-45	23985-23986	.	_	

#Text=These findings suggest that different impulsivity measures have different underlying neuro-circuitry.
156-1	23987-23992	These	_	
156-2	23993-24001	findings	_	
156-3	24002-24009	suggest	_	
156-4	24010-24014	that	_	
156-5	24015-24024	different	_	
156-6	24025-24036	impulsivity	_	
156-7	24037-24045	measures	_	
156-8	24046-24050	have	_	
156-9	24051-24060	different	_	
156-10	24061-24071	underlying	_	
156-11	24072-24087	neuro-circuitry	_	
156-12	24087-24088	.	_	

#Text=Prefrontal regions are important for response inhibition, again regions where DRD3s are low.
157-1	24089-24099	Prefrontal	_	
157-2	24100-24107	regions	_	
157-3	24108-24111	are	_	
157-4	24112-24121	important	_	
157-5	24122-24125	for	_	
157-6	24126-24134	response	_	
157-7	24135-24145	inhibition	_	
157-8	24145-24146	,	_	
157-9	24147-24152	again	_	
157-10	24153-24160	regions	_	
157-11	24161-24166	where	_	
157-12	24167-24172	DRD3s	_	
157-13	24173-24176	are	_	
157-14	24177-24180	low	_	
157-15	24180-24181	.	_	

#Text=Low DRD3 density in regions implicated in response inhibition may explain the lack of a modulatory effect of GSK598809 in our study.
158-1	24182-24185	Low	_	
158-2	24186-24190	DRD3	_	
158-3	24191-24198	density	_	
158-4	24199-24201	in	_	
158-5	24202-24209	regions	_	
158-6	24210-24220	implicated	_	
158-7	24221-24223	in	_	
158-8	24224-24232	response	_	
158-9	24233-24243	inhibition	_	
158-10	24244-24247	may	_	
158-11	24248-24255	explain	_	
158-12	24256-24259	the	_	
158-13	24260-24264	lack	_	
158-14	24265-24267	of	_	
158-15	24268-24269	a	_	
158-16	24270-24280	modulatory	_	
158-17	24281-24287	effect	_	
158-18	24288-24290	of	_	
158-19	24291-24300	GSK598809	_	
158-20	24301-24303	in	_	
158-21	24304-24307	our	_	
158-22	24308-24313	study	_	
158-23	24313-24314	.	_	

#Text=We additionally carried out exploratory investigations within the DRD3-rich regions for the GNGT.
159-1	24315-24317	We	_	
159-2	24318-24330	additionally	_	
159-3	24331-24338	carried	_	
159-4	24339-24342	out	_	
159-5	24343-24354	exploratory	_	
159-6	24355-24369	investigations	_	
159-7	24370-24376	within	_	
159-8	24377-24380	the	_	
159-9	24381-24385	DRD3	_	
159-10	24385-24386	-	_	
159-11	24386-24390	rich	_	
159-12	24391-24398	regions	_	
159-13	24399-24402	for	_	
159-14	24403-24406	the	_	
159-15	24407-24411	GNGT	_	
159-16	24411-24412	.	_	

#Text=However, no effects of GSK598809 modulations were found.
160-1	24413-24420	However	_	
160-2	24420-24421	,	_	
160-3	24422-24424	no	_	
160-4	24425-24432	effects	_	
160-5	24433-24435	of	_	
160-6	24436-24445	GSK598809	_	
160-7	24446-24457	modulations	_	
160-8	24458-24462	were	_	
160-9	24463-24468	found	_	
160-10	24468-24469	.	_	

#Text=These findings suggest that D3 agents selectively modulate brain mechanisms of incentive motivation.
161-1	24470-24475	These	_	
161-2	24476-24484	findings	_	
161-3	24485-24492	suggest	_	
161-4	24493-24497	that	_	
161-5	24498-24500	D3	_	
161-6	24501-24507	agents	_	
161-7	24508-24519	selectively	_	
161-8	24520-24528	modulate	_	
161-9	24529-24534	brain	_	
161-10	24535-24545	mechanisms	_	
161-11	24546-24548	of	_	
161-12	24549-24558	incentive	_	
161-13	24559-24569	motivation	_	
161-14	24569-24570	.	_	

#Text=Limitations
#Text=The main limitation of the study was the introduction of an order confound, arising from (ultimately groundless) concerns over study dropout.
162-1	24571-24582	Limitations	_	
162-2	24583-24586	The	_	
162-3	24587-24591	main	_	
162-4	24592-24602	limitation	_	
162-5	24603-24605	of	_	
162-6	24606-24609	the	_	
162-7	24610-24615	study	_	
162-8	24616-24619	was	_	
162-9	24620-24623	the	_	
162-10	24624-24636	introduction	_	
162-11	24637-24639	of	_	
162-12	24640-24642	an	_	
162-13	24643-24648	order	_	
162-14	24649-24657	confound	_	
162-15	24657-24658	,	_	
162-16	24659-24666	arising	_	
162-17	24667-24671	from	_	
162-18	24672-24673	(	_	
162-19	24673-24683	ultimately	_	
162-20	24684-24694	groundless	_	
162-21	24694-24695	)	_	
162-22	24696-24704	concerns	_	
162-23	24705-24709	over	_	
162-24	24710-24715	study	_	
162-25	24716-24723	dropout	_	
162-26	24723-24724	.	_	

#Text=However, practice and habituation effects were minimized by all participants having carried out the tasks in full within the scanner at screening (placebo session was either the second or third task scanning session), and the tasks being practiced outside the scanner before each session.
163-1	24725-24732	However	_	
163-2	24732-24733	,	_	
163-3	24734-24742	practice	_	
163-4	24743-24746	and	_	
163-5	24747-24758	habituation	_	
163-6	24759-24766	effects	_	
163-7	24767-24771	were	_	
163-8	24772-24781	minimized	_	
163-9	24782-24784	by	_	
163-10	24785-24788	all	_	
163-11	24789-24801	participants	_	
163-12	24802-24808	having	_	
163-13	24809-24816	carried	_	
163-14	24817-24820	out	_	
163-15	24821-24824	the	_	
163-16	24825-24830	tasks	_	
163-17	24831-24833	in	_	
163-18	24834-24838	full	_	
163-19	24839-24845	within	_	
163-20	24846-24849	the	_	
163-21	24850-24857	scanner	_	
163-22	24858-24860	at	_	
163-23	24861-24870	screening	_	
163-24	24871-24872	(	_	
163-25	24872-24879	placebo	_	
163-26	24880-24887	session	_	
163-27	24888-24891	was	_	
163-28	24892-24898	either	_	
163-29	24899-24902	the	_	
163-30	24903-24909	second	_	
163-31	24910-24912	or	_	
163-32	24913-24918	third	_	
163-33	24919-24923	task	_	
163-34	24924-24932	scanning	_	
163-35	24933-24940	session	_	
163-36	24940-24941	)	_	
163-37	24941-24942	,	_	
163-38	24943-24946	and	_	
163-39	24947-24950	the	_	
163-40	24951-24956	tasks	_	
163-41	24957-24962	being	_	
163-42	24963-24972	practiced	_	
163-43	24973-24980	outside	_	
163-44	24981-24984	the	_	
163-45	24985-24992	scanner	_	
163-46	24993-24999	before	_	
163-47	25000-25004	each	_	
163-48	25005-25012	session	_	
163-49	25012-25013	.	_	

#Text=A post hoc exploratory ROI analysis was carried out within the anterior insula, a region considered to process salience and therefore likely to be sensitive to habituation effects.
164-1	25014-25015	A	_	
164-2	25016-25020	post	_	
164-3	25021-25024	hoc	_	
164-4	25025-25036	exploratory	_	
164-5	25037-25040	ROI	_	
164-6	25041-25049	analysis	_	
164-7	25050-25053	was	_	
164-8	25054-25061	carried	_	
164-9	25062-25065	out	_	
164-10	25066-25072	within	_	
164-11	25073-25076	the	_	
164-12	25077-25085	anterior	_	
164-13	25086-25092	insula	_	
164-14	25092-25093	,	_	
164-15	25094-25095	a	_	
164-16	25096-25102	region	_	
164-17	25103-25113	considered	_	
164-18	25114-25116	to	_	
164-19	25117-25124	process	_	
164-20	25125-25133	salience	_	
164-21	25134-25137	and	_	
164-22	25138-25147	therefore	_	
164-23	25148-25154	likely	_	
164-24	25155-25157	to	_	
164-25	25158-25160	be	_	
164-26	25161-25170	sensitive	_	
164-27	25171-25173	to	_	
164-28	25174-25185	habituation	_	
164-29	25186-25193	effects	_	
164-30	25193-25194	.	_	

#Text=Notably, the anterior insula is reliably implicated in MID performance (in a meta-analysis performed by our group) but is devoid of DRD3s.
165-1	25195-25202	Notably	_	
165-2	25202-25203	,	_	
165-3	25204-25207	the	_	
165-4	25208-25216	anterior	_	
165-5	25217-25223	insula	_	
165-6	25224-25226	is	_	
165-7	25227-25235	reliably	_	
165-8	25236-25246	implicated	_	
165-9	25247-25249	in	_	
165-10	25250-25253	MID	_	
165-11	25254-25265	performance	_	
165-12	25266-25267	(	_	
165-13	25267-25269	in	_	
165-14	25270-25271	a	_	
165-15	25272-25285	meta-analysis	_	
165-16	25286-25295	performed	_	
165-17	25296-25298	by	_	
165-18	25299-25302	our	_	
165-19	25303-25308	group	_	
165-20	25308-25309	)	_	
165-21	25310-25313	but	_	
165-22	25314-25316	is	_	
165-23	25317-25323	devoid	_	
165-24	25324-25326	of	_	
165-25	25327-25332	DRD3s	_	
165-26	25332-25333	.	_	

#Text=No effects of GSK598809 or interactions were found within this region, supporting the suggestion that the effects seen were indeed drug effects rather than non-specific habituation effects.
166-1	25334-25336	No	_	
166-2	25337-25344	effects	_	
166-3	25345-25347	of	_	
166-4	25348-25357	GSK598809	_	
166-5	25358-25360	or	_	
166-6	25361-25373	interactions	_	
166-7	25374-25378	were	_	
166-8	25379-25384	found	_	
166-9	25385-25391	within	_	
166-10	25392-25396	this	_	
166-11	25397-25403	region	_	
166-12	25403-25404	,	_	
166-13	25405-25415	supporting	_	
166-14	25416-25419	the	_	
166-15	25420-25430	suggestion	_	
166-16	25431-25435	that	_	
166-17	25436-25439	the	_	
166-18	25440-25447	effects	_	
166-19	25448-25452	seen	_	
166-20	25453-25457	were	_	
166-21	25458-25464	indeed	_	
166-22	25465-25469	drug	_	
166-23	25470-25477	effects	_	
166-24	25478-25484	rather	_	
166-25	25485-25489	than	_	
166-26	25490-25502	non-specific	_	
166-27	25503-25514	habituation	_	
166-28	25515-25522	effects	_	
166-29	25522-25523	.	_	

#Text=Another limitation is the age difference between the AD and PD groups (consistent with typical clinical presentation), therefore caution should be used when interpreting AD vs PD differences.
167-1	25524-25531	Another	_	
167-2	25532-25542	limitation	_	
167-3	25543-25545	is	_	
167-4	25546-25549	the	_	
167-5	25550-25553	age	_	
167-6	25554-25564	difference	_	
167-7	25565-25572	between	_	
167-8	25573-25576	the	_	
167-9	25577-25579	AD	_	
167-10	25580-25583	and	_	
167-11	25584-25586	PD	_	
167-12	25587-25593	groups	_	
167-13	25594-25595	(	_	
167-14	25595-25605	consistent	_	
167-15	25606-25610	with	_	
167-16	25611-25618	typical	_	
167-17	25619-25627	clinical	_	
167-18	25628-25640	presentation	_	
167-19	25640-25641	)	_	
167-20	25641-25642	,	_	
167-21	25643-25652	therefore	_	
167-22	25653-25660	caution	_	
167-23	25661-25667	should	_	
167-24	25668-25670	be	_	
167-25	25671-25675	used	_	
167-26	25676-25680	when	_	
167-27	25681-25693	interpreting	_	
167-28	25694-25696	AD	_	
167-29	25697-25699	vs	_	
167-30	25700-25702	PD	_	
167-31	25703-25714	differences	_	
167-32	25714-25715	.	_	

#Text=CONCLUSION
#Text=GSK598809 enhances reward anticipatory BOLD response to non-drug rewards within abstinent substance-dependent groups, with strongest effects in those with a primary alcohol dependence.
168-1	25716-25726	CONCLUSION	_	
168-2	25727-25736	GSK598809	_	
168-3	25737-25745	enhances	_	
168-4	25746-25752	reward	_	
168-5	25753-25765	anticipatory	_	
168-6	25766-25770	BOLD	_	
168-7	25771-25779	response	_	
168-8	25780-25782	to	_	
168-9	25783-25791	non-drug	_	
168-10	25792-25799	rewards	_	
168-11	25800-25806	within	_	
168-12	25807-25816	abstinent	_	
168-13	25817-25836	substance-dependent	_	
168-14	25837-25843	groups	_	
168-15	25843-25844	,	_	
168-16	25845-25849	with	_	
168-17	25850-25859	strongest	_	
168-18	25860-25867	effects	_	
168-19	25868-25870	in	_	
168-20	25871-25876	those	_	
168-21	25877-25881	with	_	
168-22	25882-25883	a	_	
168-23	25884-25891	primary	_	
168-24	25892-25899	alcohol	_	
168-25	25900-25910	dependence	_	
168-26	25910-25911	.	_	

#Text=These results have implications for considering D3 antagonism as a potential treatment for normalizing reward deficiencies in substance dependence.
169-1	25912-25917	These	_	
169-2	25918-25925	results	_	
169-3	25926-25930	have	_	
169-4	25931-25943	implications	_	
169-5	25944-25947	for	_	
169-6	25948-25959	considering	_	
169-7	25960-25962	D3	_	
169-8	25963-25973	antagonism	_	
169-9	25974-25976	as	_	
169-10	25977-25978	a	_	
169-11	25979-25988	potential	_	
169-12	25989-25998	treatment	_	
169-13	25999-26002	for	_	
169-14	26003-26014	normalizing	_	
169-15	26015-26021	reward	_	
169-16	26022-26034	deficiencies	_	
169-17	26035-26037	in	_	
169-18	26038-26047	substance	_	
169-19	26048-26058	dependence	_	
169-20	26058-26059	.	_	

#Text=Funding and disclosure
#Text=We thank the Medical Research Council (MRC) for funding the study and GlaxoSmithKline (GSK) for supplying the study drug and funding scans at London.
170-1	26060-26067	Funding	_	
170-2	26068-26071	and	_	
170-3	26072-26082	disclosure	_	
170-4	26083-26085	We	_	
170-5	26086-26091	thank	_	
170-6	26092-26095	the	_	
170-7	26096-26103	Medical	_	
170-8	26104-26112	Research	_	
170-9	26113-26120	Council	_	
170-10	26121-26122	(	_	
170-11	26122-26125	MRC	_	
170-12	26125-26126	)	_	
170-13	26127-26130	for	_	
170-14	26131-26138	funding	_	
170-15	26139-26142	the	_	
170-16	26143-26148	study	_	
170-17	26149-26152	and	_	
170-18	26153-26168	GlaxoSmithKline	_	
170-19	26169-26170	(	_	
170-20	26170-26173	GSK	_	
170-21	26173-26174	)	_	
170-22	26175-26178	for	_	
170-23	26179-26188	supplying	_	
170-24	26189-26192	the	_	
170-25	26193-26198	study	_	
170-26	26199-26203	drug	_	
170-27	26204-26207	and	_	
170-28	26208-26215	funding	_	
170-29	26216-26221	scans	_	
170-30	26222-26224	at	_	
170-31	26225-26231	London	_	
170-32	26231-26232	.	_	

#Text=This article presents independent research funded by the Medical Research Council as part of their addiction initiative (grant number G1000018).
171-1	26233-26237	This	_	
171-2	26238-26245	article	_	
171-3	26246-26254	presents	_	
171-4	26255-26266	independent	_	
171-5	26267-26275	research	_	
171-6	26276-26282	funded	_	
171-7	26283-26285	by	_	
171-8	26286-26289	the	_	
171-9	26290-26297	Medical	_	
171-10	26298-26306	Research	_	
171-11	26307-26314	Council	_	
171-12	26315-26317	as	_	
171-13	26318-26322	part	_	
171-14	26323-26325	of	_	
171-15	26326-26331	their	_	
171-16	26332-26341	addiction	_	
171-17	26342-26352	initiative	_	
171-18	26353-26354	(	_	
171-19	26354-26359	grant	_	
171-20	26360-26366	number	_	
171-21	26367-26375	G1000018	_	
171-22	26375-26376	)	_	
171-23	26376-26377	.	_	

#Text=GSK supplied the GSK598809 drug used in this study and funded the functional and structural MRI scans that took place at Imperial College.
172-1	26378-26381	GSK	_	
172-2	26382-26390	supplied	_	
172-3	26391-26394	the	_	
172-4	26395-26404	GSK598809	_	
172-5	26405-26409	drug	_	
172-6	26410-26414	used	_	
172-7	26415-26417	in	_	
172-8	26418-26422	this	_	
172-9	26423-26428	study	_	
172-10	26429-26432	and	_	
172-11	26433-26439	funded	_	
172-12	26440-26443	the	_	
172-13	26444-26454	functional	_	
172-14	26455-26458	and	_	
172-15	26459-26469	structural	_	
172-16	26470-26473	MRI	_	
172-17	26474-26479	scans	_	
172-18	26480-26484	that	_	
172-19	26485-26489	took	_	
172-20	26490-26495	place	_	
172-21	26496-26498	at	_	
172-22	26499-26507	Imperial	_	
172-23	26508-26515	College	_	
172-24	26515-26516	.	_	

#Text=David Nutt is an advisor to British National Formulary, MRC, GMC, Department of Health, is President of the European Brain Council, past President of the British Neuroscience Association and European College of Neuropsychopharmacology, chair of DrugScience, is a member of the International Centre for Science in Drug Policy, advisor to Swedish government on drug, alcohol and tobacco research, editor of the Journal of Psychopharmacology, sits on advisory Boards at Actelion MSD, and Nalpharm, has received speaking honoraria (in addition to above) from BMS/Otsuka, GSK, Lilly, and Janssen, Servier, is a member of the Lundbeck International Neuroscience Foundation, has received grants or clinical trial payments from P1vital, MRC, NHS, Lundbeck, has share options with P1vital, has been expert witness in a number of legal cases relating to psychotropic drugs, and has edited/written 30 books—some purchased by pharma companies.
173-1	26517-26522	David	_	
173-2	26523-26527	Nutt	_	
173-3	26528-26530	is	_	
173-4	26531-26533	an	_	
173-5	26534-26541	advisor	_	
173-6	26542-26544	to	_	
173-7	26545-26552	British	_	
173-8	26553-26561	National	_	
173-9	26562-26571	Formulary	_	
173-10	26571-26572	,	_	
173-11	26573-26576	MRC	_	
173-12	26576-26577	,	_	
173-13	26578-26581	GMC	_	
173-14	26581-26582	,	_	
173-15	26583-26593	Department	_	
173-16	26594-26596	of	_	
173-17	26597-26603	Health	_	
173-18	26603-26604	,	_	
173-19	26605-26607	is	_	
173-20	26608-26617	President	_	
173-21	26618-26620	of	_	
173-22	26621-26624	the	_	
173-23	26625-26633	European	_	
173-24	26634-26639	Brain	_	
173-25	26640-26647	Council	_	
173-26	26647-26648	,	_	
173-27	26649-26653	past	_	
173-28	26654-26663	President	_	
173-29	26664-26666	of	_	
173-30	26667-26670	the	_	
173-31	26671-26678	British	_	
173-32	26679-26691	Neuroscience	_	
173-33	26692-26703	Association	_	
173-34	26704-26707	and	_	
173-35	26708-26716	European	_	
173-36	26717-26724	College	_	
173-37	26725-26727	of	_	
173-38	26728-26751	Neuropsychopharmacology	_	
173-39	26751-26752	,	_	
173-40	26753-26758	chair	_	
173-41	26759-26761	of	_	
173-42	26762-26773	DrugScience	_	
173-43	26773-26774	,	_	
173-44	26775-26777	is	_	
173-45	26778-26779	a	_	
173-46	26780-26786	member	_	
173-47	26787-26789	of	_	
173-48	26790-26793	the	_	
173-49	26794-26807	International	_	
173-50	26808-26814	Centre	_	
173-51	26815-26818	for	_	
173-52	26819-26826	Science	_	
173-53	26827-26829	in	_	
173-54	26830-26834	Drug	_	
173-55	26835-26841	Policy	_	
173-56	26841-26842	,	_	
173-57	26843-26850	advisor	_	
173-58	26851-26853	to	_	
173-59	26854-26861	Swedish	_	
173-60	26862-26872	government	_	
173-61	26873-26875	on	_	
173-62	26876-26880	drug	_	
173-63	26880-26881	,	_	
173-64	26882-26889	alcohol	_	
173-65	26890-26893	and	_	
173-66	26894-26901	tobacco	_	
173-67	26902-26910	research	_	
173-68	26910-26911	,	_	
173-69	26912-26918	editor	_	
173-70	26919-26921	of	_	
173-71	26922-26925	the	_	
173-72	26926-26933	Journal	_	
173-73	26934-26936	of	_	
173-74	26937-26955	Psychopharmacology	_	
173-75	26955-26956	,	_	
173-76	26957-26961	sits	_	
173-77	26962-26964	on	_	
173-78	26965-26973	advisory	_	
173-79	26974-26980	Boards	_	
173-80	26981-26983	at	_	
173-81	26984-26992	Actelion	_	
173-82	26993-26996	MSD	_	
173-83	26996-26997	,	_	
173-84	26998-27001	and	_	
173-85	27002-27010	Nalpharm	_	
173-86	27010-27011	,	_	
173-87	27012-27015	has	_	
173-88	27016-27024	received	_	
173-89	27025-27033	speaking	_	
173-90	27034-27043	honoraria	_	
173-91	27044-27045	(	_	
173-92	27045-27047	in	_	
173-93	27048-27056	addition	_	
173-94	27057-27059	to	_	
173-95	27060-27065	above	_	
173-96	27065-27066	)	_	
173-97	27067-27071	from	_	
173-98	27072-27075	BMS	_	
173-99	27075-27076	/	_	
173-100	27076-27082	Otsuka	_	
173-101	27082-27083	,	_	
173-102	27084-27087	GSK	_	
173-103	27087-27088	,	_	
173-104	27089-27094	Lilly	_	
173-105	27094-27095	,	_	
173-106	27096-27099	and	_	
173-107	27100-27107	Janssen	_	
173-108	27107-27108	,	_	
173-109	27109-27116	Servier	_	
173-110	27116-27117	,	_	
173-111	27118-27120	is	_	
173-112	27121-27122	a	_	
173-113	27123-27129	member	_	
173-114	27130-27132	of	_	
173-115	27133-27136	the	_	
173-116	27137-27145	Lundbeck	_	
173-117	27146-27159	International	_	
173-118	27160-27172	Neuroscience	_	
173-119	27173-27183	Foundation	_	
173-120	27183-27184	,	_	
173-121	27185-27188	has	_	
173-122	27189-27197	received	_	
173-123	27198-27204	grants	_	
173-124	27205-27207	or	_	
173-125	27208-27216	clinical	_	
173-126	27217-27222	trial	_	
173-127	27223-27231	payments	_	
173-128	27232-27236	from	_	
173-129	27237-27244	P1vital	_	
173-130	27244-27245	,	_	
173-131	27246-27249	MRC	_	
173-132	27249-27250	,	_	
173-133	27251-27254	NHS	_	
173-134	27254-27255	,	_	
173-135	27256-27264	Lundbeck	_	
173-136	27264-27265	,	_	
173-137	27266-27269	has	_	
173-138	27270-27275	share	_	
173-139	27276-27283	options	_	
173-140	27284-27288	with	_	
173-141	27289-27296	P1vital	_	
173-142	27296-27297	,	_	
173-143	27298-27301	has	_	
173-144	27302-27306	been	_	
173-145	27307-27313	expert	_	
173-146	27314-27321	witness	_	
173-147	27322-27324	in	_	
173-148	27325-27326	a	_	
173-149	27327-27333	number	_	
173-150	27334-27336	of	_	
173-151	27337-27342	legal	_	
173-152	27343-27348	cases	_	
173-153	27349-27357	relating	_	
173-154	27358-27360	to	_	
173-155	27361-27373	psychotropic	_	
173-156	27374-27379	drugs	_	
173-157	27379-27380	,	_	
173-158	27381-27384	and	_	
173-159	27385-27388	has	_	
173-160	27389-27395	edited	_	
173-161	27395-27396	/	_	
173-162	27396-27403	written	_	
173-163	27404-27406	30	_	
173-164	27407-27417	books—some	_	
173-165	27418-27427	purchased	_	
173-166	27428-27430	by	_	
173-167	27431-27437	pharma	_	
173-168	27438-27447	companies	_	
173-169	27447-27448	.	_	

#Text=Trevor W Robbins has research grants with Eli Lilly and Lundbeck, has received royalties from Cambridge Cognition (CANTAB), has received editorial honoraria from Springer Verlag, Elsevier, and Society for Neuroscience; has performed educational lectures for Merck, Sharpe, and Dohme, and does consultancy work for Cambridge Cognition, Eli Lilly, Lundbeck, Teva, and Shire Pharmaceuticals.
174-1	27449-27455	Trevor	_	
174-2	27456-27457	W	_	
174-3	27458-27465	Robbins	_	
174-4	27466-27469	has	_	
174-5	27470-27478	research	_	
174-6	27479-27485	grants	_	
174-7	27486-27490	with	_	
174-8	27491-27494	Eli	_	
174-9	27495-27500	Lilly	_	
174-10	27501-27504	and	_	
174-11	27505-27513	Lundbeck	_	
174-12	27513-27514	,	_	
174-13	27515-27518	has	_	
174-14	27519-27527	received	_	
174-15	27528-27537	royalties	_	
174-16	27538-27542	from	_	
174-17	27543-27552	Cambridge	_	
174-18	27553-27562	Cognition	_	
174-19	27563-27564	(	_	
174-20	27564-27570	CANTAB	_	
174-21	27570-27571	)	_	
174-22	27571-27572	,	_	
174-23	27573-27576	has	_	
174-24	27577-27585	received	_	
174-25	27586-27595	editorial	_	
174-26	27596-27605	honoraria	_	
174-27	27606-27610	from	_	
174-28	27611-27619	Springer	_	
174-29	27620-27626	Verlag	_	
174-30	27626-27627	,	_	
174-31	27628-27636	Elsevier	_	
174-32	27636-27637	,	_	
174-33	27638-27641	and	_	
174-34	27642-27649	Society	_	
174-35	27650-27653	for	_	
174-36	27654-27666	Neuroscience	_	
174-37	27666-27667	;	_	
174-38	27668-27671	has	_	
174-39	27672-27681	performed	_	
174-40	27682-27693	educational	_	
174-41	27694-27702	lectures	_	
174-42	27703-27706	for	_	
174-43	27707-27712	Merck	_	
174-44	27712-27713	,	_	
174-45	27714-27720	Sharpe	_	
174-46	27720-27721	,	_	
174-47	27722-27725	and	_	
174-48	27726-27731	Dohme	_	
174-49	27731-27732	,	_	
174-50	27733-27736	and	_	
174-51	27737-27741	does	_	
174-52	27742-27753	consultancy	_	
174-53	27754-27758	work	_	
174-54	27759-27762	for	_	
174-55	27763-27772	Cambridge	_	
174-56	27773-27782	Cognition	_	
174-57	27782-27783	,	_	
174-58	27784-27787	Eli	_	
174-59	27788-27793	Lilly	_	
174-60	27793-27794	,	_	
174-61	27795-27803	Lundbeck	_	
174-62	27803-27804	,	_	
174-63	27805-27809	Teva	_	
174-64	27809-27810	,	_	
174-65	27811-27814	and	_	
174-66	27815-27820	Shire	_	
174-67	27821-27836	Pharmaceuticals	_	
174-68	27836-27837	.	_	

#Text=Bill Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca, and Servier.
175-1	27838-27842	Bill	_	
175-2	27843-27849	Deakin	_	
175-3	27850-27859	currently	_	
175-4	27860-27867	advises	_	
175-5	27868-27870	or	_	
175-6	27871-27878	carries	_	
175-7	27879-27882	out	_	
175-8	27883-27891	research	_	
175-9	27892-27898	funded	_	
175-10	27899-27901	by	_	
175-11	27902-27910	Autifony	_	
175-12	27910-27911	,	_	
175-13	27912-27920	Sunovion	_	
175-14	27920-27921	,	_	
175-15	27922-27930	Lundbeck	_	
175-16	27930-27931	,	_	
175-17	27932-27943	AstraZeneca	_	
175-18	27943-27944	,	_	
175-19	27945-27948	and	_	
175-20	27949-27956	Servier	_	
175-21	27956-27957	.	_	

#Text=All payment is to the University of Manchester.
176-1	27958-27961	All	_	
176-2	27962-27969	payment	_	
176-3	27970-27972	is	_	
176-4	27973-27975	to	_	
176-5	27976-27979	the	_	
176-6	27980-27990	University	_	
176-7	27991-27993	of	_	
176-8	27994-28004	Manchester	_	
176-9	28004-28005	.	_	

#Text=Anne Lingford-Hughes has received speaking honoraria and research support from Lundbeck and GSK.
177-1	28006-28010	Anne	_	
177-2	28011-28026	Lingford-Hughes	_	
177-3	28027-28030	has	_	
177-4	28031-28039	received	_	
177-5	28040-28048	speaking	_	
177-6	28049-28058	honoraria	_	
177-7	28059-28062	and	_	
177-8	28063-28071	research	_	
177-9	28072-28079	support	_	
177-10	28080-28084	from	_	
177-11	28085-28093	Lundbeck	_	
177-12	28094-28097	and	_	
177-13	28098-28101	GSK	_	
177-14	28101-28102	.	_	

#Text=Liam J Nestor was a Senior Research Scientist employed by GSK during ICCAM data collection.
178-1	28103-28107	Liam	_	
178-2	28108-28109	J	_	
178-3	28110-28116	Nestor	_	
178-4	28117-28120	was	_	
178-5	28121-28122	a	_	
178-6	28123-28129	Senior	_	
178-7	28130-28138	Research	_	
178-8	28139-28148	Scientist	_	
178-9	28149-28157	employed	_	
178-10	28158-28160	by	_	
178-11	28161-28164	GSK	_	
178-12	28165-28171	during	_	
178-13	28172-28177	ICCAM	_	
178-14	28178-28182	data	_	
178-15	28183-28193	collection	_	
178-16	28193-28194	.	_	

#Text=The other authors declare no conflict of interest.
179-1	28195-28198	The	_	
179-2	28199-28204	other	_	
179-3	28205-28212	authors	_	
179-4	28213-28220	declare	_	
179-5	28221-28223	no	_	
179-6	28224-28232	conflict	_	
179-7	28233-28235	of	_	
179-8	28236-28244	interest	_	
179-9	28244-28245	.	_	

#Text=Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)
#Text=ICCAM Platform Collaborators
#Text=David Nutt, Anne Lingford-Hughes, Louise Paterson, John McGonigle, Remy Flechais, Csaba Orban, Bill Deakin, Rebecca Elliott, Anna Murphy, Eleanor Taylor, Trevor Robbins, Karen Ersche, John Suckling, Dana Smith, Laurence Reed, Filippo Passetti, Luca Faravelli, David Erritzoe, Inge Mick, Nicola Kalk, Adam Waldman, Liam Nestor, Shankar Kuchibatla, Venkataramana Boyapati, Antonio Metastasio, Yetunde Faluyi, Emilio Fernandez-Egea, Sanja Abbott, Barbara Sahakian, Valerie Voon, Ilan Rabiner.
180-1	28246-28259	Supplementary	_	
180-2	28260-28271	Information	_	
180-3	28272-28283	accompanies	_	
180-4	28284-28287	the	_	
180-5	28288-28293	paper	_	
180-6	28294-28296	on	_	
180-7	28297-28300	the	_	
180-8	28301-28324	Neuropsychopharmacology	_	
180-9	28325-28332	website	_	
180-10	28333-28334	(	_	
180-11	28334-28338	http	_	
180-12	28338-28339	:	_	
180-13	28339-28340	/	_	
180-14	28340-28341	/	_	
180-15	28341-28355	www.nature.com	_	
180-16	28355-28356	/	_	
180-17	28356-28359	npp	_	
180-18	28359-28360	)	_	
180-19	28361-28366	ICCAM	_	
180-20	28367-28375	Platform	_	
180-21	28376-28389	Collaborators	_	
180-22	28390-28395	David	_	
180-23	28396-28400	Nutt	_	
180-24	28400-28401	,	_	
180-25	28402-28406	Anne	_	
180-26	28407-28422	Lingford-Hughes	_	
180-27	28422-28423	,	_	
180-28	28424-28430	Louise	_	
180-29	28431-28439	Paterson	_	
180-30	28439-28440	,	_	
180-31	28441-28445	John	_	
180-32	28446-28455	McGonigle	_	
180-33	28455-28456	,	_	
180-34	28457-28461	Remy	_	
180-35	28462-28470	Flechais	_	
180-36	28470-28471	,	_	
180-37	28472-28477	Csaba	_	
180-38	28478-28483	Orban	_	
180-39	28483-28484	,	_	
180-40	28485-28489	Bill	_	
180-41	28490-28496	Deakin	_	
180-42	28496-28497	,	_	
180-43	28498-28505	Rebecca	_	
180-44	28506-28513	Elliott	_	
180-45	28513-28514	,	_	
180-46	28515-28519	Anna	_	
180-47	28520-28526	Murphy	_	
180-48	28526-28527	,	_	
180-49	28528-28535	Eleanor	_	
180-50	28536-28542	Taylor	_	
180-51	28542-28543	,	_	
180-52	28544-28550	Trevor	_	
180-53	28551-28558	Robbins	_	
180-54	28558-28559	,	_	
180-55	28560-28565	Karen	_	
180-56	28566-28572	Ersche	_	
180-57	28572-28573	,	_	
180-58	28574-28578	John	_	
180-59	28579-28587	Suckling	_	
180-60	28587-28588	,	_	
180-61	28589-28593	Dana	_	
180-62	28594-28599	Smith	_	
180-63	28599-28600	,	_	
180-64	28601-28609	Laurence	_	
180-65	28610-28614	Reed	_	
180-66	28614-28615	,	_	
180-67	28616-28623	Filippo	_	
180-68	28624-28632	Passetti	_	
180-69	28632-28633	,	_	
180-70	28634-28638	Luca	_	
180-71	28639-28648	Faravelli	_	
180-72	28648-28649	,	_	
180-73	28650-28655	David	_	
180-74	28656-28664	Erritzoe	_	
180-75	28664-28665	,	_	
180-76	28666-28670	Inge	_	
180-77	28671-28675	Mick	_	
180-78	28675-28676	,	_	
180-79	28677-28683	Nicola	_	
180-80	28684-28688	Kalk	_	
180-81	28688-28689	,	_	
180-82	28690-28694	Adam	_	
180-83	28695-28702	Waldman	_	
180-84	28702-28703	,	_	
180-85	28704-28708	Liam	_	
180-86	28709-28715	Nestor	_	
180-87	28715-28716	,	_	
180-88	28717-28724	Shankar	_	
180-89	28725-28735	Kuchibatla	_	
180-90	28735-28736	,	_	
180-91	28737-28750	Venkataramana	_	
180-92	28751-28759	Boyapati	_	
180-93	28759-28760	,	_	
180-94	28761-28768	Antonio	_	
180-95	28769-28779	Metastasio	_	
180-96	28779-28780	,	_	
180-97	28781-28788	Yetunde	_	
180-98	28789-28795	Faluyi	_	
180-99	28795-28796	,	_	
180-100	28797-28803	Emilio	_	
180-101	28804-28818	Fernandez-Egea	_	
180-102	28818-28819	,	_	
180-103	28820-28825	Sanja	_	
180-104	28826-28832	Abbott	_	
180-105	28832-28833	,	_	
180-106	28834-28841	Barbara	_	
180-107	28842-28850	Sahakian	_	
180-108	28850-28851	,	_	
180-109	28852-28859	Valerie	_	
180-110	28860-28864	Voon	_	
180-111	28864-28865	,	_	
180-112	28866-28870	Ilan	_	
180-113	28871-28878	Rabiner	_	
180-114	28878-28879	.	_	

#Text=Dopaminergic enhancement of striatal response to reward in major depression
#Text=Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans
#Text=American Psychiatric Association.
181-1	28880-28892	Dopaminergic	_	
181-2	28893-28904	enhancement	_	
181-3	28905-28907	of	_	
181-4	28908-28916	striatal	_	
181-5	28917-28925	response	_	
181-6	28926-28928	to	_	
181-7	28929-28935	reward	_	
181-8	28936-28938	in	_	
181-9	28939-28944	major	_	
181-10	28945-28955	depression	_	
181-11	28956-28967	Stop-signal	_	
181-12	28968-28978	inhibition	_	
181-13	28979-28988	disrupted	_	
181-14	28989-28991	by	_	
181-15	28992-28998	damage	_	
181-16	28999-29001	to	_	
181-17	29002-29007	right	_	
181-18	29008-29016	inferior	_	
181-19	29017-29024	frontal	_	
181-20	29025-29030	gyrus	_	
181-21	29031-29033	in	_	
181-22	29034-29040	humans	_	
181-23	29041-29049	American	_	
181-24	29050-29061	Psychiatric	_	
181-25	29062-29073	Association	_	
181-26	29073-29074	.	_	

#Text=Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revised, American Psychiatric Association: Washington, DC, 2000.
182-1	29075-29085	Diagnostic	_	
182-2	29086-29089	and	_	
182-3	29090-29101	Statistical	_	
182-4	29102-29108	Manual	_	
182-5	29109-29111	of	_	
182-6	29112-29118	Mental	_	
182-7	29119-29128	Disorders	_	
182-8	29128-29129	.	_	
182-9	29130-29133	4th	_	
182-10	29134-29141	edition	_	
182-11	29141-29142	,	_	
182-12	29143-29147	text	_	
182-13	29148-29155	revised	_	
182-14	29155-29156	,	_	
182-15	29157-29165	American	_	
182-16	29166-29177	Psychiatric	_	
182-17	29178-29189	Association	_	
182-18	29189-29190	:	_	
182-19	29191-29201	Washington	_	
182-20	29201-29202	,	_	
182-21	29203-29205	DC	_	
182-22	29205-29206	,	_	
182-23	29207-29211	2000	_	
182-24	29211-29212	.	_	

#Text=Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics
#Text=Intact inhibitory control processes in abstinent drug abusers (I): a functional neuroimaging study in former cocaine addicts
#Text=Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors
#Text=Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomographystudy
#Text=Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS Scales
#Text=Reduced dopamine response to amphetamine in subjects at ultra-high risk for addiction
#Text=Increased neural activity during high working memory load predicts low relapse risk in alcohol dependence
#Text=Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity
#Text=The neurobiology of cognitive control in successful cocaine abstinence
#Text=Error bars in within-subject designs: a comment on Baguley (2012)
#Text=Dopamine D3 receptors expressed by all mesencephalic dopamine neurons
#Text=In vivo imaging of cerebral dopamine D3 receptors in alcoholism
#Text=Opiate addicts lack error-dependent activation of rostral anterior cingulate
#Text=The neurobiology of successful abstinence
#Text=Dissociable executive functions in the dynamic control of behavior: inhibition, error detection, and correction
#Text=Neuroimaging and biomarkers in addiction treatment
#Text=Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans
#Text=Regulation of spontaneous activity and oscillatory spike firing in rat midbrain dopamine neurons recorded in vitro
#Text=Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Functional connectivity of the striatum links motivation to action control in humans
#Text=Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders
#Text=Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving
#Text=Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging
#Text=FMRI visualization of brain activity during a monetary incentive delay task
#Text=Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction
#Text=Responsiveness to drug cues and natural rewards in opiate addiction: associations with later heroin use
#Text=Occupancy of brain dopamine D3 receptors and drug craving: a translational approach
#Text=The effects of the dopamine D(3) receptor antagonist GSK598809 on attentional bias to palatable food cues in overweight and obese subjects
#Text=The dopamine theory of addiction: 40 years of highs and lows
#Text=The Imperial College Cambridge Manchester (ICCAM) platform study: an experimental medicine platform for evaluating new drugs for relapse prevention in addiction.
183-1	29213-29220	Ventral	_	
183-2	29221-29229	striatal	_	
183-3	29230-29240	activation	_	
183-4	29241-29247	during	_	
183-5	29248-29254	reward	_	
183-6	29255-29267	anticipation	_	
183-7	29268-29278	correlates	_	
183-8	29279-29283	with	_	
183-9	29284-29295	impulsivity	_	
183-10	29296-29298	in	_	
183-11	29299-29309	alcoholics	_	
183-12	29310-29316	Intact	_	
183-13	29317-29327	inhibitory	_	
183-14	29328-29335	control	_	
183-15	29336-29345	processes	_	
183-16	29346-29348	in	_	
183-17	29349-29358	abstinent	_	
183-18	29359-29363	drug	_	
183-19	29364-29371	abusers	_	
183-20	29372-29373	(	_	
183-21	29373-29374	I	_	
183-22	29374-29375	)	_	
183-23	29375-29376	:	_	
183-24	29377-29378	a	_	
183-25	29379-29389	functional	_	
183-26	29390-29402	neuroimaging	_	
183-27	29403-29408	study	_	
183-28	29409-29411	in	_	
183-29	29412-29418	former	_	
183-30	29419-29426	cocaine	_	
183-31	29427-29434	addicts	_	
183-32	29435-29441	Reward	_	
183-33	29442-29452	deficiency	_	
183-34	29453-29461	syndrome	_	
183-35	29461-29462	:	_	
183-36	29463-29464	a	_	
183-37	29465-29475	biogenetic	_	
183-38	29476-29481	model	_	
183-39	29482-29485	for	_	
183-40	29486-29489	the	_	
183-41	29490-29499	diagnosis	_	
183-42	29500-29503	and	_	
183-43	29504-29513	treatment	_	
183-44	29514-29516	of	_	
183-45	29517-29526	impulsive	_	
183-46	29526-29527	,	_	
183-47	29528-29537	addictive	_	
183-48	29537-29538	,	_	
183-49	29539-29542	and	_	
183-50	29543-29553	compulsive	_	
183-51	29554-29563	behaviors	_	
183-52	29564-29570	Higher	_	
183-53	29571-29578	binding	_	
183-54	29579-29581	of	_	
183-55	29582-29585	the	_	
183-56	29586-29594	dopamine	_	
183-57	29595-29597	D3	_	
183-58	29598-29617	receptor-preferring	_	
183-59	29618-29624	ligand	_	
183-60	29625-29626	[	_	
183-61	29626-29629	11C	_	
183-62	29629-29630	]	_	
183-63	29630-29631	-	_	
183-64	29631-29632	(	_	
183-65	29632-29633	+	_	
183-66	29633-29634	)	_	
183-67	29634-29635	-	_	
183-68	29635-29666	propyl-hexahydro-naphtho-oxazin	_	
183-69	29667-29669	in	_	
183-70	29670-29685	methamphetamine	_	
183-71	29686-29694	polydrug	_	
183-72	29695-29700	users	_	
183-73	29700-29701	:	_	
183-74	29702-29703	a	_	
183-75	29704-29712	positron	_	
183-76	29713-29721	emission	_	
183-77	29722-29737	tomographystudy	_	
183-78	29738-29748	Behavioral	_	
183-79	29749-29759	inhibition	_	
183-80	29759-29760	,	_	
183-81	29761-29771	behavioral	_	
183-82	29772-29782	activation	_	
183-83	29782-29783	,	_	
183-84	29784-29787	and	_	
183-85	29788-29797	affective	_	
183-86	29798-29807	responses	_	
183-87	29808-29810	to	_	
183-88	29811-29820	impending	_	
183-89	29821-29827	reward	_	
183-90	29828-29831	and	_	
183-91	29832-29842	punishment	_	
183-92	29842-29843	:	_	
183-93	29844-29847	the	_	
183-94	29848-29851	BIS	_	
183-95	29851-29852	/	_	
183-96	29852-29855	BAS	_	
183-97	29856-29862	Scales	_	
183-98	29863-29870	Reduced	_	
183-99	29871-29879	dopamine	_	
183-100	29880-29888	response	_	
183-101	29889-29891	to	_	
183-102	29892-29903	amphetamine	_	
183-103	29904-29906	in	_	
183-104	29907-29915	subjects	_	
183-105	29916-29918	at	_	
183-106	29919-29929	ultra-high	_	
183-107	29930-29934	risk	_	
183-108	29935-29938	for	_	
183-109	29939-29948	addiction	_	
183-110	29949-29958	Increased	_	
183-111	29959-29965	neural	_	
183-112	29966-29974	activity	_	
183-113	29975-29981	during	_	
183-114	29982-29986	high	_	
183-115	29987-29994	working	_	
183-116	29995-30001	memory	_	
183-117	30002-30006	load	_	
183-118	30007-30015	predicts	_	
183-119	30016-30019	low	_	
183-120	30020-30027	relapse	_	
183-121	30028-30032	risk	_	
183-122	30033-30035	in	_	
183-123	30036-30043	alcohol	_	
183-124	30044-30054	dependence	_	
183-125	30055-30063	Striatal	_	
183-126	30064-30072	dopamine	_	
183-127	30073-30074	D	_	
183-128	30074-30075	(	_	
183-129	30075-30076	2	_	
183-130	30076-30077	)	_	
183-131	30077-30078	/	_	
183-132	30078-30079	D	_	
183-133	30079-30080	(	_	
183-134	30080-30081	3	_	
183-135	30081-30082	)	_	
183-136	30083-30091	receptor	_	
183-137	30092-30099	binding	_	
183-138	30100-30102	in	_	
183-139	30103-30115	pathological	_	
183-140	30116-30124	gambling	_	
183-141	30125-30127	is	_	
183-142	30128-30138	correlated	_	
183-143	30139-30143	with	_	
183-144	30144-30156	mood-related	_	
183-145	30157-30168	impulsivity	_	
183-146	30169-30172	The	_	
183-147	30173-30185	neurobiology	_	
183-148	30186-30188	of	_	
183-149	30189-30198	cognitive	_	
183-150	30199-30206	control	_	
183-151	30207-30209	in	_	
183-152	30210-30220	successful	_	
183-153	30221-30228	cocaine	_	
183-154	30229-30239	abstinence	_	
183-155	30240-30245	Error	_	
183-156	30246-30250	bars	_	
183-157	30251-30253	in	_	
183-158	30254-30268	within-subject	_	
183-159	30269-30276	designs	_	
183-160	30276-30277	:	_	
183-161	30278-30279	a	_	
183-162	30280-30287	comment	_	
183-163	30288-30290	on	_	
183-164	30291-30298	Baguley	_	
183-165	30299-30300	(	_	
183-166	30300-30304	2012	_	
183-167	30304-30305	)	_	
183-168	30306-30314	Dopamine	_	
183-169	30315-30317	D3	_	
183-170	30318-30327	receptors	_	
183-171	30328-30337	expressed	_	
183-172	30338-30340	by	_	
183-173	30341-30344	all	_	
183-174	30345-30358	mesencephalic	_	
183-175	30359-30367	dopamine	_	
183-176	30368-30375	neurons	_	
183-177	30376-30378	In	_	
183-178	30379-30383	vivo	_	
183-179	30384-30391	imaging	_	
183-180	30392-30394	of	_	
183-181	30395-30403	cerebral	_	
183-182	30404-30412	dopamine	_	
183-183	30413-30415	D3	_	
183-184	30416-30425	receptors	_	
183-185	30426-30428	in	_	
183-186	30429-30439	alcoholism	_	
183-187	30440-30446	Opiate	_	
183-188	30447-30454	addicts	_	
183-189	30455-30459	lack	_	
183-190	30460-30475	error-dependent	_	
183-191	30476-30486	activation	_	
183-192	30487-30489	of	_	
183-193	30490-30497	rostral	_	
183-194	30498-30506	anterior	_	
183-195	30507-30516	cingulate	_	
183-196	30517-30520	The	_	
183-197	30521-30533	neurobiology	_	
183-198	30534-30536	of	_	
183-199	30537-30547	successful	_	
183-200	30548-30558	abstinence	_	
183-201	30559-30570	Dissociable	_	
183-202	30571-30580	executive	_	
183-203	30581-30590	functions	_	
183-204	30591-30593	in	_	
183-205	30594-30597	the	_	
183-206	30598-30605	dynamic	_	
183-207	30606-30613	control	_	
183-208	30614-30616	of	_	
183-209	30617-30625	behavior	_	
183-210	30625-30626	:	_	
183-211	30627-30637	inhibition	_	
183-212	30637-30638	,	_	
183-213	30639-30644	error	_	
183-214	30645-30654	detection	_	
183-215	30654-30655	,	_	
183-216	30656-30659	and	_	
183-217	30660-30670	correction	_	
183-218	30671-30683	Neuroimaging	_	
183-219	30684-30687	and	_	
183-220	30688-30698	biomarkers	_	
183-221	30699-30701	in	_	
183-222	30702-30711	addiction	_	
183-223	30712-30721	treatment	_	
183-224	30722-30730	Striatal	_	
183-225	30731-30739	dopamine	_	
183-226	30740-30741	D	_	
183-227	30741-30742	(	_	
183-228	30742-30743	2	_	
183-229	30743-30744	)	_	
183-230	30744-30745	/	_	
183-231	30745-30746	D	_	
183-232	30746-30747	(	_	
183-233	30747-30748	3	_	
183-234	30748-30749	)	_	
183-235	30750-30759	receptors	_	
183-236	30760-30767	mediate	_	
183-237	30768-30776	response	_	
183-238	30777-30787	inhibition	_	
183-239	30788-30791	and	_	
183-240	30792-30799	related	_	
183-241	30800-30808	activity	_	
183-242	30809-30811	in	_	
183-243	30812-30826	frontostriatal	_	
183-244	30827-30833	neural	_	
183-245	30834-30843	circuitry	_	
183-246	30844-30846	in	_	
183-247	30847-30853	humans	_	
183-248	30854-30864	Regulation	_	
183-249	30865-30867	of	_	
183-250	30868-30879	spontaneous	_	
183-251	30880-30888	activity	_	
183-252	30889-30892	and	_	
183-253	30893-30904	oscillatory	_	
183-254	30905-30910	spike	_	
183-255	30911-30917	firing	_	
183-256	30918-30920	in	_	
183-257	30921-30924	rat	_	
183-258	30925-30933	midbrain	_	
183-259	30934-30942	dopamine	_	
183-260	30943-30950	neurons	_	
183-261	30951-30959	recorded	_	
183-262	30960-30962	in	_	
183-263	30963-30968	vitro	_	
183-264	30969-30981	Distribution	_	
183-265	30982-30984	of	_	
183-266	30985-30993	dopamine	_	
183-267	30994-30996	D3	_	
183-268	30997-31005	receptor	_	
183-269	31006-31016	expressing	_	
183-270	31017-31024	neurons	_	
183-271	31025-31027	in	_	
183-272	31028-31031	the	_	
183-273	31032-31037	human	_	
183-274	31038-31047	forebrain	_	
183-275	31047-31048	:	_	
183-276	31049-31059	comparison	_	
183-277	31060-31064	with	_	
183-278	31065-31067	D2	_	
183-279	31068-31076	receptor	_	
183-280	31077-31087	expressing	_	
183-281	31088-31095	neurons	_	
183-282	31096-31099	The	_	
183-283	31100-31106	reward	_	
183-284	31107-31114	circuit	_	
183-285	31114-31115	:	_	
183-286	31116-31123	linking	_	
183-287	31124-31131	primate	_	
183-288	31132-31139	anatomy	_	
183-289	31140-31143	and	_	
183-290	31144-31149	human	_	
183-291	31150-31157	imaging	_	
183-292	31158-31168	Functional	_	
183-293	31169-31181	connectivity	_	
183-294	31182-31184	of	_	
183-295	31185-31188	the	_	
183-296	31189-31197	striatum	_	
183-297	31198-31203	links	_	
183-298	31204-31214	motivation	_	
183-299	31215-31217	to	_	
183-300	31218-31224	action	_	
183-301	31225-31232	control	_	
183-302	31233-31235	in	_	
183-303	31236-31242	humans	_	
183-304	31243-31250	Current	_	
183-305	31251-31263	perspectives	_	
183-306	31264-31266	on	_	
183-307	31267-31276	selective	_	
183-308	31277-31285	dopamine	_	
183-309	31286-31287	D	_	
183-310	31287-31288	(	_	
183-311	31288-31289	3	_	
183-312	31289-31290	)	_	
183-313	31291-31299	receptor	_	
183-314	31300-31311	antagonists	_	
183-315	31312-31314	as	_	
183-316	31315-31335	pharmacotherapeutics	_	
183-317	31336-31339	for	_	
183-318	31340-31350	addictions	_	
183-319	31351-31354	and	_	
183-320	31355-31362	related	_	
183-321	31363-31372	disorders	_	
183-322	31373-31384	Correlation	_	
183-323	31385-31392	between	_	
183-324	31393-31401	dopamine	_	
183-325	31402-31403	D	_	
183-326	31403-31404	(	_	
183-327	31404-31405	2	_	
183-328	31405-31406	)	_	
183-329	31407-31416	receptors	_	
183-330	31417-31419	in	_	
183-331	31420-31423	the	_	
183-332	31424-31431	ventral	_	
183-333	31432-31440	striatum	_	
183-334	31441-31444	and	_	
183-335	31445-31452	central	_	
183-336	31453-31463	processing	_	
183-337	31464-31466	of	_	
183-338	31467-31474	alcohol	_	
183-339	31475-31479	cues	_	
183-340	31480-31483	and	_	
183-341	31484-31491	craving	_	
183-342	31492-31501	Cingulate	_	
183-343	31502-31514	hypoactivity	_	
183-344	31515-31517	in	_	
183-345	31518-31525	cocaine	_	
183-346	31526-31531	users	_	
183-347	31532-31538	during	_	
183-348	31539-31540	a	_	
183-349	31541-31548	GO-NOGO	_	
183-350	31549-31553	task	_	
183-351	31554-31556	as	_	
183-352	31557-31565	revealed	_	
183-353	31566-31568	by	_	
183-354	31569-31582	event-related	_	
183-355	31583-31593	functional	_	
183-356	31594-31602	magnetic	_	
183-357	31603-31612	resonance	_	
183-358	31613-31620	imaging	_	
183-359	31621-31625	FMRI	_	
183-360	31626-31639	visualization	_	
183-361	31640-31642	of	_	
183-362	31643-31648	brain	_	
183-363	31649-31657	activity	_	
183-364	31658-31664	during	_	
183-365	31665-31666	a	_	
183-366	31667-31675	monetary	_	
183-367	31676-31685	incentive	_	
183-368	31686-31691	delay	_	
183-369	31692-31696	task	_	
183-370	31697-31705	Neuronal	_	
183-371	31706-31715	circuitry	_	
183-372	31716-31726	underlying	_	
183-373	31727-31730	the	_	
183-374	31731-31737	impact	_	
183-375	31738-31740	of	_	
183-376	31741-31743	D3	_	
183-377	31744-31752	receptor	_	
183-378	31753-31760	ligands	_	
183-379	31761-31763	in	_	
183-380	31764-31768	drug	_	
183-381	31769-31778	addiction	_	
183-382	31779-31793	Responsiveness	_	
183-383	31794-31796	to	_	
183-384	31797-31801	drug	_	
183-385	31802-31806	cues	_	
183-386	31807-31810	and	_	
183-387	31811-31818	natural	_	
183-388	31819-31826	rewards	_	
183-389	31827-31829	in	_	
183-390	31830-31836	opiate	_	
183-391	31837-31846	addiction	_	
183-392	31846-31847	:	_	
183-393	31848-31860	associations	_	
183-394	31861-31865	with	_	
183-395	31866-31871	later	_	
183-396	31872-31878	heroin	_	
183-397	31879-31882	use	_	
183-398	31883-31892	Occupancy	_	
183-399	31893-31895	of	_	
183-400	31896-31901	brain	_	
183-401	31902-31910	dopamine	_	
183-402	31911-31913	D3	_	
183-403	31914-31923	receptors	_	
183-404	31924-31927	and	_	
183-405	31928-31932	drug	_	
183-406	31933-31940	craving	_	
183-407	31940-31941	:	_	
183-408	31942-31943	a	_	
183-409	31944-31957	translational	_	
183-410	31958-31966	approach	_	
183-411	31967-31970	The	_	
183-412	31971-31978	effects	_	
183-413	31979-31981	of	_	
183-414	31982-31985	the	_	
183-415	31986-31994	dopamine	_	
183-416	31995-31996	D	_	
183-417	31996-31997	(	_	
183-418	31997-31998	3	_	
183-419	31998-31999	)	_	
183-420	32000-32008	receptor	_	
183-421	32009-32019	antagonist	_	
183-422	32020-32029	GSK598809	_	
183-423	32030-32032	on	_	
183-424	32033-32044	attentional	_	
183-425	32045-32049	bias	_	
183-426	32050-32052	to	_	
183-427	32053-32062	palatable	_	
183-428	32063-32067	food	_	
183-429	32068-32072	cues	_	
183-430	32073-32075	in	_	
183-431	32076-32086	overweight	_	
183-432	32087-32090	and	_	
183-433	32091-32096	obese	_	
183-434	32097-32105	subjects	_	
183-435	32106-32109	The	_	
183-436	32110-32118	dopamine	_	
183-437	32119-32125	theory	_	
183-438	32126-32128	of	_	
183-439	32129-32138	addiction	_	
183-440	32138-32139	:	_	
183-441	32140-32142	40	_	
183-442	32143-32148	years	_	
183-443	32149-32151	of	_	
183-444	32152-32157	highs	_	
183-445	32158-32161	and	_	
183-446	32162-32166	lows	_	
183-447	32167-32170	The	_	
183-448	32171-32179	Imperial	_	
183-449	32180-32187	College	_	
183-450	32188-32197	Cambridge	_	
183-451	32198-32208	Manchester	_	
183-452	32209-32210	(	_	
183-453	32210-32215	ICCAM	_	
183-454	32215-32216	)	_	
183-455	32217-32225	platform	_	
183-456	32226-32231	study	_	
183-457	32231-32232	:	_	
183-458	32233-32235	an	_	
183-459	32236-32248	experimental	_	
183-460	32249-32257	medicine	_	
183-461	32258-32266	platform	_	
183-462	32267-32270	for	_	
183-463	32271-32281	evaluating	_	
183-464	32282-32285	new	_	
183-465	32286-32291	drugs	_	
183-466	32292-32295	for	_	
183-467	32296-32303	relapse	_	
183-468	32304-32314	prevention	_	
183-469	32315-32317	in	_	
183-470	32318-32327	addiction	_	
183-471	32327-32328	.	_	

#Text=Part A: Study description
#Text=Factor structure of the Barratt impulsiveness scale
#Text=Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO
#Text=The neural basis of drug craving: an incentive-sensitization theory of addiction
#Text=The phasic reward signal of primate dopamine neurons
#Text=
#Text=Increased presynaptic regulation of dopamine neurotransmission in the nucleus accumbens core following chronic ethanol self-administration in female macaques
#Text=Ventral pallidum roles in reward and motivation
#Text=The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders
#Text=Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities
#Text=Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach
#Text=Blunted dopamine release as a biomarker for vulnerability for substance use disorders
#Text=Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy
#Text=Integration of cognitive and motivational context information in the primate prefrontalcortex
#Text=Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics
#Text=D(3) receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens
#Text=Dopamine D1 and D3 receptors modulate heroin-induced cognitive impairment through opponent actions in mice
#Text=Knutson B, Bjork JM, Fong GW, Hommer D, Mattay VS, Weinberger DR (2004).
184-1	32329-32333	Part	_	
184-2	32334-32335	A	_	
184-3	32335-32336	:	_	
184-4	32337-32342	Study	_	
184-5	32343-32354	description	_	
184-6	32355-32361	Factor	_	
184-7	32362-32371	structure	_	
184-8	32372-32374	of	_	
184-9	32375-32378	the	_	
184-10	32379-32386	Barratt	_	
184-11	32387-32400	impulsiveness	_	
184-12	32401-32406	scale	_	
184-13	32407-32417	Heightened	_	
184-14	32418-32420	D3	_	
184-15	32421-32429	dopamine	_	
184-16	32430-32438	receptor	_	
184-17	32439-32445	levels	_	
184-18	32446-32448	in	_	
184-19	32449-32456	cocaine	_	
184-20	32457-32467	dependence	_	
184-21	32468-32471	and	_	
184-22	32472-32485	contributions	_	
184-23	32486-32488	to	_	
184-24	32489-32492	the	_	
184-25	32493-32502	addiction	_	
184-26	32503-32513	behavioral	_	
184-27	32514-32523	phenotype	_	
184-28	32523-32524	:	_	
184-29	32525-32526	a	_	
184-30	32527-32535	positron	_	
184-31	32536-32544	emission	_	
184-32	32545-32555	tomography	_	
184-33	32556-32561	study	_	
184-34	32562-32566	with	_	
184-35	32567-32568	[	_	
184-36	32568-32571	11C	_	
184-37	32571-32572	]	_	
184-38	32572-32573	-	_	
184-39	32573-32574	+	_	
184-40	32574-32575	-	_	
184-41	32575-32579	PHNO	_	
184-42	32580-32583	The	_	
184-43	32584-32590	neural	_	
184-44	32591-32596	basis	_	
184-45	32597-32599	of	_	
184-46	32600-32604	drug	_	
184-47	32605-32612	craving	_	
184-48	32612-32613	:	_	
184-49	32614-32616	an	_	
184-50	32617-32640	incentive-sensitization	_	
184-51	32641-32647	theory	_	
184-52	32648-32650	of	_	
184-53	32651-32660	addiction	_	
184-54	32661-32664	The	_	
184-55	32665-32671	phasic	_	
184-56	32672-32678	reward	_	
184-57	32679-32685	signal	_	
184-58	32686-32688	of	_	
184-59	32689-32696	primate	_	
184-60	32697-32705	dopamine	_	
184-61	32706-32713	neurons	_	
184-62	32715-32724	Increased	_	
184-63	32725-32736	presynaptic	_	
184-64	32737-32747	regulation	_	
184-65	32748-32750	of	_	
184-66	32751-32759	dopamine	_	
184-67	32760-32777	neurotransmission	_	
184-68	32778-32780	in	_	
184-69	32781-32784	the	_	
184-70	32785-32792	nucleus	_	
184-71	32793-32802	accumbens	_	
184-72	32803-32807	core	_	
184-73	32808-32817	following	_	
184-74	32818-32825	chronic	_	
184-75	32826-32833	ethanol	_	
184-76	32834-32853	self-administration	_	
184-77	32854-32856	in	_	
184-78	32857-32863	female	_	
184-79	32864-32872	macaques	_	
184-80	32873-32880	Ventral	_	
184-81	32881-32889	pallidum	_	
184-82	32890-32895	roles	_	
184-83	32896-32898	in	_	
184-84	32899-32905	reward	_	
184-85	32906-32909	and	_	
184-86	32910-32920	motivation	_	
184-87	32921-32924	The	_	
184-88	32925-32933	dopamine	_	
184-89	32934-32936	D3	_	
184-90	32937-32945	receptor	_	
184-91	32945-32946	:	_	
184-92	32947-32948	a	_	
184-93	32949-32960	therapeutic	_	
184-94	32961-32967	target	_	
184-95	32968-32971	for	_	
184-96	32972-32975	the	_	
184-97	32976-32985	treatment	_	
184-98	32986-32988	of	_	
184-99	32989-33005	neuropsychiatric	_	
184-100	33006-33015	disorders	_	
184-101	33016-33024	Adaptive	_	
184-102	33025-33033	increase	_	
184-103	33034-33036	in	_	
184-104	33037-33039	D3	_	
184-105	33040-33048	dopamine	_	
184-106	33049-33058	receptors	_	
184-107	33059-33061	in	_	
184-108	33062-33065	the	_	
184-109	33066-33071	brain	_	
184-110	33072-33078	reward	_	
184-111	33079-33087	circuits	_	
184-112	33088-33090	of	_	
184-113	33091-33096	human	_	
184-114	33097-33104	cocaine	_	
184-115	33105-33115	fatalities	_	
184-116	33116-33127	Impulsivity	_	
184-117	33128-33130	in	_	
184-118	33131-33140	abstinent	_	
184-119	33141-33148	alcohol	_	
184-120	33149-33152	and	_	
184-121	33153-33161	polydrug	_	
184-122	33162-33172	dependence	_	
184-123	33172-33173	:	_	
184-124	33174-33175	a	_	
184-125	33176-33192	multidimensional	_	
184-126	33193-33201	approach	_	
184-127	33202-33209	Blunted	_	
184-128	33210-33218	dopamine	_	
184-129	33219-33226	release	_	
184-130	33227-33229	as	_	
184-131	33230-33231	a	_	
184-132	33232-33241	biomarker	_	
184-133	33242-33245	for	_	
184-134	33246-33259	vulnerability	_	
184-135	33260-33263	for	_	
184-136	33264-33273	substance	_	
184-137	33274-33277	use	_	
184-138	33278-33287	disorders	_	
184-139	33288-33295	Imaging	_	
184-140	33296-33304	dopamine	_	
184-141	33305-33314	receptors	_	
184-142	33315-33317	in	_	
184-143	33318-33324	humans	_	
184-144	33325-33329	with	_	
184-145	33330-33331	[	_	
184-146	33331-33334	11C	_	
184-147	33334-33335	]	_	
184-148	33335-33336	-	_	
184-149	33336-33337	(	_	
184-150	33337-33338	+	_	
184-151	33338-33339	)	_	
184-152	33339-33340	-	_	
184-153	33340-33344	PHNO	_	
184-154	33344-33345	:	_	
184-155	33346-33356	dissection	_	
184-156	33357-33359	of	_	
184-157	33360-33362	D3	_	
184-158	33363-33369	signal	_	
184-159	33370-33373	and	_	
184-160	33374-33381	anatomy	_	
184-161	33382-33393	Integration	_	
184-162	33394-33396	of	_	
184-163	33397-33406	cognitive	_	
184-164	33407-33410	and	_	
184-165	33411-33423	motivational	_	
184-166	33424-33431	context	_	
184-167	33432-33443	information	_	
184-168	33444-33446	in	_	
184-169	33447-33450	the	_	
184-170	33451-33458	primate	_	
184-171	33459-33475	prefrontalcortex	_	
184-172	33476-33487	Dysfunction	_	
184-173	33488-33490	of	_	
184-174	33491-33497	reward	_	
184-175	33498-33508	processing	_	
184-176	33509-33519	correlates	_	
184-177	33520-33524	with	_	
184-178	33525-33532	alcohol	_	
184-179	33533-33540	craving	_	
184-180	33541-33543	in	_	
184-181	33544-33554	detoxified	_	
184-182	33555-33565	alcoholics	_	
184-183	33566-33567	D	_	
184-184	33567-33568	(	_	
184-185	33568-33569	3	_	
184-186	33569-33570	)	_	
184-187	33571-33579	receptor	_	
184-188	33580-33587	ligands	_	
184-189	33588-33596	modulate	_	
184-190	33597-33610	extracellular	_	
184-191	33611-33619	dopamine	_	
184-192	33620-33629	clearance	_	
184-193	33630-33632	in	_	
184-194	33633-33636	the	_	
184-195	33637-33644	nucleus	_	
184-196	33645-33654	accumbens	_	
184-197	33655-33663	Dopamine	_	
184-198	33664-33666	D1	_	
184-199	33667-33670	and	_	
184-200	33671-33673	D3	_	
184-201	33674-33683	receptors	_	
184-202	33684-33692	modulate	_	
184-203	33693-33707	heroin-induced	_	
184-204	33708-33717	cognitive	_	
184-205	33718-33728	impairment	_	
184-206	33729-33736	through	_	
184-207	33737-33745	opponent	_	
184-208	33746-33753	actions	_	
184-209	33754-33756	in	_	
184-210	33757-33761	mice	_	
184-211	33762-33769	Knutson	_	
184-212	33770-33771	B	_	
184-213	33771-33772	,	_	
184-214	33773-33778	Bjork	_	
184-215	33779-33781	JM	_	
184-216	33781-33782	,	_	
184-217	33783-33787	Fong	_	
184-218	33788-33790	GW	_	
184-219	33790-33791	,	_	
184-220	33792-33798	Hommer	_	
184-221	33799-33800	D	_	
184-222	33800-33801	,	_	
184-223	33802-33808	Mattay	_	
184-224	33809-33811	VS	_	
184-225	33811-33812	,	_	
184-226	33813-33823	Weinberger	_	
184-227	33824-33826	DR	_	
184-228	33827-33828	(	_	
184-229	33828-33832	2004	_	
184-230	33832-33833	)	_	
184-231	33833-33834	.	_	

#Text=Amphetamine modulates human incentive processing.
185-1	33835-33846	Amphetamine	_	
185-2	33847-33856	modulates	_	
185-3	33857-33862	human	_	
185-4	33863-33872	incentive	_	
185-5	33873-33883	processing	_	
185-6	33883-33884	.	_	

#Text=Neuron43: 261–269..
186-1	33885-33893	Neuron43	_	
186-2	33893-33894	:	_	
186-3	33895-33898	261	_	
186-4	33898-33899	–	_	
186-5	33899-33902	269	_	
186-6	33902-33903	.	_	
186-7	33903-33904	.	_	

#Text=Supplementary Material
#Text=Regions of interest: (a) ROIs for the MID task, left/blue (when in color) shows the ventral striatum, middle/red shows the ventral pallidum (both defined according to the guidelines of), and right/yellow shows the substantia nigra.
187-1	33905-33918	Supplementary	_	
187-2	33919-33927	Material	_	
187-3	33928-33935	Regions	_	
187-4	33936-33938	of	_	
187-5	33939-33947	interest	_	
187-6	33947-33948	:	_	
187-7	33949-33950	(	_	
187-8	33950-33951	a	_	
187-9	33951-33952	)	_	
187-10	33953-33957	ROIs	_	
187-11	33958-33961	for	_	
187-12	33962-33965	the	_	
187-13	33966-33969	MID	_	
187-14	33970-33974	task	_	
187-15	33974-33975	,	_	
187-16	33976-33980	left	_	
187-17	33980-33981	/	_	
187-18	33981-33985	blue	_	
187-19	33986-33987	(	_	
187-20	33987-33991	when	_	
187-21	33992-33994	in	_	
187-22	33995-34000	color	_	
187-23	34000-34001	)	_	
187-24	34002-34007	shows	_	
187-25	34008-34011	the	_	
187-26	34012-34019	ventral	_	
187-27	34020-34028	striatum	_	
187-28	34028-34029	,	_	
187-29	34030-34036	middle	_	
187-30	34036-34037	/	_	
187-31	34037-34040	red	_	
187-32	34041-34046	shows	_	
187-33	34047-34050	the	_	
187-34	34051-34058	ventral	_	
187-35	34059-34067	pallidum	_	
187-36	34068-34069	(	_	
187-37	34069-34073	both	_	
187-38	34074-34081	defined	_	
187-39	34082-34091	according	_	
187-40	34092-34094	to	_	
187-41	34095-34098	the	_	
187-42	34099-34109	guidelines	_	
187-43	34110-34112	of	_	
187-44	34112-34113	)	_	
187-45	34113-34114	,	_	
187-46	34115-34118	and	_	
187-47	34119-34124	right	_	
187-48	34124-34125	/	_	
187-49	34125-34131	yellow	_	
187-50	34132-34137	shows	_	
187-51	34138-34141	the	_	
187-52	34142-34152	substantia	_	
187-53	34153-34158	nigra	_	
187-54	34158-34159	.	_	

#Text=(b) ROIs for the GNG task, left/cyan shows the right inferior frontal gyrus, middle/green shows the left inferior frontal gyrus, and right/purple shows the anterior cingulate.
188-1	34160-34161	(	_	
188-2	34161-34162	b	_	
188-3	34162-34163	)	_	
188-4	34164-34168	ROIs	_	
188-5	34169-34172	for	_	
188-6	34173-34176	the	_	
188-7	34177-34180	GNG	_	
188-8	34181-34185	task	_	
188-9	34185-34186	,	_	
188-10	34187-34191	left	_	
188-11	34191-34192	/	_	
188-12	34192-34196	cyan	_	
188-13	34197-34202	shows	_	
188-14	34203-34206	the	_	
188-15	34207-34212	right	_	
188-16	34213-34221	inferior	_	
188-17	34222-34229	frontal	_	
188-18	34230-34235	gyrus	_	
188-19	34235-34236	,	_	
188-20	34237-34243	middle	_	
188-21	34243-34244	/	_	
188-22	34244-34249	green	_	
188-23	34250-34255	shows	_	
188-24	34256-34259	the	_	
188-25	34260-34264	left	_	
188-26	34265-34273	inferior	_	
188-27	34274-34281	frontal	_	
188-28	34282-34287	gyrus	_	
188-29	34287-34288	,	_	
188-30	34289-34292	and	_	
188-31	34293-34298	right	_	
188-32	34298-34299	/	_	
188-33	34299-34305	purple	_	
188-34	34306-34311	shows	_	
188-35	34312-34315	the	_	
188-36	34316-34324	anterior	_	
188-37	34325-34334	cingulate	_	
188-38	34334-34335	.	_	

#Text=ROI response during the MID task: mean reward-neutral anticipation BOLD contrast estimate for both the placebo and the GSK598809 sessions.
189-1	34336-34339	ROI	_	
189-2	34340-34348	response	_	
189-3	34349-34355	during	_	
189-4	34356-34359	the	_	
189-5	34360-34363	MID	_	
189-6	34364-34368	task	_	
189-7	34368-34369	:	_	
189-8	34370-34374	mean	_	
189-9	34375-34389	reward-neutral	_	
189-10	34390-34402	anticipation	_	
189-11	34403-34407	BOLD	_	
189-12	34408-34416	contrast	_	
189-13	34417-34425	estimate	_	
189-14	34426-34429	for	_	
189-15	34430-34434	both	_	
189-16	34435-34438	the	_	
189-17	34439-34446	placebo	_	
189-18	34447-34450	and	_	
189-19	34451-34454	the	_	
189-20	34455-34464	GSK598809	_	
189-21	34465-34473	sessions	_	
189-22	34473-34474	.	_	

#Text=White bars represent the placebo session, whereas light gray/blue (when in color) represent the GSK598809 session.
190-1	34475-34480	White	_	
190-2	34481-34485	bars	_	
190-3	34486-34495	represent	_	
190-4	34496-34499	the	_	
190-5	34500-34507	placebo	_	
190-6	34508-34515	session	_	
190-7	34515-34516	,	_	
190-8	34517-34524	whereas	_	
190-9	34525-34530	light	_	
190-10	34531-34535	gray	_	
190-11	34535-34536	/	_	
190-12	34536-34540	blue	_	
190-13	34541-34542	(	_	
190-14	34542-34546	when	_	
190-15	34547-34549	in	_	
190-16	34550-34555	color	_	
190-17	34555-34556	)	_	
190-18	34557-34566	represent	_	
190-19	34567-34570	the	_	
190-20	34571-34580	GSK598809	_	
190-21	34581-34588	session	_	
190-22	34588-34589	.	_	

#Text=Histograms on the top show the main effect of drug within each ROI (*p<0.01, **p<0.001), whereas histograms below show the BOLD contrast estimates for the placebo and GSK598809 sessions for each group separately (†significant effect of group at p<0.01 in the placebo condition only).
191-1	34590-34600	Histograms	_	
191-2	34601-34603	on	_	
191-3	34604-34607	the	_	
191-4	34608-34611	top	_	
191-5	34612-34616	show	_	
191-6	34617-34620	the	_	
191-7	34621-34625	main	_	
191-8	34626-34632	effect	_	
191-9	34633-34635	of	_	
191-10	34636-34640	drug	_	
191-11	34641-34647	within	_	
191-12	34648-34652	each	_	
191-13	34653-34656	ROI	_	
191-14	34657-34658	(	_	
191-15	34658-34659	*	_	
191-16	34659-34660	p	_	
191-17	34660-34661	<	_	
191-18	34661-34665	0.01	_	
191-19	34665-34666	,	_	
191-20	34667-34668	*	_	
191-21	34668-34669	*	_	
191-22	34669-34670	p	_	
191-23	34670-34671	<	_	
191-24	34671-34676	0.001	_	
191-25	34676-34677	)	_	
191-26	34677-34678	,	_	
191-27	34679-34686	whereas	_	
191-28	34687-34697	histograms	_	
191-29	34698-34703	below	_	
191-30	34704-34708	show	_	
191-31	34709-34712	the	_	
191-32	34713-34717	BOLD	_	
191-33	34718-34726	contrast	_	
191-34	34727-34736	estimates	_	
191-35	34737-34740	for	_	
191-36	34741-34744	the	_	
191-37	34745-34752	placebo	_	
191-38	34753-34756	and	_	
191-39	34757-34766	GSK598809	_	
191-40	34767-34775	sessions	_	
191-41	34776-34779	for	_	
191-42	34780-34784	each	_	
191-43	34785-34790	group	_	
191-44	34791-34801	separately	_	
191-45	34802-34803	(	_	
191-46	34803-34804	†	_	
191-47	34804-34815	significant	_	
191-48	34816-34822	effect	_	
191-49	34823-34825	of	_	
191-50	34826-34831	group	_	
191-51	34832-34834	at	_	
191-52	34835-34836	p	_	
191-53	34836-34837	<	_	
191-54	34837-34841	0.01	_	
191-55	34842-34844	in	_	
191-56	34845-34848	the	_	
191-57	34849-34856	placebo	_	
191-58	34857-34866	condition	_	
191-59	34867-34871	only	_	
191-60	34871-34872	)	_	
191-61	34872-34873	.	_	

#Text=Error bars indicate within-subject SEM suitable for assessing drug rather than group effects.
192-1	34874-34879	Error	_	
192-2	34880-34884	bars	_	
192-3	34885-34893	indicate	_	
192-4	34894-34908	within-subject	_	
192-5	34909-34912	SEM	_	
192-6	34913-34921	suitable	_	
192-7	34922-34925	for	_	
192-8	34926-34935	assessing	_	
192-9	34936-34940	drug	_	
192-10	34941-34947	rather	_	
192-11	34948-34952	than	_	
192-12	34953-34958	group	_	
192-13	34959-34966	effects	_	
192-14	34966-34967	.	_	

#Text=A full color version of this figure is available at the Neuropsychopharmacology journal online.
193-1	34968-34969	A	_	
193-2	34970-34974	full	_	
193-3	34975-34980	color	_	
193-4	34981-34988	version	_	
193-5	34989-34991	of	_	
193-6	34992-34996	this	_	
193-7	34997-35003	figure	_	
193-8	35004-35006	is	_	
193-9	35007-35016	available	_	
193-10	35017-35019	at	_	
193-11	35020-35023	the	_	
193-12	35024-35047	Neuropsychopharmacology	_	
193-13	35048-35055	journal	_	
193-14	35056-35062	online	_	
193-15	35062-35063	.	_	

#Text=ROI response during the GNG task: mean ‘stops-go’ BOLD contrast estimate within each ROI for the placebo (white bars) and the GSK598809 (gray or blue when in color) sessions.
194-1	35064-35067	ROI	_	
194-2	35068-35076	response	_	
194-3	35077-35083	during	_	
194-4	35084-35087	the	_	
194-5	35088-35091	GNG	_	
194-6	35092-35096	task	_	
194-7	35096-35097	:	_	
194-8	35098-35102	mean	_	
194-9	35103-35104	‘	_	
194-10	35104-35112	stops-go	_	
194-11	35112-35113	’	_	
194-12	35114-35118	BOLD	_	
194-13	35119-35127	contrast	_	
194-14	35128-35136	estimate	_	
194-15	35137-35143	within	_	
194-16	35144-35148	each	_	
194-17	35149-35152	ROI	_	
194-18	35153-35156	for	_	
194-19	35157-35160	the	_	
194-20	35161-35168	placebo	_	
194-21	35169-35170	(	_	
194-22	35170-35175	white	_	
194-23	35176-35180	bars	_	
194-24	35180-35181	)	_	
194-25	35182-35185	and	_	
194-26	35186-35189	the	_	
194-27	35190-35199	GSK598809	_	
194-28	35200-35201	(	_	
194-29	35201-35205	gray	_	
194-30	35206-35208	or	_	
194-31	35209-35213	blue	_	
194-32	35214-35218	when	_	
194-33	35219-35221	in	_	
194-34	35222-35227	color	_	
194-35	35227-35228	)	_	
194-36	35229-35237	sessions	_	
194-37	35237-35238	.	_	

#Text=Error bars indicate within-subject SEM.
195-1	35239-35244	Error	_	
195-2	35245-35249	bars	_	
195-3	35250-35258	indicate	_	
195-4	35259-35273	within-subject	_	
195-5	35274-35277	SEM	_	
195-6	35277-35278	.	_	

#Text=*Main effect of group, significant at a Bonferroni corrected value of p<0.017.
196-1	35279-35280	*	_	
196-2	35280-35284	Main	_	
196-3	35285-35291	effect	_	
196-4	35292-35294	of	_	
196-5	35295-35300	group	_	
196-6	35300-35301	,	_	
196-7	35302-35313	significant	_	
196-8	35314-35316	at	_	
196-9	35317-35318	a	_	
196-10	35319-35329	Bonferroni	_	
196-11	35330-35339	corrected	_	
196-12	35340-35345	value	_	
196-13	35346-35348	of	_	
196-14	35349-35350	p	_	
196-15	35350-35351	<	_	
196-16	35351-35356	0.017	_	
196-17	35356-35357	.	_	

#Text=A full color version of this figure is available at the Neuropsychopharmacology journal online.
197-1	35358-35359	A	_	
197-2	35360-35364	full	_	
197-3	35365-35370	color	_	
197-4	35371-35378	version	_	
197-5	35379-35381	of	_	
197-6	35382-35386	this	_	
197-7	35387-35393	figure	_	
197-8	35394-35396	is	_	
197-9	35397-35406	available	_	
197-10	35407-35409	at	_	
197-11	35410-35413	the	_	
197-12	35414-35437	Neuropsychopharmacology	_	
197-13	35438-35445	journal	_	
197-14	35446-35452	online	_	
197-15	35452-35453	.	_	

#Text=Results from ROIs and Whole-brain Analyses for the MID (Top Two Subtables) and GNG (Bottom Two Subtables) Tasks
#Text=MID ROI analysis\t \tRegion\tEffect of drug\tGroup × drug interaction\tEffect of group\t \tVentral striatum\tF(1,79)=8.35, p=0.005, GSK>PBO\tF(2,79)=1.31, p=0.28, NS\tF(2,79)=3.16, p=0.048, NS\t \tVentral pallidum\tF(1,79)=30.83, p<0.001, GSK>PBO\tF(2,79)=3.32, p=0.041, NS\tF(2,79)=2.01, p=0.141, NS\t \tSubstantia nigra\tF(1,79)=7.28, p=0.009, GSK>BPO\tF(2,79)=0.86, p=0.43, NS\tF(2,79)=3.29, p=0.042, NS\t \t
#Text=MID whole brain\t \tContrast\tRegion\tCluster size\tMNI coordinates\tF-value\tp-Value (FWE corrected)\tDirection\t \tMain effect of the drug\tVentral pallidum\t11\t−15,5,−10\t34.77\t0.001\tGSK>Plac\t \t \tMiddle frontal gyrus\t11\t30,29,29\t29.22\t0.003\tGSK>Plac\t \t \tRight cerebellum\t9\t39,−49,−28\t27.81\t0.007\tGSK>Plac\t \t \tCaudate\t19\t−15,−1,20\t26.51\t0.01\tGSK>Plac\t \tDrug session × group\tMiddle frontal gyrus\t6\t30,32,32\t29.22\t0.003\tGSK>PBO, AD>HC, PD\t \tMain effect of the group\tNo significant clusters\t \t \t \t \t \t \t
#Text=GNG ROI analysis\t \tRegion\tEffect of drug\tGroup × drug interaction\tEffect of group\t \tRight inferior frontal gyrus\tF(1,70)=1.66, p=0.20, NS\tF(2,70)=0.88, p=0.42, NS\tF(2,70)=4.45,p=0.015, PD>HC\t \tLeft inferior frontal gyrus\tF(1,70)=0.35, p<0.56, NS\tF(2,70)=1.12, p=0.29, NS\tF(2,70)=3.49, p=0.036, NS\t \tAnterior cingulate cortex\tF(1,70)=0.99, p=0.32, NS\tF(2,70)=1.02, p=0.37, NS\tF(2,70)=3.29, p=0.119, NS\t \t
#Text=GNG whole brain\t \tContrast\tRegion\tCluster size\tMNI coordinates\tF-value\tp-Value (FWE corrected)\tDirection\t \tMain effect of the drug\tNo significant clusters\t \tDrug session × group\tNo significant clusters\t \tMain effect of the group\tMidbrain\t13\t15,−7,−10\t19.13\t0.003\tAD>HC,PD
198-1	35454-35461	Results	_	
198-2	35462-35466	from	_	
198-3	35467-35471	ROIs	_	
198-4	35472-35475	and	_	
198-5	35476-35487	Whole-brain	_	
198-6	35488-35496	Analyses	_	
198-7	35497-35500	for	_	
198-8	35501-35504	the	_	
198-9	35505-35508	MID	_	
198-10	35509-35510	(	_	
198-11	35510-35513	Top	_	
198-12	35514-35517	Two	_	
198-13	35518-35527	Subtables	_	
198-14	35527-35528	)	_	
198-15	35529-35532	and	_	
198-16	35533-35536	GNG	_	
198-17	35537-35538	(	_	
198-18	35538-35544	Bottom	_	
198-19	35545-35548	Two	_	
198-20	35549-35558	Subtables	_	
198-21	35558-35559	)	_	
198-22	35560-35565	Tasks	_	
198-23	35566-35569	MID	_	
198-24	35570-35573	ROI	_	
198-25	35574-35582	analysis	_	
198-26	35585-35591	Region	_	
198-27	35592-35598	Effect	_	
198-28	35599-35601	of	_	
198-29	35602-35606	drug	_	
198-30	35607-35612	Group	_	
198-31	35613-35614	×	_	
198-32	35615-35619	drug	_	
198-33	35620-35631	interaction	_	
198-34	35632-35638	Effect	_	
198-35	35639-35641	of	_	
198-36	35642-35647	group	_	
198-37	35650-35657	Ventral	_	
198-38	35658-35666	striatum	_	
198-39	35667-35668	F	_	
198-40	35668-35669	(	_	
198-41	35669-35673	1,79	_	
198-42	35673-35674	)	_	
198-43	35674-35675	=	_	
198-44	35675-35679	8.35	_	
198-45	35679-35680	,	_	
198-46	35681-35682	p	_	
198-47	35682-35683	=	_	
198-48	35683-35688	0.005	_	
198-49	35688-35689	,	_	
198-50	35690-35693	GSK	_	
198-51	35693-35694	>	_	
198-52	35694-35697	PBO	_	
198-53	35698-35699	F	_	
198-54	35699-35700	(	_	
198-55	35700-35704	2,79	_	
198-56	35704-35705	)	_	
198-57	35705-35706	=	_	
198-58	35706-35710	1.31	_	
198-59	35710-35711	,	_	
198-60	35712-35713	p	_	
198-61	35713-35714	=	_	
198-62	35714-35718	0.28	_	
198-63	35718-35719	,	_	
198-64	35720-35722	NS	_	
198-65	35723-35724	F	_	
198-66	35724-35725	(	_	
198-67	35725-35729	2,79	_	
198-68	35729-35730	)	_	
198-69	35730-35731	=	_	
198-70	35731-35735	3.16	_	
198-71	35735-35736	,	_	
198-72	35737-35738	p	_	
198-73	35738-35739	=	_	
198-74	35739-35744	0.048	_	
198-75	35744-35745	,	_	
198-76	35746-35748	NS	_	
198-77	35751-35758	Ventral	_	
198-78	35759-35767	pallidum	_	
198-79	35768-35769	F	_	
198-80	35769-35770	(	_	
198-81	35770-35774	1,79	_	
198-82	35774-35775	)	_	
198-83	35775-35776	=	_	
198-84	35776-35781	30.83	_	
198-85	35781-35782	,	_	
198-86	35783-35784	p	_	
198-87	35784-35785	<	_	
198-88	35785-35790	0.001	_	
198-89	35790-35791	,	_	
198-90	35792-35795	GSK	_	
198-91	35795-35796	>	_	
198-92	35796-35799	PBO	_	
198-93	35800-35801	F	_	
198-94	35801-35802	(	_	
198-95	35802-35806	2,79	_	
198-96	35806-35807	)	_	
198-97	35807-35808	=	_	
198-98	35808-35812	3.32	_	
198-99	35812-35813	,	_	
198-100	35814-35815	p	_	
198-101	35815-35816	=	_	
198-102	35816-35821	0.041	_	
198-103	35821-35822	,	_	
198-104	35823-35825	NS	_	
198-105	35826-35827	F	_	
198-106	35827-35828	(	_	
198-107	35828-35832	2,79	_	
198-108	35832-35833	)	_	
198-109	35833-35834	=	_	
198-110	35834-35838	2.01	_	
198-111	35838-35839	,	_	
198-112	35840-35841	p	_	
198-113	35841-35842	=	_	
198-114	35842-35847	0.141	_	
198-115	35847-35848	,	_	
198-116	35849-35851	NS	_	
198-117	35854-35864	Substantia	_	
198-118	35865-35870	nigra	_	
198-119	35871-35872	F	_	
198-120	35872-35873	(	_	
198-121	35873-35877	1,79	_	
198-122	35877-35878	)	_	
198-123	35878-35879	=	_	
198-124	35879-35883	7.28	_	
198-125	35883-35884	,	_	
198-126	35885-35886	p	_	
198-127	35886-35887	=	_	
198-128	35887-35892	0.009	_	
198-129	35892-35893	,	_	
198-130	35894-35897	GSK	_	
198-131	35897-35898	>	_	
198-132	35898-35901	BPO	_	
198-133	35902-35903	F	_	
198-134	35903-35904	(	_	
198-135	35904-35908	2,79	_	
198-136	35908-35909	)	_	
198-137	35909-35910	=	_	
198-138	35910-35914	0.86	_	
198-139	35914-35915	,	_	
198-140	35916-35917	p	_	
198-141	35917-35918	=	_	
198-142	35918-35922	0.43	_	
198-143	35922-35923	,	_	
198-144	35924-35926	NS	_	
198-145	35927-35928	F	_	
198-146	35928-35929	(	_	
198-147	35929-35933	2,79	_	
198-148	35933-35934	)	_	
198-149	35934-35935	=	_	
198-150	35935-35939	3.29	_	
198-151	35939-35940	,	_	
198-152	35941-35942	p	_	
198-153	35942-35943	=	_	
198-154	35943-35948	0.042	_	
198-155	35948-35949	,	_	
198-156	35950-35952	NS	_	
198-157	35956-35959	MID	_	
198-158	35960-35965	whole	_	
198-159	35966-35971	brain	_	
198-160	35974-35982	Contrast	_	
198-161	35983-35989	Region	_	
198-162	35990-35997	Cluster	_	
198-163	35998-36002	size	_	
198-164	36003-36006	MNI	_	
198-165	36007-36018	coordinates	_	
198-166	36019-36026	F-value	_	
198-167	36027-36034	p-Value	_	
198-168	36035-36036	(	_	
198-169	36036-36039	FWE	_	
198-170	36040-36049	corrected	_	
198-171	36049-36050	)	_	
198-172	36051-36060	Direction	_	
198-173	36063-36067	Main	_	
198-174	36068-36074	effect	_	
198-175	36075-36077	of	_	
198-176	36078-36081	the	_	
198-177	36082-36086	drug	_	
198-178	36087-36094	Ventral	_	
198-179	36095-36103	pallidum	_	
198-180	36104-36106	11	_	
198-181	36107-36108	−	_	
198-182	36108-36112	15,5	_	
198-183	36112-36113	,	_	
198-184	36113-36114	−	_	
198-185	36114-36116	10	_	
198-186	36117-36122	34.77	_	
198-187	36123-36128	0.001	_	
198-188	36129-36132	GSK	_	
198-189	36132-36133	>	_	
198-190	36133-36137	Plac	_	
198-191	36140-36141	 	_	
198-192	36142-36148	Middle	_	
198-193	36149-36156	frontal	_	
198-194	36157-36162	gyrus	_	
198-195	36163-36165	11	_	
198-196	36166-36174	30,29,29	_	
198-197	36175-36180	29.22	_	
198-198	36181-36186	0.003	_	
198-199	36187-36190	GSK	_	
198-200	36190-36191	>	_	
198-201	36191-36195	Plac	_	
198-202	36198-36199	 	_	
198-203	36200-36205	Right	_	
198-204	36206-36216	cerebellum	_	
198-205	36217-36218	9	_	
198-206	36219-36221	39	_	
198-207	36221-36222	,	_	
198-208	36222-36223	−	_	
198-209	36223-36225	49	_	
198-210	36225-36226	,	_	
198-211	36226-36227	−	_	
198-212	36227-36229	28	_	
198-213	36230-36235	27.81	_	
198-214	36236-36241	0.007	_	
198-215	36242-36245	GSK	_	
198-216	36245-36246	>	_	
198-217	36246-36250	Plac	_	
198-218	36253-36254	 	_	
198-219	36255-36262	Caudate	_	
198-220	36263-36265	19	_	
198-221	36266-36267	−	_	
198-222	36267-36269	15	_	
198-223	36269-36270	,	_	
198-224	36270-36271	−	_	
198-225	36271-36275	1,20	_	
198-226	36276-36281	26.51	_	
198-227	36282-36286	0.01	_	
198-228	36287-36290	GSK	_	
198-229	36290-36291	>	_	
198-230	36291-36295	Plac	_	
198-231	36298-36302	Drug	_	
198-232	36303-36310	session	_	
198-233	36311-36312	×	_	
198-234	36313-36318	group	_	
198-235	36319-36325	Middle	_	
198-236	36326-36333	frontal	_	
198-237	36334-36339	gyrus	_	
198-238	36340-36341	6	_	
198-239	36342-36350	30,32,32	_	
198-240	36351-36356	29.22	_	
198-241	36357-36362	0.003	_	
198-242	36363-36366	GSK	_	
198-243	36366-36367	>	_	
198-244	36367-36370	PBO	_	
198-245	36370-36371	,	_	
198-246	36372-36374	AD	_	
198-247	36374-36375	>	_	
198-248	36375-36377	HC	_	
198-249	36377-36378	,	_	
198-250	36379-36381	PD	_	
198-251	36384-36388	Main	_	
198-252	36389-36395	effect	_	
198-253	36396-36398	of	_	
198-254	36399-36402	the	_	
198-255	36403-36408	group	_	
198-256	36409-36411	No	_	
198-257	36412-36423	significant	_	
198-258	36424-36432	clusters	_	
198-259	36433-36442	 	 	 	 	 	_	
198-260	36446-36449	GNG	_	
198-261	36450-36453	ROI	_	
198-262	36454-36462	analysis	_	
198-263	36465-36471	Region	_	
198-264	36472-36478	Effect	_	
198-265	36479-36481	of	_	
198-266	36482-36486	drug	_	
198-267	36487-36492	Group	_	
198-268	36493-36494	×	_	
198-269	36495-36499	drug	_	
198-270	36500-36511	interaction	_	
198-271	36512-36518	Effect	_	
198-272	36519-36521	of	_	
198-273	36522-36527	group	_	
198-274	36530-36535	Right	_	
198-275	36536-36544	inferior	_	
198-276	36545-36552	frontal	_	
198-277	36553-36558	gyrus	_	
198-278	36559-36560	F	_	
198-279	36560-36561	(	_	
198-280	36561-36565	1,70	_	
198-281	36565-36566	)	_	
198-282	36566-36567	=	_	
198-283	36567-36571	1.66	_	
198-284	36571-36572	,	_	
198-285	36573-36574	p	_	
198-286	36574-36575	=	_	
198-287	36575-36579	0.20	_	
198-288	36579-36580	,	_	
198-289	36581-36583	NS	_	
198-290	36584-36585	F	_	
198-291	36585-36586	(	_	
198-292	36586-36590	2,70	_	
198-293	36590-36591	)	_	
198-294	36591-36592	=	_	
198-295	36592-36596	0.88	_	
198-296	36596-36597	,	_	
198-297	36598-36599	p	_	
198-298	36599-36600	=	_	
198-299	36600-36604	0.42	_	
198-300	36604-36605	,	_	
198-301	36606-36608	NS	_	
198-302	36609-36610	F	_	
198-303	36610-36611	(	_	
198-304	36611-36615	2,70	_	
198-305	36615-36616	)	_	
198-306	36616-36617	=	_	
198-307	36617-36621	4.45	_	
198-308	36621-36622	,	_	
198-309	36622-36623	p	_	
198-310	36623-36624	=	_	
198-311	36624-36629	0.015	_	
198-312	36629-36630	,	_	
198-313	36631-36633	PD	_	
198-314	36633-36634	>	_	
198-315	36634-36636	HC	_	
198-316	36639-36643	Left	_	
198-317	36644-36652	inferior	_	
198-318	36653-36660	frontal	_	
198-319	36661-36666	gyrus	_	
198-320	36667-36668	F	_	
198-321	36668-36669	(	_	
198-322	36669-36673	1,70	_	
198-323	36673-36674	)	_	
198-324	36674-36675	=	_	
198-325	36675-36679	0.35	_	
198-326	36679-36680	,	_	
198-327	36681-36682	p	_	
198-328	36682-36683	<	_	
198-329	36683-36687	0.56	_	
198-330	36687-36688	,	_	
198-331	36689-36691	NS	_	
198-332	36692-36693	F	_	
198-333	36693-36694	(	_	
198-334	36694-36698	2,70	_	
198-335	36698-36699	)	_	
198-336	36699-36700	=	_	
198-337	36700-36704	1.12	_	
198-338	36704-36705	,	_	
198-339	36706-36707	p	_	
198-340	36707-36708	=	_	
198-341	36708-36712	0.29	_	
198-342	36712-36713	,	_	
198-343	36714-36716	NS	_	
198-344	36717-36718	F	_	
198-345	36718-36719	(	_	
198-346	36719-36723	2,70	_	
198-347	36723-36724	)	_	
198-348	36724-36725	=	_	
198-349	36725-36729	3.49	_	
198-350	36729-36730	,	_	
198-351	36731-36732	p	_	
198-352	36732-36733	=	_	
198-353	36733-36738	0.036	_	
198-354	36738-36739	,	_	
198-355	36740-36742	NS	_	
198-356	36745-36753	Anterior	_	
198-357	36754-36763	cingulate	_	
198-358	36764-36770	cortex	_	
198-359	36771-36772	F	_	
198-360	36772-36773	(	_	
198-361	36773-36777	1,70	_	
198-362	36777-36778	)	_	
198-363	36778-36779	=	_	
198-364	36779-36783	0.99	_	
198-365	36783-36784	,	_	
198-366	36785-36786	p	_	
198-367	36786-36787	=	_	
198-368	36787-36791	0.32	_	
198-369	36791-36792	,	_	
198-370	36793-36795	NS	_	
198-371	36796-36797	F	_	
198-372	36797-36798	(	_	
198-373	36798-36802	2,70	_	
198-374	36802-36803	)	_	
198-375	36803-36804	=	_	
198-376	36804-36808	1.02	_	
198-377	36808-36809	,	_	
198-378	36810-36811	p	_	
198-379	36811-36812	=	_	
198-380	36812-36816	0.37	_	
198-381	36816-36817	,	_	
198-382	36818-36820	NS	_	
198-383	36821-36822	F	_	
198-384	36822-36823	(	_	
198-385	36823-36827	2,70	_	
198-386	36827-36828	)	_	
198-387	36828-36829	=	_	
198-388	36829-36833	3.29	_	
198-389	36833-36834	,	_	
198-390	36835-36836	p	_	
198-391	36836-36837	=	_	
198-392	36837-36842	0.119	_	
198-393	36842-36843	,	_	
198-394	36844-36846	NS	_	
198-395	36850-36853	GNG	_	
198-396	36854-36859	whole	_	
198-397	36860-36865	brain	_	
198-398	36868-36876	Contrast	_	
198-399	36877-36883	Region	_	
198-400	36884-36891	Cluster	_	
198-401	36892-36896	size	_	
198-402	36897-36900	MNI	_	
198-403	36901-36912	coordinates	_	
198-404	36913-36920	F-value	_	
198-405	36921-36928	p-Value	_	
198-406	36929-36930	(	_	
198-407	36930-36933	FWE	_	
198-408	36934-36943	corrected	_	
198-409	36943-36944	)	_	
198-410	36945-36954	Direction	_	
198-411	36957-36961	Main	_	
198-412	36962-36968	effect	_	
198-413	36969-36971	of	_	
198-414	36972-36975	the	_	
198-415	36976-36980	drug	_	
198-416	36981-36983	No	_	
198-417	36984-36995	significant	_	
198-418	36996-37004	clusters	_	
198-419	37007-37011	Drug	_	
198-420	37012-37019	session	_	
198-421	37020-37021	×	_	
198-422	37022-37027	group	_	
198-423	37028-37030	No	_	
198-424	37031-37042	significant	_	
198-425	37043-37051	clusters	_	
198-426	37054-37058	Main	_	
198-427	37059-37065	effect	_	
198-428	37066-37068	of	_	
198-429	37069-37072	the	_	
198-430	37073-37078	group	_	
198-431	37079-37087	Midbrain	_	
198-432	37088-37090	13	_	
198-433	37091-37093	15	_	
198-434	37093-37094	,	_	
198-435	37094-37095	−	_	
198-436	37095-37096	7	_	
198-437	37096-37097	,	_	
198-438	37097-37098	−	_	
198-439	37098-37100	10	_	
198-440	37101-37106	19.13	_	
198-441	37107-37112	0.003	_	
198-442	37113-37115	AD	_	
198-443	37115-37116	>	_	
198-444	37116-37118	HC	_	
198-445	37118-37119	,	_	
198-446	37119-37121	PD	_	
